Journal Pre-proof

Clinical Practice Guideline for detection and management of diabetic kidney disease: a consensus report by the Spanish Society of Nephrology

Nuria Montero MD PhD Laia Oliveras MD Alberto Martínez-Castelao MD PhD FERA José Luis Gorriz Teruel María José Soler Romeo Beatriz Fernández Fernández MD PhD Maria Quero Ramos MD PhD Clara García Carro Paula Garcia Sancho Marian Goicechea Diezhandino MD PhD Juan José Gorgojo Martínez MD Pablo Molina Vila MD PhD María Jesús Puchades Montesa MD Diana Rodríguez Espinosa Nery Sablón González MD Rafael Santamaría Olmo Juan Francisco Navarro González MD PhD, on behalf of GEENDIAB (Spanish Diabetic Nephropathy Study Group)

PII: S0211-6995(24)00111-5

DOI: https://doi.org/doi:10.1016/j.nefro.2024.11.002

Reference: NEFRO 1300

To appear in: *NEFROLOGÍA*

Received Date: 20 October 2024

Accepted Date: 12 November 2024

Please cite this article as: Montero N, Oliveras L, Martínez-Castelao A, Luis Gorriz Teruel J, Romeo MJS, Fernández BF, Ramos MQ, Carro CG, Sancho PG, Diezhandino MG, Martínez JJG, Vila PM, Montesa MJP, Espinosa DR, González NS, Olmo RS, González JFN, Clinical Practice Guideline for detection and management of diabetic kidney disease: a consensus report by the Spanish Society of Nephrology (2024), doi: https://doi.org/10.1016/j.nefro.2024.11.002

Special article

Guía de práctica clínica sobre detección y manejo de la enfermedad renal diabética: documento de consenso de la Sociedad Española de Nefrología

Clinical Practice Guideline for detection and management of diabetic kidney disease: a consensus report by the Spanish Society of Nephrology

Nuria Montero, MD, PhD[a,], Laia Oliveras, MD[b], Alberto Martínez-Castelao, MD; PhD; FERA[c], José Luis Gorriz Teruel[d], María José Soler Romeo[e], Beatriz Fernández Fernández, MD, PhD[f], Maria Quero Ramos, MD, PhD[g], Clara García Carro[h], Paula Garcia Sancho[i], Marian Goicechea Diezhandino, MD, PhD[j], Juan José Gorgojo Martínez, MD[k], Pablo Molina Vila, MD, PhD[l], María Jesús Puchades Montesa, MD[m], Diana Rodríguez Espinosa[n], Nery Sablón González, MD[o], Rafael Santamaría Olmo[p], Juan Francisco Navarro González, MD, PhD[q], on behalf of GEENDIAB (Spanish Diabetic Nephropathy Study Group)*

[a] *Department of Nephrology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain. ORCID 0000-0002-5123-4603*

[b] *Department of Nephrology, Hospital Universitari de Bellvitge. L'Hospitalet de Llobregat, Barcelona, Spain. ORCID 0009-0002-5317-7304*

[c] *Department of Nephrology, Hospital Univertsitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain. RICORS2040 Kidney Disease (RD21/0005/0013). ORCID 0000-0003-3889-5578*

[d] *Department of Nephrology, Hospital Clínico Universitario de València, Universitat de València, València, Spain. ORCID 0000-0002-1134-9051*

[e] *Department of Nephrology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institute of Research, Barcelona, Spain. ORCID: 0000-0003-3621-0766*

[f] *Department of Nephrology and Hypertension, IIS-Fundación Jiménez Díaz, RICORS2040, Department of Medicine, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain. ORCID 0000-0002-6727-1943*

[g] *Department of Nephrology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain. ORCID 0000-0002-6515-4591*

[h] *Department of Nephrology, Hospital Universitario Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain*

[i] *Department of Endocrinology and Nutrition, Complex Hospitalari Universitari Moises Broggi, Barcelona, Spain. ORCID 0000-0002-7813-3917*

[j] *Department of Nephrology, Hospital General Universitario Gregorio Marañón, RICORS 2040 Kidney Disease, ORCID: 0000-0002-7614-0830*

[k] *Department of Endocrinology and Nutrition, Hospital Universitario Fundación Alcorcón, Madrid, Spain, ORCID 0000-0002-8679-0968*

[l] *Department of Nephrology, FISABIO, Hospital Universitari Dr. Peset, Universitat de València, València, Spain. ORCID: 0000-0002-8311-6214*

[m] *Nephrology Unit, Hospital Clínico Universitario de València, Universitat de València, València, Spain. ORCID 0000-0001-6927-071X*

[n] *Department of Nephrology, Hospital Clínic de Barcelona, Barcelona, Spain. ORCID: 0000-0002-1027-7156*

[o] *Department of Nephrology, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain. ORCID 0000-0001-8205-0447*

[p] *Department of Nephrology, Hospital Universitario Reina Sofia, Maimonides Biomedical Research Institute of Cordoba (IMIBIC) / University of Cordoba, Córdoba, Spain. ORCID 0000-0002-2627-1445*

[q] *Research Unit and Department of Nephrology, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain. RICORS2040 Kidney Disease (RD21/0005/0013), Instituto de Salud Carlos III, Madrid, Spain. Instituto de Tecnologías Biomédicas, Universidad de La Laguna, Tenerife, Spain. Facultad de Ciencias de la Salud, Universidad Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Spain. ORCID: 0000-0002-5015-7474*

* Corresponding author.

E-mail address: nuriamonteroperez@gmail.com (Nuria Montero).

E-mail address: jnavgon@gobiernodecanarias.org (Juan Francisco Navarro González).

A B S T R A C T

To address all the changes in the management of people with diabetes (DM) and chronic kidney disease (CKD), under the auspices of the Spanish Society of Nephrology (SEN), the Spanish Diabetic Nephropathy Study Group (GEENDIAB) decided to publish an updated Clinical Practice Guideline for detection and management of diabetic kidney disease (DKD). It is aimed at a wide audience of clinicians treating diabetes and CKD. The terminology of kidney disease in diabetic patients has evolved towards a more inclusive nomenclature that avoids underdiagnosis of this entity. Thus, the terms “diabetes and kidney disease” and “diabetic kidney disease” are those proposed in the latest KDIGO 2022 guidelines to designate the whole spectrum of patients who can benefit from a comprehensive therapeutic approach only differentiated according to eGFR range and albuminuria.

Recommendations have been divided into five main areas of interest: Chapter 1: Screening and diagnosis of diabetic kidney disease, Chapter 2: Metabolic control in people with diabetes and CKD, Chapter 3: Blood pressure control in people with diabetic kidney disease, Chapter 4: Treatment targeting progression of CKD in people with diabetic kidney disease, and Chapter 5: Antiplatelet or anticoagulant therapy in people with diabetes and CKD.

World Health Organization (WHO) recommendations for guideline development were followed to report this guideline. Systematic reviews were carried out, with outcome ratings and summaries of findings, and we reported the strength of recommendations following the “Grading of Recommendations Assessment, Development and Evaluation” GRADE evidence profiles.

R E S U M E N

Para abordar todas las novedades en el manejo de las personas con diabetes (DM) y enfermedad renal crónica (ERC), el Grupo Español de Estudio de Nefropatía Diabética (GEENDIAB), bajo los auspicios de la Sociedad Española de Nefrología (S.E.N.), ha decidido publicar una Actualización de la Guía de Práctica Clínica para la detección y manejo de la enfermedad renal diabética (ERC), dirigida a una amplia audiencia de clínicos que tratan la diabetes y la ERC. La terminología de la enfermedad renal en pacientes diabéticos ha evolucionado hacia una nomenclatura más inclusiva que evita el infradiagnóstico de esta entidad. Así, los términos "diabetes y enfermedad renal" y "enfermedad renal diabética" son los propuestos en las últimas

guías KDIGO 2022 para designar a todo el espectro de pacientes que pueden beneficiarse de un abordaje terapéutico integral, solo diferenciado según el rango de FGe y la albuminuria.
Las recomendaciones se han dividido en 5 áreas principales de interés: Capítulo 1: Cribado y diagnóstico de la enfermedad renal diabética, Capítulo 2: Control metabólico en personas con diabetes y ERC, Capítulo 3: Control de la presión arterial en personas con enfermedad renal diabética, Capítulo 4: Tratamiento dirigido a la progresión de la ERC en personas con enfermedad renal diabética y Capítulo 5: Tratamiento antiagregante plaquetario o anticoagulante en personas con diabetes y ERC. Para elaborar esta guía se siguieron las recomendaciones de la Organización Mundial de la Salud (OMS) para el desarrollo de guías. Se realizaron revisiones sistemáticas, con evaluación de los resultados y resúmenes de los hallazgos, y se informó de la fuerza de las recomendaciones siguiendo los perfiles de evidencia GRADE "Grading of Recommendations Assessment, Development and Evaluation".

Keywords:
Diabetes mellitus
Guidelines
Diabetic kidney diseases
Diabetic nephropathy

Palabras clave:
Diabetes mellitus
Guías de práctica clínica
Enfermedades renales diabéticas
Nefropatía diabética

ARTICLE INFORMATION

Article history:
Received XXX
Accepted XXX
Available online XXX

Executive summary

Chapter 1: Screening and diagnosis of diabetic kidney disease

Recommendation 1.1. Annual screening is recommended for the detection of diabetic kidney disease. In type 1 diabetes (T1D), this should start five years after the diagnosis of diabetes, and in type 2 diabetes (T2D) or latent autoimmune diabetes in adults (LADA), from the moment the disease is detected. Measurement of the presence of albuminuria (evaluating urine albumin-to-creatinine ratio of a random urine sample) and evaluation of estimated glomerular filtration rate (eGFR) using CKD-EPI formulae would be recommendable (2D).

Recommendation 1.2. Referring people with diabetes to a nephrologist may be appropriate in any situation where a physician needs assistance in managing diabetic kidney disease according to current recommendations (2D).

Recommendation 1.3. Performing a kidney biopsy on people with diabetes should be indicated in the following situations: 1) when there is a rapid increase in proteinuria or nephrotic range proteinuria, 2) proteinuria > 1g/day in 24h urine collection in diabetes with under five years of progress, 3) deterioration of kidney function with and without diabetic retinopathy, 4) alterations in the urinary sediment (dysmorphic red blood cells) not associated with an infectious process (urinary infection), 5) rapid decrease in glomerular filtration rate in patients with previous stable kidney function or 6) clinical and/or analytical signs of associated immune disease (2D).

Chapter 2: Metabolic control in people with diabetes and CKD

Recommendation 2.1. Patients with T2D and CKD should be treated with a sodium-glucose cotransporter-2 inhibitor and, if necessary, additional pharmacological treatment should be introduced to improve glycemic control (1B).

Recommendation 2.2. Glucagon-like peptide-1 receptor agonists are recommended as additional pharmacological treatment, as they have proven cardiovascular benefit and, recently, kidney benefit in terms of CKD progression in people with T2D (1B).

Chapter 3: Blood pressure control in people with diabetic kidney disease

Recommendation 3.1. We recommend blood pressure control with a target systolic blood pressure (SBP) of <130 mm Hg, when tolerated, in patients with diabetic kidney disease. Otherwise, a general target of SBP < 140 is recommended (2C).

Recommendation 3.2. We recommend starting angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB) for patients with either hypertension or diabetic kidney disease (2B).

Recommendation 3.3. Steroidal mineralocorticoid receptor antagonists (MRA) are probably useful for managing hypertension in patients with eGFR> 30 ml/min/1.73 m2 and serum potassium < 4.8 mmol/L (2D).

Recommendation 3.4. Although nonsteroidal MRA may be helpful in blood pressure control, we do not recommend them for blood pressure management due to the current lack of evidence (2B).

Recommendation 3.5. The combination of ACEi with ARB or aliskiren therapy in patients with diabetes and CKD should be avoided (2D).

Chapter 4: Treatment targeting progression of CKD in people with diabetic kidney disease

Recommendation 4.1. Patients with T2D and CKD with an eGFR ≥20 ml/min/1.73 m^2 should be treated with a sodium-glucose cotransporter-2 inhibitor and continue until end-stage kidney disease (dialysis or kidney transplant) (1A).

Recommendation 4.2. We recommend that treatment with an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB) should be initiated in patients with diabetes, hypertension, and albuminuria. These medications should be titrated to the highest approved tolerated dose (1A).

Recommendation 4.3. Patients with T2D, eGFR ≥25 ml/min/1.73 m2, and increased albuminuria (uACR > 100 mg/g) on a stable maximal tolerated dose of RAS inhibitors should be treated with a GLP1RA with proven kidney benefit (1A).

Recommendation 4.4. We suggest initiating a nonsteroidal mineralocorticoid receptor antagonist (MRA) with proven kidney and/or cardiovascular benefit for patients with T2D, eGFR ≥25 ml/min/1.73 m^2, normal serum potassium concentration, and albuminuria (uACR ≥30 mg/g) despite the maximum tolerated dose of renin-angiotensin system (RAS) inhibitor (1B).

Recommendation 4.5. We suggest maintaining a protein intake of 0.6-0.8 g/kg (weight)/day for patients with diabetes and CKD not treated with dialysis (2C).

Chapter 5: Antiplatelet or anticoagulant therapy in people with diabetes and CKD

Recommendation 5.1. Patients with T1D or T2D and chronic kidney disease with established atherosclerotic cardiovascular disease should be treated with low-dose aspirin (75-100 mg/day) for secondary prevention (1B).

Recommendation 5.2. Dual antiplatelet therapy (with low-dose aspirin and a $P2Y_{12}$ inhibitor) is recommended after acute coronary syndrome or percutaneous coronary intervention, followed by single antiplatelet therapy with a duration determined by a multidisciplinary team based on the benefit-risk profile (1B).

Recommendation 5.3. In patients with T1D or T2D and CKD and a previous non-cardioembolic ischemic stroke or transient ischemic stroke, the long-term use of antiplatelet therapy to reduce the risk of recurrent stroke is recommended (1C).

Recommendation 5.4. Dual antiplatelet therapy (with low-dose aspirin and a $P2Y_{12}$ inhibitor) after acute non-cardioembolic ischemic stroke/transient ischemic attack in patients with T1D or T2D and CKD followed by single antiplatelet therapy should be considered (2C).

Recommendation 5.5. There is no clear evidence of a favorable benefit-risk profile of low-dose aspirin for primary prevention of atherosclerotic cardiovascular disease in patients with T1D or T2D and CKD stage 3 or higher to recommend its prescription (2C).

Recommendation 5.6. Patients with T1D or T2D and CKD with non-valvular atrial fibrillation should preferably be treated with direct oral anticoagulants versus vitamin K antagonists in patients with CKD stages 1-4 (dabigatran up to stage 3b) (1B).

Recommendation 5.7. Patients with T1D or T2D and CKD with venous thromboembolism should preferably be treated with direct oral anticoagulants over vitamin K antagonists in patients with CKD stages 1-4 (dabigatran up to stage 3b) (2C).

Methods for guideline development

The consensus development process was governed by the Spanish Diabetic Nephropathy Study Group (GEENDIAB) under the auspices of the Spanish Society of Nephrology (SEN).

These guidelines adhered to World Health Organization (WHO) recommendations for guideline development (Appendix 1) (Suppl. Materials)[1] and have been reported in accordance with the Appraisal of Guidelines for Research and Evaluation (AGREE) II reporting checklist[2].

The phases of execution of the guidelines were as follows:

1. *Defining the scope of the guideline*. The key guideline questions were asked using the Population, Intervention, Comparator and Outcome (PICO) methodology (Table 1).
2. *Defining the steering committee*. A topic-specific steering committee was selected, consisting of experts including nephrologists and endocrinologists in the topic area, members of the Spanish Diabetic Nephropathy Study Group (GEENDIAB) and two methodologists.
3. *Implementing literature search strategies focused on each of the PICO questions*. Relevant studies were obtained from a systematic literature search. We searched MEDLINE and CENTRAL (Cochrane Central Register of Controlled Trials) until July 2023 (Appendix 2) (Suppl. Materials).
4. *Selecting studies according to predefined inclusion criteria*. For Chapter 1, selection was not limited to randomized clinical trials but also included studies that used a pre/post or case-control design, prospective and retrospective studies (cohorts or registry), and systematic reviews and guidelines from other societies. For the remaining chapters, only randomized controlled trials (RCTs) including people with diabetes and chronic kidney disease were included. Reviews and meta-analyses were included for hand-searching of bibliographies for additional literature.
5. *Conducting data extraction and critical appraisal of the literature*. Standard data extraction forms were used to extract data. For randomized controlled trials, risk of bias was assessed using the Cochrane Risk of Bias assessment tool[3] and for observational studies the ROBINS-I tool was used[4].
6. Perform the evidence synthesis and meta-analysis of included studies. Explored outcomes were: all-cause mortality, cardiovascular mortality, death from kidney causes, individual cardiovascular events (myocardial infarction, stroke, heart failure), need for initiation of RRT, doubling of serum creatinine, new onset of albuminuria > 300 mg/g, kidney composite, major adverse cardiovascular events, heart failure, myocardial infarction, stroke, treatment dropouts due to adverse effects, serious adverse effects, hyperkalemia, glycated hemoglobin (HbA1c) (%), eGFR, % change from baseline uACR, diabetic retinopathy progression, diabetic ketoacidosis, urinary tract infections, gastrointestinal adverse effects, hypoglycemia, amputations, fractures.

Outcome analyses were performed including all RCTs. For dichotomous outcomes, results were expressed as risk ratios (RR) with 95% confidence intervals (CI). Where continuous measurement scales were used to assess treatment effects, the mean difference (MD) was used. We approached time-to-event outcomes as continuous variables. For counts and rates, the results of a study were expressed as a RR, and the (natural) logarithms of the rate ratios were combined across studies using the generic inverse variance method. Data were pooled using the random-effects model.

Multiple intervention group studies were analyzed with different methods: 1) using only the groups with the intervention of interest to create a single pair-wise comparison (if there were three groups including different induction therapies, only one induction therapy was included) and 2) including each pair-wise comparison separately, but with shared intervention groups approximately divided out evenly among the comparisons. In this last case, for dichotomous outcomes, both the number of events and the total number of patients were divided up and for continuous outcomes, only the total number of participants were divided up and the means and standard deviations were left unchanged.

Evaluation of important numerical data such as screened, randomized patients, intention-to-treat (ITT), as-treated, and per-protocol (PP) population was carefully performed. Dropouts, losses to follow-up and withdrawals were investigated. Issues of missing data and imputation methods were critically appraised. Heterogeneity was analyzed using a chi-squared test on N-1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I^2 test. I^2 values of 30-60%, 50-90%, and 75-100% correspond to moderate, substantial and considerable levels of heterogeneity. Funnel plots were used to assess the potential existence of small study bias.

Summary of findings (SoF) tables were developed to include a description of the population and the intervention and comparator. In addition, the SoF tables included results from the data synthesis as relative and absolute effect estimates. The grading of the quality of the evidence for each critical and important outcome is also provided in these tables. The SoF tables are available in Appendix 3 (Suppl. Materials).

7. *Grading the strength of the recommendations based on the quality of the evidence using the GRADE approach*. For rating guideline recommendations, the GRADE (Grading of Recommendations Assessment, Development and Evaluation) nomenclature was used[5]. The strength of individual recommendations was rated as strong (Level 1) or weak (Level

2), and the quality of the supporting evidence was shown as A (high), B (moderate), C (low), or D (very low) (Appendix 4) (Suppl. Materials).

8. *Finalizing guideline recommendations and supporting rationale*. The steering committee integrated the literature evidence and wrote the graded recommendations and the underlying rationale, graded the strength of the recommendations and developed practice points.
9. *Convening a public review of the guideline draft in December 2023*.
10. *Amending the guideline based on the external review feedback*. A committee of validating experts validated the recommendations using the AGREE II guidelines[2].
11. *Finalizing and publishing the guideline*.

Summary of recommendation statements

Chapter 1: Screening and diagnosis of diabetic kidney disease

Recommendation 1.1. Annual screening is recommended for the detection of diabetic kidney disease. In type 1 diabetes (T1D), this should start five years after the diagnosis of diabetes, and in type 2 diabetes (T2D) or Latent Autoimmune Diabetes in Adults (LADA), from the moment the disease is detected. Measurement of the presence of albuminuria (evaluating urine albumin-to-creatinine ratio of a random urine sample) and evaluation of estimated glomerular filtration rate (eGFR) using CKD-EPI formulae would be recommendable.

Strength of recommendation: 2D.

Rationale: In adult individuals, most guidelines recommend that the assessment of proteinuria should be performed by determination of the uACR, preferably in the first urine of the morning. The urine protein or albumin concentration should always be referred to as the creatinine concentration to minimize the effect of the degree of hydration (urine concentration). This result approximates to the 24-hour loss if there is no large body surface area deviation[6-9]. It must be considered that there is high variability among albuminuria measurements, so to confirm the existence of pathological albuminuria, more than one sample is required[10,11]. Factors that may influence albuminuria determination independent of kidney damage are exercise, infections, fever, congestive heart failure, menstruation and hyperglycemia or very high blood pressure[12]. Two elevated values in three samples obtained at least three months apart are necessary to consider the presence of significant albuminuria. UPCR is recommended

in patients with suspected renal interstitial pathology (Sjögren's syndrome, antiretroviral nephrotoxicity, etc.) since in these situations proteinuria is mainly produced by low molecular weight tubular proteins other than albumin. The existence of a significant dissociation between the uACR and protein-to-creatinine ratio should also suggest the possibility of the presence of free light chains in the urine (Bence-Jones proteinuria) or immunoglobulins (as in impure nephrotic syndrome).

On the other hand, there are various methods that can be used to measure GFR: creatinine clearance measured in 24-hour urine, creatinine clearance estimated by the Cockcroft-Gault formula, glomerular filtration rate estimated by MDRD, EKFC or CKD-EPI equations with creatinine (2009) or the CKD-EPI creatinine-cystatin equation (2021), glomerular filtration rate measured by isotopic methods, or glomerular filtration rate measured by iohexol. At present, the most frequently used method is estimation of eGFR using the CKD-EPI creatinine equation, which is implemented in practically all hospital and health center laboratories[13,14]. Cystatin C-based methods have the disadvantage of being expensive and not commonly implemented in laboratories, but are likely more reliable, especially in older populations or patients with illness other than CKD (heart failure, cancer, malnutrition, cirrhosis) and its measurement is advocated by some guidelines. Isotopic methods are very reliable but can only be applied in a hospital setting[15,16]. It is very probable that in the near future, we will see a more common use of GFR measurement by iohexol, which seems very reliable but is not yet widespread[17].

There are other methods that can be used to evaluate kidney disease in patients with diabetes: a) Reno-vesical ultrasound: some studies suggest ultrasonographic data that may give rise to suspicion of the presence of nephropathy as well as to make a differential diagnosis with other causes[18,19] or b) other biomarkers in the early detection of kidney disease in patients with diabetes[20-28], such as inflammation, endothelial dysfunction and urinary and tubular markers, GWAS genetic studies and others (cystatin, NAG, NGAL, KIM-1, IL-6, Netrin-1, thrombospondin-2, urinary glycans, urinary exosomes, VEGF, galectin-3, GDF-15, soluble TNF alpha). At present, several research groups are working on biomarker batteries or combined systems with multiple data (gradient boosting machines), which for now are difficult to apply in daily clinical practice[29-37]. Therefore, we believe that more evidence needs to be generated. We recommend the application of well-recognized biomarkers, even if they can be surrogated.

Recommendation 1.2. Referring people with diabetes to a nephrologist may be appropriate in any situation where a physician needs assistance in managing diabetic kidney disease according to current recommendations.

Strength of recommendation: 2D.

Rationale: The situations where evaluation by a nephrologist would be recommendable are:

1. Albuminuria of uACR > 300 mg/g maintained in two successive controls[9].
2. Reduced eGFR: To date, all consensus documents and clinical practice guidelines recommend referral of patients with diabetes when eGFR < 30 ml/min/1.73 m^2 or when there is uACR > 300 mg/g. However, recent publications suggest earlier referral, for shared control with primary care physicians and other specialists involved in the care of patients with T1D and T2D[38] and as a more appropriate practice for better early "prevention" of diabetic kidney disease.
3. Rapid decline of kidney function: A patient can be considered to have renal progression when there is a decrease in eGFR > 5 ml/min/year or > 10 ml/min in five years. Progression is defined based on two aspects: progression to a higher or more severe category of kidney function impairment (KDIGO stages 1-5) or albuminuria (< 30, 30-299, > 300 mg/g). Progression is also considered as a percentage change from baseline (>25% deterioration in eGFR) or more than a 50% increase in the uACR ratio. However, it should be noted that a recent international consensus document to define renal progression outcomes indicates decreases of 30, 40, 50 or 57% of kidney function as possible surrogates for "progression", depending on factors such as the rate of progression, the choice of initial eGFR starting point or the effect of interventions with acute consequences on eGFR[39].
4. Poorly controlled arterial blood pressure: systolic blood pressure (SBP) > 140 mm Hg and/or diastolic blood pressure (DBP) > 85 mm Hg despite adequate antihypertensive treatment or resistant arterial hypertension (BP ≥ 180/110 mm Hg despite treatment with three antihypertensive drugs at maximum tolerated dose, one of which is a diuretic).
5. Renal anemia with hemoglobin (Hb) of < 10 g/day requiring treatment with erythropoiesis-stimulating agents after having excluded other causes (iron, folate or cobalamin deficiency)[40].
6. Disorders of acid-base balance: primarily uncontrolled metabolic acidosis.
7. Deterioration of kidney function after initiation of renin-angiotensin-aldosterone system (RAAS) inhibitors or iSGLT2: decrease in eGFR, maintained and not reversible equal to

or greater than 30% over baseline or hyperkalemia greater than 5.5 mEq/L, not controllable[41].

8. Doubts about whether there is nondiabetic renal involvement: Potential differential diagnoses will be raised and should be referred to the nephrologist for evaluation, in case of: active urinary sediment (presence of hematuria); absence of diabetic retinopathy; short duration of diabetes over time or well-controlled HbA1c; associated systemic symptomatology that raises suspicion of other pathologies; rapid progression of kidney dysfunction or rapid increase in proteinuria or the presence of nephrotic syndrome.

Recommendation 1.3. Performing a kidney biopsy on people with diabetes should be indicated in the following situations: 1) when there is a rapid increase in proteinuria or nephrotic range proteinuria, 2) proteinuria > 1g/day in 24h urine collection in diabetes with under five years of progress, 3) deterioration of kidney function with and without diabetic retinopathy, 4) alterations in the urinary sediment (dysmorphic red blood cells) not associated with an infectious process (urinary infection), 5) rapid decrease in eGFR in patients with previous stable kidney function or 6) clinical and/or analytical signs of associated immune disease[42,43].

Strength of recommendation: 2D.

Rationale: Some studies have described the following factors associated with nondiabetic kidney lesions: elevated SBP, adequate HbA1c, short duration of diabetes, and absence of retinopathy[44]. Diabetic retinopathy has high sensitivity (87%) and specificity (93%) in predicting more severe histological lesions of diabetic kidney disease. However not all studies show the same results, as some often describe histologic lesions of diabetic kidney disease in the absence of diabetic retinopathy[45].

The presence of a nondiabetic kidney disease can lead to different treatments depending on the underlying pathology and, therefore, to a different prognosis. Progression to advanced CKD is much higher in patients with diabetic kidney disease (44%), compared to mixed forms (18%) or nondiabetic forms (12%). Fiorentino et al[46] published a meta-analysis including 48 studies of kidney biopsies in patients with diabetes, including a total of 4,876 biopsies. It showed a highly variable prevalence of diabetic nephropathy (6.5 to 94%), nondiabetic nephropathies (3 to 83%) and mixed forms (4 to 45%). Their first important conclusion is that the diagnosis of nondiabetic nephropathy is very high, with IgA nephropathy being the most frequent (3-59%). It is important to consider the potential risks and benefits of performing a kidney biopsy for each individual patient before indicating it.

Chapter 2: Metabolic control in people with diabetes and CKD

As primary prevention, strict metabolic control is the most effective intervention to achieve nephroprotection, both in T1D and T2D[47]. The lower the HbA1c value obtained, the lower the risk of albuminuria, as strict metabolic control decreases the risk of the onset and progression of CKD in people with diabetes. In T2D, better glycemic control is also associated with fewer microangiopathic complications and reduced progression of albuminuria: in secondary prevention, tight glycemic control may decrease the progression of albuminuria. HbA1c <7% is recommended on an individualized basis and targets of lower than 6.5% could be considered in patients with a long life expectancy, provided that they can be achieved with glucose-lowering drugs with no risk of hypoglycemia. Similarly, less stringent targets (<8%) are valid in patients with a history of severe hypoglycemia, short life expectancy, or extensive microvascular or macrovascular complications that require treatment with insulin, glinides or sulphonylureas. Nonetheless, the HbA1c target should be adapted to the possible risk of hypoglycemia of the antihyperglycemic drugs prescribed. The use of continuous glucose monitoring hypoglycemia could potentially prevent hypoglycemia.

Lifestyle interventions must be an important part of care for people with diabetes and CKD and should be reinforced, as low sodium intake, physical exercise and smoking cessation are cornerstones of treatment. In any case, most patients will need dietary advice and selected drugs for a comprehensive approach to the disease.

Recommendation 2.1. Patients with T2D and CKD should be treated with a sodium-glucose cotransporter-2 inhibitor (SGLT2i) and, if necessary, additional pharmacological treatment required to improve glycemic control (Table S2.1).

Strength of recommendation: 1B.

Rationale: In recent years, the emergence of SGLT2i has represented a major leap forward in the evidence base for cardiorenal protection in CKD. SGLT2i should be used as the first line of therapy for most of the population considering the eGFR (Figure 1), as SGLT2i have proven to decrease CKD onset, progression, and major adverse cardiovascular events (MACE) in patients with T2D, irrespective of their effect on glycemic control.

SGLT2i decrease hyperglycemia by increasing urinary glucose excretion, since the SGLT2 cotransporter is responsible for 90% of glucose reabsorption in the proximal tubule. SGLT2i were first found to have cardiovascular and kidney-protective effects in cardiovascular safety trials, in which nephroprotection was a secondary endpoint. In April 2019, the CREDENCE

study[48] was published. It was the first clinical trial to investigate the effects of SGLT2i on patients with DM and CKD (eGFR ≥30 ml/min/1.73 m^2 and albuminuria ≥300 mg/g) with primary kidney targets. Canagliflozin decreased the incidence of kidney events (advanced CKD, doubling of serum creatinine, or renal or cardiovascular death) by 30%. The magnitude of the benefit caused the trial to stop prematurely. The DAPA-CKD trial[49] (a study to evaluate the effect of dapagliflozin on kidney outcomes and cardiovascular mortality in patients with chronic kidney disease) enrolled participants with and without T2D, demonstrating cardiorenal benefits in both groups. EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)[50] studied the effect of another SGLT2i, empagliflozin, and demonstrated similar results in a wider CKD population, thus confirming the benefit of SGLT2 inhibition on the risk of progression of kidney disease or death from cardiovascular causes in diabetic and nondiabetic CKD in a wider spectrum of patients. This study included patients without albuminuria, previously underrepresented in most of the trials. It showed that SGLT2i agents have evidence-based benefits in reducing the rate of progression of CKD to kidney failure. In summary, SGLT2i should be prescribed to eligible patients to address the global burden of diabetic kidney disease, CKD and its cardiovascular complications independently of glycemic control, as the improvement in HbA1c is quite modest in patients with low eGFR (Table 2).
This guideline recommends the use of SGLT2i as nephroprotective agents in patients with T2D and an eGFR >20 ml/min/1.73 m^2, independently of the use of metformin. SGLT2i should be continued until end-stage kidney disease (dialysis or kidney transplant). Given their mechanism of action, kidney and cardiovascular protective effects persist even when the GFR decreases < 45 ml/min/1.73 m^2 where the effect on lowering glycemia is minimal.

Recommendation 2.2. Glucagon-like peptide-1 receptor agonists are recommended as additional pharmacological treatment, as they have proven cardiovascular benefit and, recently, kidney benefit in terms of CKD progression in people with T2D (Tables S2.2-S2.10).
Strength of recommendation: 1B.
Rationale: GLP1RA provide cardiovascular protection in patients with CKD. Moreover, both SGLT2i and GLP1RA have proven cardio-kidney-metabolic benefits both in patients with or without metformin[51] (GLP1RA (mainly semaglutide) have proven CV and kidney benefits. In addition, they are safe in patients with CKD, even with an eGFR as low as 15 ml/min/1.73m^2. Current GLP1RA are GLP-1 analogs, which are gut-derived incretin hormones that promote insulin secretion by stimulating GLP1 receptors and decrease glucagon secretion after a meal by stimulating pancreatic GLP1 receptors. They induce weight loss, increase satiety sensation

and initially slow gastric emptying. GLP1ra have also proven to lower blood pressure and albuminuria in RCT. Preclinical studies suggest that GLP-1RA regulate kidney inflammation. GLP-1RA inhibited AGE-stimulated IL-6 and TNF-α production in mesangial cells and diabetic rats treated with GLP-1RA showed inhibition of renal NF-κB activation, decreasing proinflammatory factors (TNF-α, IL-1β and CCL-2) and reduced oxidative stress. Information on GLP1ra anti-inflammatory actions in CKD is limited. In this regard, REMODEL[52] will evaluate anti-inflammatory mechanisms of kidney protection by semaglutide[53].

Cardiovascular safety trials such as REWIND (dulaglutide)[54], LEADER (dulaglutide)[55], SUSTAIN6 (semaglutide)[56], HARMONY (albiglutide)[57] and AMPLITUDE (efpeglenatide)[58] demonstrated a reduction in risk of CVD events, even in patients with decreased kidney function. In major kidney secondary outcomes, these trials have shown a decrease in albuminuria and lower glomerular filtration loss, mostly by decreasing albuminuria in populations with T2D and CKD. However, changes in glucose control, weight or blood pressure only account for 10-25% of kidney benefits, suggesting that these drugs have additional effects on kidney protection. In this regard, ongoing RCT are trying to address the mechanisms for kidney protection in diabetic kidney disease[52] with subcutaneous semaglutide (Table 3).

The FLOW study (Evaluate Renal Function with Semaglutide Once Weekly)[59] is the first GLP1RA clinical trial with a kidney endpoint as a primary outcome using subcutaneous semaglutide at a dose of 1mg once weekly. It evaluated the effect of semaglutide in 3533 participants with T2D, eGFR 25-75 ml/min/1.73 m^2 and albuminuria 100-5000 mg/g. It prematurely stopped after the interim analysis demonstrated efficacy. In terms of metabolic control, semaglutide had an increased effect on lowering HbA1c (-0.87% vs. -0.06%, estimated difference -0.81 (95%CI -0.9 to 0.72%).

Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and GLP1 receptors (twincretin). Tirzepatide is currently the most effective drug in glycemic control and weight loss in patients with type 2 diabetes, showing superiority in clinical trials over semaglutide 1 mg or basal insulins and without risk of hypoglycemia. Despite this evidence, the drug has not yet received FDA (Food and Drug Administration) approval. It also improves other cardiorenal risk factors (blood pressure, LDL cholesterol and albuminuria) in populations with type 2 diabetes or obesity. The SURPASS-4 trial[60] studied the effect of tirzepatide on participants with T2D and high cardiovascular risk. It improved a prespecified secondary composite kidney endpoint (eGFR decline ≥40% from baseline, renal death, kidney failure, or new onset albuminuria > 300 mg/g) when compared to insulin glargine, although the

risk reduction was mainly driven by albuminuria of > 300 mg/g reduction. Tirzepatide also slowed a decline of eGFR, but to our knowledge, there are no RCTs evaluating this drug in a trial with kidney endpoints as primary outcomes so far.

DPP-4 inhibitors modestly lower blood glucose with a low risk of hypoglycemia and can be used in fragile patients or those with intolerance or contraindications to GLP-1RAs, but have not demonstrated an improvement in kidney or cardiovascular outcomes. They must not be used in combination with GLP1RA.

Metformin must not be used in patients with eGFR below 30 ml/min/1.73 m^2 due to the risk of secondary lactic acidosis and must be used cautiously in patients with eGFR between 30-44 ml/min/1.73m^2, reducing the drug to a maximum of 1000 mg/day. DPP-4 inhibitors, GLP-1RAs and SGLT2i can be prescribed in patients with advanced CKD. The antihyperglycemic effect of the first two classes is maintained in this population and although this effect is partially lost with SGLT-2i, they are also recommended for their CV and kidney benefit.

Treatment with sulfonylureas or glinides is not recommended in patients with lower GFR as they can induce hypoglycemia.

Insulin and high doses of glitazone should be avoided, where possible, in people with CKD and T2DM, as this decreases natriuresis and increases fluid retention[61]. If treatment with insulin is required, the dose should be adjusted and lowered in the event of CKD progression because of its delayed renal elimination[61,62]. If the patient requires insulin, basal insulin therapy with insulin analogs is recommended, due to the lower risk of hypoglycemia. In a CV safety trial (DEVOTE), insulin degludec showed a lower risk of severe hypoglycemia versus glargine U100 in patients with DM2 and high CV risk (including patients with CKD)[63].

In light of new evidence and results in kidney and cardiovascular protection, recommendations cannot only be made on glycemic control and would go beyond metabolic intervention, since new therapeutic groups act on several aspects.

Table 4 and Figure 1 summarize the key points about the treatment of people with diabetes and chronic kidney disease.

Chapter 3: Blood pressure control in people with diabetic kidney disease

Recommendation 3.1. We recommend blood pressure (BP) control with a target systolic blood pressure (SBP) of <130 mm Hg, when tolerated, in patients with diabetic kidney disease. Otherwise, a general target of SBP < 140 mm Hg is recommended (Table S3.1).

Strength of recommendation: 2C.

Rationale: There is evidence from the SPRINT trial that intensive blood pressure control, defined as targeting systolic blood pressure <120mm Hg, reduces cardiovascular events and all-cause mortality in CKD patients (64). However, the SPRINT trial exclusively involved participants who did not have diabetes and the benefits observed in the SPRINT trial are not evident in studies involving patients with diabetes. Specific evidence on the blood pressure control target in patients with chronic kidney disease and diabetes is very limited, and the evidence is generated from clinical trials that include patients with diabetes mellitus, both with and without kidney disease.

Upon reviewing the ACCORD BP (57), ADVANCE (58) and ABCD (59) trials, which involved patients with diabetes with and without CKD, intensive control of blood pressure might lead to minimal or no variation in all-cause and cardiovascular mortality compared to standard blood pressure control.[63-65] Some studies examined cardiovascular events[65,66], and intensive blood pressure control may not be associated with better outcomes. When cardiovascular events were evaluated separately, intensive blood pressure control in patients with CKD and diabetes may result in little to no difference in stroke[66-68] and heart failure[66-68]. However, such control might reduce the risk of myocardial infarction[57-59], although the quality of evidence is moderate. The ACCORD BP trial did demonstrate a significant reduction in stroke in the intensive blood pressure control group.

Therefore[63-65], to generate recommendations for CKD and T2D, certain trial characteristics must be taken into consideration. We must consider that most of the patients included in these trials presented albuminuria as a manifestation of kidney disease. In most of them, the mean creatinine levels were normal and with well-preserved eGFR[65-67]. In the ACCORD BP trial, only patients with T2D were included, and individuals with a serum creatinine level greater than 1.5 mg/dL (132.6 µmol/L) were excluded. In the ADVANCE trial, patients might present albuminuria, although this was not mandatory, and the mean serum creatinine was 87 µmol/L in both groups. The ABCD trial included normotensive patients with diabetes without hypertension treatment and the mean creatinine clearance was >80ml/min in both groups. Concerning kidney disease, patients were excluded if they were receiving dialysis and/or had a serum creatinine level greater than 3 mg/dL. In Estacio et al.[65] 129 patients with type 2 diabetes and BP ranging from 140/80 to 90 mm Hg without significant albuminuria were randomized to intensive BP management (diastolic BP target of 75 mm Hg) using valsartan, and moderate BP management (diastolic BP between 80 and 90 mm Hg), initially with a placebo.

In patients with chronic kidney disease (CKD) and diabetes, blood pressure management is particularly crucial due to the compound risk of cardiovascular disease and the progression of kidney impairment. Historically, information about blood pressure targets in these populations was provided by a narrower range of clinical studies that may not fully encapsulate the complexity of patient profiles seen today, such as the increased prevalence of obesity and metabolic syndrome. The introduction of new pharmacotherapeutic agents, including SGLT2 inhibitors, GLP-1 receptor agonists and mineralocorticoid receptor antagonists, has significantly broadened treatment options. These agents offer benefits beyond blood pressure reduction, including improved cardiovascular outcomes and slowed CKD progression.

The evolving patient demographics and the availability of these novel therapeutic options highlight the need for contemporary clinical trials. These trials should investigate blood pressure targets tailored to the nuanced needs of CKD and diabetic patients, taking into account the wider spectrum of comorbidities and the potential for improved outcomes with new treatments.

Recommendation 3.2. We recommend starting ACEI or ARB for patients with either hypertension or diabetic kidney disease (Table S3.2, Table S3.3).

Strength of recommendation: 2B.

Recommendation 3.3. Steroidal MRA are probably useful for managing hypertension in patients with eGFR> 30 ml/min/1.73 m2 and serum potassium < 4.8 mmol/L (Table S3.4).

Strength of recommendation: 2D.

Recommendation 3.4. Although nonsteroidal MRA may be helpful in blood pressure control, we do not recommend them for blood pressure management (Table S3.5).

Strength of recommendation: 2B.

Rationale: The different effects of angiotensin II receptor antagonists (ARBs) on blood pressure control compared to angiotensin-converting enzyme inhibitors (ACE inhibitors) are not well-defined[67,68].

Only two RCTs with a low number of participants evaluated this outcome and the authors showed a trend towards better BP control in patients treated with ARBs compared to ACEI[68-72].

In terms of BP control, ARBs can reduce systolic BP, but may produce a slight reduction or no difference in diastolic BP compared to the standard treatment[73-75]. In the RENAAL[73], the

ORIENT[74] and the Irbesartan Diabetic Trial[75], the primary outcome was the kidney outcome, a composite of doubling of the baseline serum creatinine, the onset of end-stage kidney disease, a need for chronic dialysis and/or transplantation and all-cause death. Based on these three RCTs[73-75], ARBs may be beneficial in terms of kidney outcomes compared to standard blood pressure control, despite similar BP control between the groups.

In terms of cardiovascular outcomes, ARBs probably reduce the risk of heart failure and myocardial infarction compared to placebo or standard of care[73,74], but ARBs did not reduce the risk of all-cause mortality[73-75].

Even though the quality of evidence is low due to the serious risk of inconsistency and imprecision, ARB may result in a slightly higher risk of no difference in hyperkalemia compared to standard of care[74,75].

Moreover, evidence regarding the use of steroidal MRA in patients with diabetes and proteinuria is very limited, as only a few small-scale studies[76,77] have analyzed this. Based on 86 patients and with low quality of evidence due to the serious risk of bias and imprecision, steroidal MRA may reduce both SBP and DBP, and may reduce uACR compared to standard of care[75-77].

As blood pressure reduction related to nonsteroidal MRA was modest using finerenone in the FIDELIO-DKD study[78] or esaxerenone[79], it was hypothesized that the beneficial effect on cardiorenal outcomes was primarily influenced through non-hemodynamic pathways. The ARTS-DN trial[80] was designed to deepen the effect of finerenone on albuminuria and assessed the effects of the treatment on 24-hour ambulatory BP monitoring in a subset of 240 participants. In this group of patients, 24-hour ambulatory BP monitoring was measured at baseline, 60 days after the start of finerenone and at the last on-treatment visit. These trials suggest that nonsteroidal MRA may reduce SBP and slightly reduce DBP compared to standard of care[77,78].

Regarding adverse events, nonsteroidal MRA probably increases the risk of treatment discontinuation due to side effects, with a moderate quality of evidence (RR 1.25 (1.03 to 1.52))[78,79]. Adding these drugs to a patient already on ACEi/ARB increases the risk of hyperkalemia[78,79], highlighting the importance of regularly monitoring serum potassium levels in these patients.

Recommendation 3.5. The combination of ACEi with ARB or aliskiren therapy in patients with diabetes and CKD should be avoided (Table S3.6 and S3.7, Table S4.4).

Strength of recommendation: 2D.

Rationale: The published evidence regarding the use of aliskiren as an antihypertensive therapy in patients with diabetes and chronic kidney disease is very limited. Two[81,82] out of the three studies analyzed compare the use of this drug with ARB, while in the third study, patients received either aliskiren or ARB[83]. Aliskiren may slightly reduce systolic and diastolic blood pressure compared to standard of care, however the evidence is very uncertain.

Chapter 4: Treatment targeting progression of CKD in people with diabetic kidney disease

Recommendation 4.1. Patients with T2D and CKD with an eGFR ≥20 ml/min/1.73 m^2 should be treated with a sodium-glucose cotransporter-2 inhibitor and continue until end-stage kidney disease (dialysis or kidney transplant) (Table S4.7) (Figure 2).

Strength of recommendation: 1A.

Rationale: Patients with T2D and CKD are at increased risk of progression to kidney failure. Currently, there is consistent evidence to confirm that SGLT2i confers significant kidney protective effects in these patients.

The potential for SGLT2i to modify the risk of CKD progression was first demonstrated by a sub-analysis of the EMPA-REG OUTCOME trial in T2D patients with established cardiovascular disease[84]. Analyses plotting mean eGFR against time showed a reduction in the rate of eGFR decline over time, which resulted in a 46% reduction in the risk of the composite kidney disease progression outcome (ESKD, renal death, and doubling of serum creatinine). Benefit is also seen with canaglifozin[48] or dapaglifozin[85], but not with ertuglifozin[86].

Three subsequent dedicated clinical trials were designed to test the effect of SGLT2i on CKD progression: CREDENCE[48], DAPA-CKD[49] and EMPA-KIDNEY[50]. The results from these studies have definitively confirmed the kidney-protective benefits of SGLT2i in patients with T2D and CKD and in a substudy of DAPA-CKD[87], those who continued with treatment after initiating dialysis had lower mortality levels compared to those who discontinued with it. CREDENCE recruited patients with T2D, an eGFR 30-90 ml/min/1.73m^2 and a uACR of 300-5000 mg/g under treatment with an ACEi or ARB. Canagliflozin reduced the risk of its primary composite outcome (sustained doubling of serum creatinine, ESKD, or death from kidney or cardiovascular causes) by 30% compared to placebo (HR=0.70; 95%CI: 0.59-0.82). Importantly, there was a reduction in the risk of kidney disease progression, including ESKD. The risk of maintenance dialysis, kidney transplantation or renal death was significantly reduced by 28%. DAPA-CKD included people with and without T2D. Kidney-related inclusion criteria were an eGFR 25-75 ml/min/1.73m^2 plus a uACR 200-5000 mg/g and treatment with a stable dose of an ACEi or ARB for ≥4 weeks. Dapagliflozin demonstrated a reduction in the primary composite outcome (sustained 50% decline in eGFR, ESKD, or death from kidney or cardiovascular causes) by 39% compared to placebo (HR=0.61; 95%CI: 0.51-0.72). It must be noted that these relative risk reductions were again evident for the kidney disease progression component of the primary composite. EMPA-KIDNEY recruited a wide

range of participants (with and without T2D) at risk of CKD progression using an eGFR 20-45 ml/min/1.73m² (with no indication regarding uACR) or an eGFR ≥45-<90 ml/min/1.73m^2 plus a uACR ≥200 mg/g (or protein-to-creatinine ratio ≥300 mg/g) as inclusion criteria. EMPA-KIDNEY reported a reduction in the primary composite outcome of kidney disease progression (sustained decrease in eGFR to <10 ml/min/1.73m^2, a sustained decrease in eGFR of ≥40% from baseline, ESKD or death from kidney causes) or death from cardiovascular causes, by 28% (HR=0.72; 95%CI: 0.64-0.82). Similar effects were also observed for the individual components of kidney disease progression.

A unified definition of kidney disease progression was adopted in a comprehensive meta-analysis of large randomized clinical trials with SGLT2i as a sustained eGFR reduction ≥50% from randomization, kidney failure, or death from kidney failure[88]. The results demonstrated an overall 37% reduction in risk of kidney disease progression (HR=0.63, 95%CI 0.58-0.69), which was similar among participants with and without T2D. In subjects with diabetes, the HR for kidney disease progression outcome was 0.64 (95%CI: 0.52-0.79) in CREDENCE, 0.57 (95%CI: 0.45-0.73) in DAPA-CKD and 0.55 (95%CI: 0.44-0.71) in EMPA-KIDNEY.

Recommendation 4.2. We recommend that treatment with an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB) should be initiated in patients with diabetes, hypertension, and albuminuria and that these medications be titrated to the highest approved tolerated dose (Tables S4.1-3).

Strength of recommendation: 1A.

Rationale: The cornerstone of CKD management in patients with T2D has been the use of renin-angiotensin system inhibitors (RAS). Several randomized trials demonstrated the reduction in CKD progression and the risk of kidney outcomes in high-risk subjects with moderately or severely increased albuminuria.

The IRMA-2 (Irbesartan in Patients With Type 2 Diabetes and Albuminuria)[89] and the INNOVATION (The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy)[90] clinical trials were designed to test whether RAS blockade reduced the risk of progression of CKD in diabetes, defined as the development of severely increased albuminuria (uACR >300 mg/g). These studies enrolled patients with T2D and moderately increased albuminuria (uACR between 30 and 300 mg/g). The IRMA-2 study showed that treatment with irbesartan, an angiotensin-receptor blocker (ARB), was associated with a dose-dependent reduction in the risk of progression of CKD. The highest dose of 300 mg/day was associated with an almost three-fold risk reduction at two years of follow-up, a

result that was independent of the blood pressure–lowering effect of irbesartan. On the other hand, a lower transition rate to overt nephropathy with respect to placebo after one year of follow-up was observed in the INNOVATION trial with the ARB telmisartan. In this study, the beneficial effect of telmisartan in slowing progression to overt nephropathy was also independent of blood pressure reduction with telmisartan.

Regarding the benefit of RAS blockade in patients with severely increased albuminuria, this was tested in two clinical trials that enrolled patients with urine albumin excretion ≥ 300 mg/day. In the RENAAL trial (The Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus with the Angiotensin II Antagonist losartan)[73], 1513 patients were randomly assigned to receive losartan or placebo once daily, along with conventional antihypertensive therapy as needed (excluding ACEi and ARB). The primary composite endpoint of doubling of serum creatinine concentration, end-stage kidney disease, or death was reduced by 16% in patients under treatment with losartan according to the intention-to-treat analysis (P=0.02), an effect that remained after adjustment for blood pressure. The individual components of the primary composite endpoint that assessed the progression of kidney disease showed a significant benefit, with a reduction in the risk of doubling of serum creatinine concentration by 25% (P<0.01) and in the risk of end-stage kidney disease by 28% (P=0.002) in the losartan group compared to the placebo group. In addition, among the patients who continued to receive their assigned study treatment according to the per-protocol analysis, losartan conferred a 22% reduction in the risk of the primary composite endpoint (P<0.01)[91].

Unlike RENAAL, the Irbesartan Diabetic Nephropathy Trial (IDNT) included an active comparator in addition to a placebo. This study recruited 1715 patients with T2D aged between 30 and 70 years, with hypertension and urinary protein excretion ≥ 900 mg/24 hours, who were randomized to receive treatment with irbesartan, amlodipine, or placebo[75]. The primary endpoint was the composite of doubling of the baseline serum creatinine, the onset of ESRD (initiation of dialysis, kidney transplantation, or a serum creatinine concentration ≥ 6.0 mg/dL), or death from any cause. The relative risk of the primary endpoint in the placebo and amlodipine groups did not differ significantly. However, treatment with irbesartan was associated with a 20% lower risk of the primary composite endpoint than the placebo group (P=0.02) and 23% lower than that in the amlodipine group (P=0.006). The risk of doubling of serum creatinine concentration was 33% lower in the irbesartan group than in the placebo group (P=0.003) and 37% lower in the irbesartan group than in the amlodipine group (P<0.001). The relative risk of ESRD in patients receiving irbesartan was 23% lower than that in both other groups (P=0.07 for both comparisons). These differences were independent of the blood

pressure reached. The serum creatinine concentration increased 24% more slowly in the irbesartan group than in the placebo group (P=0.008) and 21% more slowly than in the amlodipine group (P=0.02).

The evidence does not demonstrate proven differences in outcomes or superior efficacy when comparing ACEi to ARB treatment. Thus, either agent can be used when treating patients with T2D and CKD, and the choice between ACEi and ARB will depend on other factors (patient preferences, cost, side-effect profile, etc.)[92,93].

Recommendation 4.3. Patients with T2D, an eGFR ≥25 ml/min/1.73 m2, and increased albuminuria (uACR > 100 mg/g) on a stable maximal tolerated dose of RAS inhibitors should be treated with a GLP1RA with proven kidney benefit (Table S4.8).

Strength of recommendation: 1A.

Rationale: There is new evidence for the kidney-protective properties of the GLP1RA semaglutide. In a *post hoc* analysis of the SUSTAIN 6/PIONEER 6 trials including pooled data from 6480 participants at high cardiovascular risk, there was a significant difference in the estimated treatment effect (semaglutide versus placebo) on eGFR slope: 0.59 ml/min/1.73 m^2 (95% CI: 0.29 - 0.89)[56,94]. This effect was numerically largest in subjects with an eGFR between 30 and 60 ml/min per 1.73 m^2 [1.06 ml/min/1.73 m^2 (95% CI: 0.45 - 1.67)], but without significant interaction for treatment effect by subgroup.

This suggestion that semaglutide may reduce the rate of eGFR decline and have kidney-protective benefits has been evaluated in a dedicated clinical trial investigating the effects of once-weekly subcutaneous semaglutide (1 mg) in a population of patients with T2D and CKD at high risk of kidney disease progression. The FLOW study[59] that prematurely stopped after the interim analysis demonstrated efficacy after enrolling 3533 adults with T2D and kidney disease (defined by an eGFR of 25 to 75 ml/min/1.73 m^2, with a uACR of greater than 300 to less than 5000 mg/g if the eGFR was ≥ 50 ml/min/1.73 m^2 or a uACR > 100 and < 5000 mg/g if the eGFR was between 25 and less than 50 ml/min/1.73 m^2) and a stable maximal labeled dose or the maximal dose without unacceptable side effects of RAS inhibitors.

The results demonstrated a 24% relative risk reduction of the primary composite outcome in the semaglutide group with respect to the placebo group (HR=0.76; 95% CI: 0.66 to 0.88; P=0.0003), with similar results for a composite of the kidney specific components of the primary outcome (HR=0.79; 95% CI: 0.66 to 0.94). In addition, there were three key confirmatory secondary outcomes, which were assessed using a prespecified hierarchical testing approach: the annual rate of change in eGFR from randomization to the end of the study

(total eGFR slope); a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes (MACE – major adverse cardiovascular events); and death from any cause. All the results for these confirmatory outcomes favored semaglutide: the total eGFR slope showed a lower reduction of 1.16 ml/min/1.73 m^2/year (P<0.001); the risk of MACE was 18% lower (HR=0.82; 95% CI: 0.68 to 0.98; P=0.029); and the risk of death from any cause was 20% lower (HR=0.80; 95% CI, 0.67 to 0.95; P=0.01).

Recommendation 4.4. We suggest a nonsteroidal mineralocorticoid receptor antagonist with proven kidney or cardiovascular benefit for patients with T2D, an eGFR ≥25 ml/min/1.73 m^2, normal serum potassium concentration (K ≤ 5.1mmol/L), and albuminuria (uACR ≥30 mg/g) despite the maximum tolerated dose of RAS inhibitor (Table S4.6).

Strength of recommendation: 1A.

Rationale: A nonsteroidal MRA can be added to first-line therapy for patients with T2D and high residual risk of kidney disease progression, as evidenced by persistent albuminuria (uACR ≥30 mg/g). The choice of a nonsteroidal MRA should prioritize agents with documented kidney or cardiovascular benefits. Finerenone is currently the only nonsteroidal MRA with proven clinical kidney and cardiovascular benefits.

The initial evidence for the clinical effectiveness of finerenone in improving kidney function and slowing the worsening of CKD comes from the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD) trial[78]. In this phase 3, randomized, double-blind, multicenter, placebo-controlled trial, 5734 adults with T2D and CKD were randomly assigned to receive finerenone or a placebo. Eligible patients had an eGFR of between 25 and less than 60 ml/min/1.73m^2, a uACR of between 30 and less than 300 mg/g, and diabetic retinopathy, or they had an eGFR of between 25 and less than 75 ml/min/1.73m^2, a uACR of 300 to 5000. All the participants were treated with optimized RAS blockade before randomization. The primary outcome was the time to the first event of a composite endpoint consisting of a sustained decrease of at least 40% in the eGFR from baseline over at least four weeks, the onset of kidney failure (defined as an eGFR of less than 15 ml/min/1.73m^2 or ESKD (initiation of long-term dialysis (for ≥90 days) or kidney transplantation)), or renal death. Results showed that the incidence of the primary composite outcome was significantly lower in the finerenone group than in the placebo group (17.8% vs. 21.1%, respectively), resulting in an HR=0.82; 95% CI: 0.73 to 0.93; P=0.001). Additionally, the incidences of the primary outcome components were consistently lower with finerenone than with placebo.

Additional clinical evidence was provided by the FIGARO-DKD (Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease)[95] and FIDELITY (Finerenone in Chronic Kidney Disease and Type 2 Diabetes: Combined FIDELIO-DKD and FIGARO-DKD Trial Programme Analysis)[96] studies. The FIGARO study included adult patients with T2D and CKD stage 1 or 2 (eGFR ≥ 60 ml/min/1.73m^2) with a uACR of 300 to 5000 mg/g or CKD stage 2 to 4 (eGFR 25-90 ml/min/1.73m^2) with a uACR of between 30 and less than 300 mg/g. Similarly to FIDELIO-DKD, RAS blockade was optimized in all patients before randomization. The primary outcome was cardiovascular (a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure), whereas the first secondary outcome was a composite of a sustained decrease in the eGFR ≥ 40% from baseline, kidney failure, or death from kidney causes. A total of 7437 patients underwent randomization. The incidence of the primary outcome was significantly lower in the finerenone group (HR=0.87; 95% CI: 0.76 to 0.98; P=0.03), with the benefit driven primarily by a lower incidence of hospitalization for heart failure. The incidence of the main secondary outcome was 9.5% in the finerenone group and 10.8% in the placebo group (HR= 0.87; 95% CI: 0.76 to 1.01), although the difference did not reach statistical significance. Analysis of the components of the first secondary outcome showed an incidence of end-stage kidney disease of 0.9% in the finerenone group and of 1.3% in the placebo group (HR=0.64; 95% CI: 0.41 to 0.99). The kidney composite outcome of kidney failure, a sustained decrease from baseline of at least 57% in the eGFR, or death from kidney causes occurred in 2.9% of patients in the finerenone group and in 3.8% in the placebo group (HR=0.77; 95% CI: 0.60 to 0.99).

Lastly, the FIDELITY study was a prespecified pooled analysis from FIDELIO-DKD and FIGARO-DKD aimed to provide more robust estimates of finerenone efficacy and safety across the spectrum of patients with CKD and T2D. This study included a total of 13171 subjects and showed that patients receiving finerenone had a lower risk for the composite cardiovascular outcome of time to cardiovascular death, nonfatal MI, nonfatal stroke or hospitalization for HF (HR=0.86; 95%CI: 0.78–0.95) and the composite kidney outcome of time to first onset of kidney failure, sustained eGFR decrease ≥57% or renal death (HR=0.77; 95%CI: 0.67–0.88). Among the components of the kidney outcome, a 20% reduction in the risk for ESKD (HR=0.80; 95%CI: 0.64–0.99) was noted.

Recommendation 4.5. We suggest maintaining a protein intake of 0.6-0.8 g/kg (weight)/day for patients with diabetes and CKD not treated with dialysis (Table S4.12).

Strength of recommendation: 2C.

Rationale: Early animal studies demonstrated that high protein intake contributes to the development of increased intraglomerular pressure and glomerular hyperfiltration, which in turn leads to tubulointerstitial damage and glomerulosclerosis[97]. On this basis, reduced dietary protein intake has been demonstrated to reduce glomerular hyperfiltration and slow progression of CKD compared to a standard dietary protein intake of 0.8 g/kg/day[98-100]. However, these studies mainly included patients with advanced CKD and subjects without diabetes[101], while there is a lack of clinical studies that compare different levels of protein content in the diet in patients with diabetes and CKD. Although two meta-analyses show a small beneficial impact of LPD on eGFR decline[102,103], the high heterogeneity of the studies (type of diabetes, stages of CKD, types of interventions, duration, and adherence to recommendations) does not make it possible for strong recommendations to be made. Thus, we consider it advisable to apply the KDIGO guidelines regarding daily protein intake to patients with diabetes and CKD not receiving dialysis (0.6-0.8 g/kg/day), whereas a dietary protein intake > 1.2 g/kg body weight per day should be advised for diabetic CKD patients receiving dialysis[104].

Lastly, it is important to note the potential dangers of an excessive reduction in protein intake in people with diabetes to less than 0.6 g/kg/day. This protein restriction may result in a decrease in quality of life, increasing risk for episodes of hypoglycemia, inadequate weight loss and malnutrition.

Table 4 summarizes the key points concerning the management of T2D patients with CKD.

Chapter 5: Antiplatelet or anticoagulant therapy in people with diabetes and CKD

Recommendation 5.1. Patients with T1D or T2D and CKD with established atherosclerotic cardiovascular disease should be treated with low-dose aspirin (75-100 mg/day) for secondary prevention.

Strength of recommendation: 1B.

Recommendation 5.2. Dual antiplatelet therapy (with low-dose aspirin and a $P2Y_{12}$ inhibitor) is recommended after acute coronary syndrome or percutaneous coronary intervention, followed by single antiplatelet therapy with a duration determined by a multidisciplinary team based on the benefit-risk profile.

Strength of recommendation: 1B.

Recommendation 5.3. In patients with T1D or T2D and CKD and a previous non-cardioembolic ischemic stroke or transient ischemic stroke, the long-term use of antiplatelet therapy to reduce the risk of recurrent stroke is recommended.
Strength of recommendation: 1C.

Recommendation 5.4. Dual antiplatelet therapy (with low-dose aspirin and a $P2Y_{12}$ inhibitor) after acute non-cardioembolic ischemic stroke/transient ischemic attack in patients with T1D or T2D and CKD followed by single antiplatelet therapy should be considered.
Strength of recommendation: 2C.

Recommendation 5.5. There is no clear evidence of a favorable benefit-risk profile of low-dose aspirin for primary prevention of atherosclerotic cardiovascular disease in patients with T1D or T2D and CKD stage 3 or higher to recommend its prescription.
Strength of recommendation: 2C.
Rationale: Low-dose aspirin (75-100 mg/day) should be prescribed for secondary prevention of atherosclerotic cardiovascular disease among patients with diabetes and CKD and atherosclerotic cardiovascular disease, according to all guidelines and the available evidence[105-109]. The recent *post hoc* analysis of the ADAPTABLE trial among the subset of patients with diabetes showed that there were no differences in terms of efficacy and safety of low dose (81 mg/day vs. 325 mg/day) or type (enteric-coated vs. uncoated) of aspirin, although a reduction in bleeding with enteric-coated aspirin could not be excluded. In this study, patients with diabetes showed a higher risk of bleeding than nondiabetics, although no subanalysis according to the baseline kidney function was reported[110].
Dual antiplatelet therapy (low-dose aspirin plus a $P2Y_{12}$ inhibitor) is recommended for patients after acute coronary syndrome or percutaneous coronary intervention as per clinical guidelines[2,4,5]. However, the optimal duration of dual antiplatelet therapy in patients with diabetes and CKD, especially among those with advanced CKD (eGFR < 30 ml/min/1.73 m2), needs to be carefully evaluated as they are at higher risk of bleeding[111,112]. Patients with diabetes and CKD and reduced eGFR experience a higher risk of cardiovascular events after acute coronary syndrome or percutaneous coronary intervention[111,113-115], as well as a higher risk of bleeding[111,113-115], but few trials have analyzed the efficacy and safety of dual antiplatelet therapy in this population. In a *post hoc* analysis of the PLATO (Platelet Inhibition and Patient Outcomes) trial, which randomized patients with acute coronary syndrome to ticagrelor versus clopidogrel, ticagrelor reduced the incidence of the composite primary endpoint

(cardiovascular death, myocardial infarction, or stroke within twelve months) consistently across subgroups of patients with diabetes and/or CKD, but with an increased absolute risk reduction in DM+/CKD+, while there was no increased risk of major bleeding with ticagrelor compared to clopidogrel in the subgroup of patients with DM+/CKD+[115]. In a *post hoc* analysis of the GLOBAL-LEADERS trial, the effects of one-month dual antiplatelet therapy followed by 23-month ticagrelor monotherapy versus twelve-month dual antiplatelet therapy followed by twelve-month aspirin alone were analyzed according to DM/CKD status in patients undergoing percutaneous coronary intervention. Among patients with DM+/CKD+, ticagrelor monotherapy was not associated with lower rates of all-cause death, new Q-wave myocardial infarction, or major bleeding complications. Nonetheless, it was associated with lower rates of the patient-oriented composite endpoint (composite of all-cause death, any stroke, site-reported myocardial infarction, and any revascularization), and net adverse clinical events (a combination of patient-oriented composite endpoint with Bleeding Academic Research Consortium type 3 or 5 bleeding events). However, the authors stated that these findings should be considered hypothesis-generating[113]. In a *post hoc* analysis of the Ticagrelor with Aspirin or Alone in High-Risk Patients after Coronary Intervention (TWILIGHT) trial, after three-month dual antiplatelet therapy with ticagrelor and aspirin post-percutaneous coronary intervention, event-free patients were randomized to either aspirin or placebo in addition to ticagrelor for twelve months. The authors concluded that in DM+/CKD+ patients, ticagrelor monotherapy reduced the risk of bleeding without significantly increasing ischemic events compared to ticagrelor plus aspirin. However, this population had numerically higher rates of ischemic events[114]. Similarly, the Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study (THEMIS) trial found that in patients with stable coronary artery disease and DM but no history of myocardial infarction or stroke, combining ticagrelor with aspirin lowered ischemic event risks. Nonetheless, an increase in bleeding complications offset this benefit. Despite the lack of interaction by eGFR, patients with reduced eGFR tended to derive lower benefits in terms of efficacy and an increased risk of bleeding[116]. In the subgroup of patients from the THEMIS trial who had undergone previous percutaneous coronary intervention, the combination of ticagrelor and aspirin was found to have a net clinical benefit. However, despite no significant interaction, the benefits were lower among those with CKD stage 3 or higher[117]. In the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54 (PEGASUS-TIMI 54) trial, adding ticagrelor to aspirin reduced the risk of recurrent ischemic events, including cardiovascular and coronary heart disease death in

patients with DM and prior myocardial infarction, but the combination was also associated with a higher risk of TIMI major bleeding[118], and no subanalysis was performed on kidney function. In the CHARISMA trial, patients with established atherosclerotic cardiovascular disease (symptomatic) or multiple risk factors for atherosclerotic disease (asymptomatic), but without active acute coronary syndrome, were randomly assigned to receive either clopidogrel plus aspirin or placebo plus aspirin. Patients with diabetes and nephropathy who received clopidogrel did not have an increased risk of bleeding, but they experienced a significantly higher risk of CV and overall mortality compared to the placebo group. This suggests that clopidogrel may be harmful in patients with diabetes and CKD[119].

Similarly, in stroke prevention guidelines among patients with a recent non-cardioembolic stroke/transient ischemic attack, the dual antiplatelet therapy strategy with aspirin and clopidogrel is recommended for 21 days, while dual antiplatelet therapy for longer than three months is discouraged[106,107,120]. In The Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and ASA for Prevention of Stroke and Death (THALES trial) among patients with a mild-to-moderate acute non-cardioembolic ischemic stroke or transient ischemic attack who were not undergoing intravenous or endovascular thrombolysis, the risk of the composite of stroke or death within 30 days was lower with ticagrelor–aspirin than with aspirin alone, however there were no differences in incidence of disability between the two groups and severe bleeding was more frequent with ticagrelor. Furthermore, in the analysis of subgroups, the efficacy endpoint appeared to be negligible among patients with diabetes, and no analysis was performed on eGFR[121].

Concerning the long-term secondary prevention of ischemic stroke in patients with diabetes and CKD, we found no evidence from randomized controlled trials, and we suggest following the guidelines for the general population recommending the use of antiplatelet agents to reduce the risk of stroke recurrence[106,107].

Although some guidelines state that aspirin may be considered for primary prevention among high-risk individuals including patients with DM, based on the higher risk of atherosclerotic cardiovascular disease[2,4,5], this should be balanced against their increased risk for bleeding, including platelet dysfunction associated with reduced eGFR[122]. The ASCEND (A Study of Cardiovascular Events iN Diabetes) trial randomized patients with diabetes and no evident cardiovascular disease to 100 mg daily aspirin or placebo. During a mean follow-up of 7.4 years, there was a significant 12% reduction in the primary efficacy endpoint but an increase in major bleeding events in the aspirin group, where most cases were gastrointestinal and others extracranial bleeding. Thus, it was concluded that the absolute benefits were largely

counterbalanced by the bleeding hazard, with a number needed to treat and needed to harm (NNT/NNH) ratio of 0.8[123]. However, no *post hoc* analysis of this study stratified by the presence of CKD has been reported. Among patients with diabetes and CKD, there is no strong evidence for a favorable benefit-risk profile from results in *post hoc* analysis of randomized controlled trials. The Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) trial was a prospective, randomized, open-label trial that enrolled patients with T2D without a history of atherosclerotic cardiovascular disease (n=2539). The primary endpoint was a composite of sudden death: death from coronary, cerebrovascular and aortic causes; nonfatal acute myocardial infarction; unstable angina; newly developed exertional angina; nonfatal ischemic and hemorrhagic stroke; transient ischemic attack; or nonfatal aortic and peripheral vascular disease. After adjusting several variables, low-dose aspirin did not significantly reduce the primary endpoint in patients with an eGFR <60 ml/min/1.73 m^2 [124], which was confirmed in the ten-year follow-up of the study (JPAD2[125]) in the subset of patients with an eGFR <60 ml/min/1.73 m^2. However, it increased the risk of gastrointestinal bleeding in the whole population. More recently, the International Polycap Study 3 (TIPS-3) randomized patients to aspirin (75 mg/day) or placebo in primary prevention, although aspirin did not reduce the rate of cardiovascular death, myocardial infarction, or stroke in the whole population. Patients with diabetes and those with eGFR < 60 ml/min/1.73 m^2 tended to show a benefit (although the p for interaction was nonsignificant, as the number of patients with reduced eGFR was only 17.2% of the population and no *post hoc* analysis was conducted on patients with diabetes and reduced eGFR)[126,127]. Therefore, there is limited evidence for the benefit of low-dose aspirin in terms of efficacy and safety for the primary prevention of atherosclerotic cardiovascular disease in patients with diabetes and CKD stage 3 or higher.

One limitation of these studies is that patients with advanced CKD or on dialysis were excluded, limiting the generalization of the results to this population.

According to the new 2024 American Diabetes Association (ADA) guidelines, the combination of aspirin plus low-dose rivaroxaban should be considered in patients with diabetes and stable coronary artery disease and/or peripheral artery disease and low bleeding risk to prevent major adverse limb and cardiovascular events[105] based on the positive results of the COMPASS (patients with diabetes subgroup)[128] and VOYAGER-PAD[129] trials, despite the higher risk of bleeding with this combination. However, no data on efficacy and safety among patients with diabetes and CKD stage 3 or higher have been reported. Still, no interaction in terms of effectiveness and safety by reduced eGFR or diabetes status was observed in the original COMPASS trial[130], but there was a tendency to a lower benefit in patients with diabetes, as

well as a higher risk of bleeding among patients with diabetes and patients with reduced eGFR in the VOYAGER PAD trial[129]. Furthermore, patients with CKD stage 5 or 5D were excluded from these trials, limiting the extrapolation of the results to this subgroup of patients with diabetes and CKD.

Recommendation 5.6. Patients with T1D or T2D and CKD with non-valvular atrial fibrillation should preferably be treated with direct oral anticoagulants versus vitamin K antagonists in patients with CKD stages 1-4 (dabigatran up to stage 3b).

Strength of recommendation: 1B.

Rationale: Atrial fibrillation is the most common arrhythmia worldwide and substantially increases the risk of stroke and thromboembolic events[131]. Both DM and CKD are associated with an increased risk of developing atrial fibrillation as compared to the general population[131-133]. Furthermore, the presence of DM and/or CKD in patients with atrial fibrillation increases the risk of thromboembolic events[134-137], as well as mortality and bleeding risks[137,138].

The most common score used to estimate the thromboembolic risk and indication for oral anticoagulation is the CHA_2DS_2-VASc[131], and DM is one of the score items, therefore most patients with diabetes and CKD will indicate oral anticoagulation. The risk of bleeding under anticoagulation is usually estimated with the HAS-BLED score that includes kidney dysfunction as an item[131].

There are currently two classes of commercially available oral anticoagulants: vitamin K antagonists (warfarin, acenocoumarol, etc.) and direct oral anticoagulants (apixaban, rivaroxaban, edoxaban, and dabigatran). CKD affects the bioavailability and pharmacokinetics of direct oral anticoagulants since they are all, at least partially, excreted by the kidneys (the renal clearance of dabigatran is around 80%, of edoxaban 50%, of rivaroxaban 33%, and of apixaban 27%) and may require dose adjustments in patients with reduced eGFR. Its indication is not recommended in patients with CKD stage ≥ 4 (dabigatran) or CKD stage 5 (edoxaban, rivaroxaban, or apixaban)[139]. No clinical trials evaluated its use in patients with diabetes and CKD. However, *post hoc* analysis or metanalysis of RCTs has demonstrated the efficacy and safety of direct oral anticoagulants versus vitamin K antagonists in patients with diabetes and the CKD population, and both metanalyses found a lower risk of thromboembolic events, intracerebral hemorrhage and death, with similar risk in major bleeding versus vitamin K antagonists until advanced stages of CKD[137,140].

Furthermore, vitamin K antagonists show a shorter time in therapeutic range in CKD that worsens as the disease progresses, which is associated with a greater risk of thromboembolic

and hemorrhagic events[139,141]. In addition, data derived from RCTs with dabigatran and rivaroxaban suggest that direct oral anticoagulants could have a benefit in terms of reducing the progression of CKD[38,39]. In CKD stages 5 and 5D, direct oral anticoagulants and vitamin K antagonists are not recommended[131] because the efficacy and safety in this population are based on a scarce number of RCTs and guidelines give no clear recommendations in this setting[139]. Furthermore, direct oral anticoagulants are not indicated in patients with valvular arrhythmias and/or heart valve prostheses[131].

Recommendation 5.7. Patients with T1D or T2D and CKD with venous thromboembolism should preferably be treated with direct oral anticoagulants over vitamin K antagonists in patients with CKD stages 1-4 (dabigatran up to stage 3b).

Strength of recommendation: 2C.

Rationale: Venous thromboembolism, which includes deep vein thrombosis and pulmonary embolism (PE), is also an indication of anticoagulation[142,143]. There is an increased risk of venous thromboembolism both in patients with diabetes[144] as well as in those with CKD[145], where the risk of venous thromboembolism increases as kidney function declines[145]. Furthermore, diabetes mellitus and CKD are risk factors for recurrent venous thromboembolism[44,45]. Among deep vein thrombosis, unprovoked deep vein thrombosis refers to venous thrombosis in the absence of identifiable risk factors. Similarly, provoked deep vein thrombosis occurs in the presence of such risk factors, which can be further classified as transient or persistent. The provoked or unprovoked nature of deep vein thrombosis, as well as the chronicity of any provoking risk factors (transient or persistent), has significant prognostic and treatment implications, as recurrence risk and anticoagulation regimens differ accordingly[142]. Deep vein thrombosis requires anticoagulation with unfractionated heparin, fondaparinux, low molecular weight heparins, direct oral anticoagulants, or vitamin K antagonists. Among direct oral anticoagulants, apixaban and rivaroxaban can be started without initial parenteral anticoagulation[142].

Among patients with pulmonary embolism, those with high risk require treatment with unfractionated heparin in the acute phase. Nonetheless, among those with intermediate or low risk when oral anticoagulation is indicated, a direct oral anticoagulant (dabigatran, rivaroxaban, apixaban, or edoxaban) is preferred over vitamin K antagonists[41]. Direct oral anticoagulants provide similar efficacy and a lower risk of major bleeding and intracranial hemorrhage or fatal bleeding than low molecular weight heparins and vitamin K antagonists; the benefit was also observed in the population of reduced creatinine clearance[146,147] and although the trials were

performed in patients with creatinine clearances up to 25-30 ml/min/1.73m^2, there is evidence for some of them of its safety in patients with creatinine clearances up to 15 ml/min/1.73m^2 [148]. However, direct oral anticoagulants are not recommended in patients with venous thromboembolism and advanced CKD, or antiphospholipid syndrome, or who are pregnant or lactating [143].

The optimal duration of oral anticoagulation will depend on the type of deep vein thrombosis (provoked or unprovoked), the duration of the risk factor (transient or persistent), and the risk of recurrence of venous thromboembolism[142,143]. However, no data on patients with diabetes and CKD and reduced eGFR were found in this review.

Conclusions

Patients with diabetes and CKD should be treated according to the most up-to-date recommendations.

Most of this guideline is based on high-quality evidence. Especially for pharmacological treatments, many data from randomized clinical trials have been evaluated.

The main limitations of this guideline are that research in the field of diabetes is still active and additional data on existing and novel approaches are awaited. Another limitation is that we have not covered the chapter on dyslipidemia or pregnancy, as this was not foreseen in the initial approach, so we recommend referring to the published guidelines of other scientific societies. In addition, high cost and other resource constraints in health systems will limit the application of some recommendations across individuals and populations.

Clinical practice guidelines will continue to evolve. It is likely that new guidelines focused on the diagnosis and treatment of people with diabetes and CKD will be needed in the near future.

Acknowledgments

We are especially grateful to the Work Group members for their expertise throughout the entire process of literature review, data extraction, meeting participation, and the critical writing and editing of the statements and rationale, which made the publication of this guideline possible.

Finally, and on behalf of the Work Group, we gratefully acknowledge the careful assessment of the draft guideline by external reviewers. The Work Group considered all of the valuable comments made, and where appropriate, suggested changes were incorporated into the final publication. The following individuals provided feedback during the public review of the draft guideline: CIGARRAN GULDRIS, Secundino; De ALVARO MORENO, Fernando; EGIDO DE LOS RIOS, Jesús; LLORENTE GOMEZ DE SEGURA, Iñaki; MARQUES VIDAS, María; MORILLAS ARIÑO, Carlos; ORTIZ ARDUAN, Alberto; ROBLES PEREZ-MONTEOLIVA, Nicolás Roberto.

Funding

This research was supported by a grant from the SENEFRO Foundation (Spanish Society of Nephrology, GPC-DC/TP S.E.N. 2019) and a Mundipharma grant.

Authorship

NM participated in research design, performance of research, data analyses and writing the paper. LO participated in the performance of research, data retrieval and analyses and writing the paper. AMC, MG, JLG, MJS, BFF, MQ, DRE and JFN participated in data retrieval and writing the paper. CG, PG, JG, PM, MJP, NS and RS participated in data retrieval and analyses. All authors approved the final version of the article.

Information on the supplement

This article is part of the supplement entitled “Clinical Practice Guideline for detection and management of diabetic kidney disease: a consensus report by the Spanish Society of Nephrology”, sponsored by the Spanish Society of Nephrology, with funding from Mundipharma.

Disclosure

AMC has received honoraria as a speaker from Bayer, Boëhringer-Ingelheim, Lilly, Novo-Nordisk, Esteve and Merck-Sharp-Dhôme, and has participated in advisory boards from Boëhringer-Ingelheim, Lilly and Merck-Sharp-Dhôme. JLG has been an advisor on scientific boards for AstraZeneca, Bayer and Novo Nordisk; lectures for AstraZeneca, Boehringer Ingelheim, Esteve, Bayer, Eli Lilly and Company, Bayer, Astellas and Novo Nordisk and research activities for AstraZeneca. MS received grants or contracts from Boehringer, ISCIII, and Marató TV3; honoraria for lectures from NovoNordisk, Jansen, Boehringer, Mundipharma, AstraZeneca, Ingelheim Lilly, Vifor, ICU Medical, Fresenius, and Travere Therapeutics; support for attending meetings from Travere; participation on a data safety, monitoring board or advisory board from NovoNordisk, Jansen, Boehringer, Mundipharma, AstraZeneca, Ingelheim Lilly, Vifor, ICU Medical, Bayer, GE Healthcare, and Travere Therapeutics. MS has the following leadership or fiduciary roles: SEC board member, SEN board member, former ERA board member, former ASN Board News, former ERA-EDTA SAB, former ERA council member, Western Europe ISN co-chair. BFF has received grants from Esteve and AstraZeneca and consultancy or speaker fees or travel support from AstraZeneca, Bayer, Menarini, Novo-Nordisk, Boehringer, Lilly, Amgen and Mundipharma. BFF is editor for Nefroplus and CME chair of the European Renal Association. JJGM has the following financial relationships: advisor on scientific boards for AstraZeneca, Bayer, Janssen Pharmaceuticals, Eli Lilly and Company, Menarini and Novo-Nordisk; lectures for Abbott, Amarin, AstraZeneca, Boehringer Ingelheim Pharmaceuticals Inc, Janssen Pharmaceuticals, Eli Lilly and Company, Menarini, Mundipharma Pharmaceuticals, Novo-Nordisk and Roche Pharma, and research activities for AstraZeneca, Eli Lilly and Company, Mundipharma Pharmaceuticals and NovoNordisk. MPM has received consultancy, speaker fees or travel support from Astellas, AstraZeneca, Boehringer Ingelheim, CSL Vifor, Lilly, Menarini and Novo Nordisk. RS has received consultancy or speaker fees or travel support from AstraZeneca, Boehringer Ingelheim, Menarini, Novartis, NovoNordisk and Vifor Pharma. CGC has received travel and congress fees support from AstraZeneca, Esteve, NovoNordisk, Boehringer Ingelheim Lilly, Astellas, Otsuka, Novartis, Astellas, and Baxter; has given scientific lectures and participated in advisory boards organized by AstraZeneca, Boehringer Ingelheim Lilly, Mundipharma, Esteve, Otsuka, and NovoNordisk; and she is part of the Clinical Kidney Journal Editorial Board, Kidney News Editorial Board, and the Spanish Young Nephrologist Group Board (Spanish Society of Nephrology). PM has received consulting and/or speaker fees from CSL Vifor, Fresenius Kabi, Abbot, Baxter, Palex and Medtronic. JFNG has received grants from Abbvie, Bionet Medical, Boehringer Ingelheim, Sanofi-

Genzyme, Shire and CSL Vifor, and consultancy or speaker fees or travel support from AstraZeneca, Amgen, Bayer, Bionet Medical, Boehringer Ingelheim, Eli Lilly, Esteve, GlaxoSmithKline, Janssen, Menarini, MSD, Mundipharma, Novartis, Novo-Nordisk, Sanofi-Genzyme, Servier and CSL Vifor. JFNG is member of the Scientific Advisory Board of the European Renal Association. NS has the following financial relationships: advisor on scientific boards for AstraZeneca, Eli Lilly and Company, Menarini and Novo-Nordisk; lectures for AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Menarini, Mundipharma Pharmaceuticals and Novo-Nordisk.

References

1. World Health Organization. WHO handbook for guideline development, 2nd Edition. 2nd ed. 2014.
2. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. Can Med Assoc J. 2010 Dec 14;182(18):E839–42.
3. Higgins JPT, Green S editors. Handbook for Systematic Reviews of Interventions Version 5.1.0 updated March 2011.
4. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016 Oct 12;i4919.
5. Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: A new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011 Apr;64(4):380–2.
6. Yarnoff BO, Hoerger TJ, Simpson SK, Leib A, Burrows NR, Shrestha SS, et al. The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease. BMC Nephrol. 2017 Mar 13;18(1):85.
7. Gómez-Huelgas R, Martínez-Castelao A, Artola S, Górriz JL, Menéndez E, en nombre del Grupo de Trabajo para el Documento de Consenso sobre el tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal crónica. Documento de Consenso sobre el tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal crónica. . Med Clin (Barc). 2014 Jan 21;142(2):85.e1-10.
8. Martínez-Castelao A, Górriz JL, Segura-de la Morena J, Cebollada J, Escalada J, Esmatjes E, et al. Consensus document for the detection and management of chronic kidney disease. Nefrologia. 2014;34(2):243–62.
9. Montañés Bermúdez R, Gràcia García S, Pérez Surribas D, Martínez Castelao A, Bover Sanjuán J, Sociedad Española de Bioquímica Clínica y Patología Molecular, et al. Consensus document. Recommendations on assessing proteinuria during the diagnosis and follow-up of chronic kidney disease. Nefrologia. 2011;31(3):331–45.

10. Naresh CN, Hayen A, Weening A, Craig JC, Chadban SJ. Day-to-Day Variability in Spot Urine Albumin-Creatinine Ratio. American Journal of Kidney Diseases. 2013 Dec;62(6):1095–101.
11. Gomes MB, Gonçalves MF. Is there a physiological variability for albumin excretion rate? Study in patients with diabetes type 1 and non-diabetic individuals. Clin Chim Acta. 2001 Feb;304(1–2):117–23.
12. Tankeu AT, Kaze FF, Noubiap JJ, Chelo D, Dehayem MY, Sobngwi E. Exercise-induced albuminuria and circadian blood pressure abnormalities in type 2 diabetes. World J Nephrol. 2017 Jul 6;6(4):209–16.
13. McFarlane SI, McCullough PA, Sowers JR, Soe K, Chen SC, Li S, et al. Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study Equations: Prevalence of and Risk Factors for Diabetes Mellitus in CKD in the Kidney Early Evaluation Program (KEEP). American Journal of Kidney Diseases. 2011 Mar;57(3):S24–31.
14. Levey AS, Stevens LA, Schmid CH, Zhang Y (Lucy), Castro AF, Feldman HI, et al. A New Equation to Estimate Glomerular Filtration Rate. Ann Intern Med. 2009 May 5;150(9):604.
15. Rigalleau V, Beauvieux MC, Le Moigne F, Lasseur C, Chauveau P, Raffaitin C, et al. Cystatin C improves the diagnosis and stratification of chronic kidney disease, and the estimation of glomerular filtration rate in diabetes. Diabetes Metab. 2008 Nov;34(5):482–9.
16. MacIsaac RJ, Tsalamandris C, Thomas MC, Premaratne E, Panagiotopoulos S, Smith TJ, et al. The accuracy of cystatin C and commonly used creatinine- based methods for detecting moderate and mild chronic kidney disease in diabetes. Diabetic Medicine. 2007 Apr 21;24(4):443–8.
17. Åsberg A, Bjerre A, Almaas R, Luis-Lima S, Robertsen I, Salvador CL, et al. Measured GFR by Utilizing Population Pharmacokinetic Methods to Determine Iohexol Clearance. Kidney Int Rep. 2020 Feb;5(2):189–98.
18. Rigalleau V, Garcia M, Lasseur C, Laurent F, Montaudon M, Raffaitin C, et al. Large kidneys predict poor renal outcome in subjects with diabetes and chronic kidney disease. BMC Nephrol. 2010 Dec 3;11(1):3.
19. Nishimura M, Terawaki H, Hoshiyama Y, Joh K, Hamaguchi K, Yamada K. Renal ultrasonography is useful for evaluating diabetic renal failure. Clin Nephrol. 2003 Mar 1;59(03):174–9.

20. Osman WM, Jelinek HF, Tay GK, Khandoker AH, Khalaf K, Almahmeed W, et al. Clinical and genetic associations of renal function and diabetic kidney disease in the United Arab Emirates: a cross-sectional study. BMJ Open. 2018 Dec;8(12):e020759.
21. Nauta FL, Boertien WE, Bakker SJL, van Goor H, van Oeveren W, de Jong PE, et al. Glomerular and Tubular Damage Markers Are Elevated in Patients With Diabetes. Diabetes Care. 2011 Apr 1;34(4):975–81.
22. Regmi A, Liu G, Zhong X, Hu S, Ma R, Gou L, et al. Evaluation of Serum microRNAs in Patients with Diabetic Kidney Disease: A Nested Case-Controlled Study and Bioinformatics Analysis. Medical Science Monitor. 2019 Mar 5;25:1699–708.
23. Sawada R, Hashimoto Y, Senmaru T, Tanaka M, Ushigome E, Yamazaki M, et al. Serum N-terminal Pro-brain Natriuretic Peptide Level is Associated with the Development of Chronic Kidney Diseases in Patients with Type 2 Diabetes. Endocr Metab Immune Disord Drug Targets. 2018 Oct 5;18(6):590–5.
24. Mise K, Imamura M, Yamaguchi S, Teshigawara S, Tone A, Uchida HA, et al. Identification of Novel Urinary Biomarkers for Predicting Renal Prognosis in Patients With Type 2 Diabetes by Glycan Profiling in a Multicenter Prospective Cohort Study: U-CARE Study 1. Diabetes Care. 2018 Aug 1;41(8):1765–75.
25. Baker NL, Hunt KJ, Stevens DR, Jarai G, Rosen GD, Klein RL, et al. Association Between Inflammatory Markers and Progression to Kidney Dysfunction: Examining Different Assessment Windows in Patients With Type 1 Diabetes. Diabetes Care. 2018 Jan 1;41(1):128–35.
26. Saulnier PJ, Wheelock KM, Howell S, Weil EJ, Tanamas SK, Knowler WC, et al. Advanced Glycation End Products Predict Loss of Renal Function and Correlate With Lesions of Diabetic Kidney Disease in American Indians With Type 2 Diabetes. Diabetes. 2016 Dec 1;65(12):3744–53.
27. Hussain S, Habib A, Hussain MS, Najmi AK. Potential biomarkers for early detection of diabetic kidney disease. Diabetes Res Clin Pract. 2020 Mar;161:108082.
28. Gerstein HC, Paré G, McQueen MJ, Lee SF, Bangdiwala SI, Kannt A, et al. Novel Biomarkers for Change in Renal Function in People With Dysglycemia. Diabetes Care. 2020 Feb 1;43(2):433–9.
29. Tsai MH, Jhou MJ, Liu TC, Fang YW, Lu CJ. An integrated machine learning predictive scheme for longitudinal laboratory data to evaluate the factors determining

renal function changes in patients with different chronic kidney disease stages. Front Med (Lausanne). 2023 Oct 4;10.

30. Sun Z, Wang K, Yun C, Bai F, Yuan X, Lee Y, et al. Correlation Between the Variability of Different Obesity Indices and Diabetic Kidney Disease: A Retrospective Cohort Study Based on Populations in Taiwan. Diabetes, Metabolic Syndrome and Obesity. 2023 Sep;Volume 16:2791–802.
31. Song X, Waitman LR, Hu Y, Yu ASL, Robins D, Liu M. Robust clinical marker identification for diabetic kidney disease with ensemble feature selection. Journal of the American Medical Informatics Association. 2019 Mar 1;26(3):242–53.
32. Otieno FCF, Ogola EN, Kimando MW, Mutai K. The burden of unrecognised chronic kidney disease in patients with type 2 diabetes at a county hospital clinic in Kenya: implications to care and need for screening. BMC Nephrol. 2020 Dec 28;21(1):73.
33. Oshima M, Shimizu M, Yamanouchi M, Toyama T, Hara A, Furuichi K, et al. Trajectories of kidney function in diabetes: a clinicopathological update. Nat Rev Nephrol. 2021 Nov 6;17(11):740–50.
34. Kramer MK, Kriska AM, Venditti EM, Miller RG, Brooks MM, Burke LE, et al. Translating the Diabetes Prevention Program. Am J Prev Med. 2009 Dec;37(6):505–11.
35. Cusick MM, Tisdale RL, Chertow GM, Owens DK, Goldhaber-Fiebert JD. Population-Wide Screening for Chronic Kidney Disease. Ann Intern Med. 2023 Jun;176(6):788–97.
36. Chen W, Abeyaratne A, Gorham G, George P, Karepalli V, Tran D, et al. Development and validation of algorithms to identify patients with chronic kidney disease and related chronic diseases across the Northern Territory, Australia. BMC Nephrol. 2022 Sep 23;23(1):320.
37. Brown WW, Peters RM, Ohmit SE, Keane WF, Collins A, Chen SC, et al. Early detection of kidney disease in community settings: the kidney early evaluation program (KEEP). American Journal of Kidney Diseases. 2003 Jul;42(1):22–35.
38. Martínez-Castelao A, Soler MJ, Górriz Teruel JL, Navarro-González JF, Fernandez-Fernandez B, de Alvaro Moreno F, et al. Optimizing the timing of nephrology referral for patients with diabetic kidney disease. Clin Kidney J. 2021 Feb 3;14(1):5–8.
39. Levin A, Agarwal R, Herrington WG, Heerspink HL, Mann JFE, Shahinfar S, et al. International consensus definitions of clinical trial outcomes for kidney failure: 2020. Kidney Int. 2020 Oct;98(4):849–59.

40. Fishbane S, Spinowitz B. Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018. American Journal of Kidney Diseases. 2018 Mar;71(3):423–35.
41. Meraz-Muñoz AY, Weinstein J, Wald R. eGFR Decline after SGLT2 Inhibitor Initiation: The Tortoise and the Hare Reimagined. Kidney360. 2021 Jun;2(6):1042–7.
42. Santoro D, Torreggiani M, Pellicanò V, Cernaro V, Messina RM, Longhitano E, et al. Kidney Biopsy in Type 2 Diabetic Patients: Critical Reflections on Present Indications and Diagnostic Alternatives. Int J Mol Sci. 2021 May 21;22(11):5425.
43. Di Paolo S, Fiorentino M, De Nicola L, Reboldi G, Gesualdo L, Barutta F, et al. Indications for renal biopsy in patients with diabetes. Joint position statement of the Italian Society of Nephrology and the Italian Diabetes Society. Nutrition, Metabolism and Cardiovascular Diseases. 2020 Nov;30(12):2123–32.
44. Penno G, Solini A, Bonora E, Orsi E, Fondelli C, Zerbini G, et al. Defining the contribution of chronic kidney disease to all-cause mortality in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. Acta Diabetol. 2018 Jun 24;55(6):603–12.
45. Bermejo S, González E, López-Revuelta K, Ibernon M, López D, Martín-Gómez A, et al. Risk factors for non-diabetic renal disease in diabetic patients. Clin Kidney J. 2020 Jan 3;
46. Fiorentino M, Bolignano D, Tesar V, Pisano A, Van Biesen W, D''Arrigo G, et al. Renal Biopsy in 2015 - From Epidemiology to Evidence-Based Indications. Am J Nephrol. 2016;43(1):1–19.
47. de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2022 Nov;102(5):974–89.
48. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine. 2019 Jun 13;380(24):2295–306.
49. Heerspink HJL, Stefánsson B V., Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine. 2020 Oct 8;383(15):1436–46.

50. EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine [Internet]. 2023 Jan 12;388(2):117–27. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2204233
51. Escobar C, Barrios V, Cosín J, Gámez Martínez JM, Huelmos Rodrigo AI, Ortíz Cortés C, et al. SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose- lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review. Diabetic Medicine. 2021 Mar 4;38(3).
52. A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial) (REMODEL). Updated: October 27, 2023.
53. Rayego-Mateos S, Rodrigues-Diez RR, Fernandez-Fernandez B, Mora-Fernández C, Marchant V, Donate-Correa J, et al. Targeting inflammation to treat diabetic kidney disease: the road to 2030. Kidney Int. 2023 Feb;103(2):282–96.
54. Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018 Aug 1;6(8):605–17.
55. Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. New England Journal of Medicine. 2017 Aug 24;377(8):723–32.
56. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016 Nov 10;375(19):1834–44.
57. Hernandez AF, Green JB, Janmohamed S, D'Agostino RB, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018 Oct 27;392(10157):1519–29.
58. Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. N Engl J Med. 2021 Sep 2;385(10):896–907.
59. Perkovic V, Tuttle K, Rossing P, Mahaffey K, Mann J, Bakris G, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024 Aug 31;

60. Heerspink HJL, Sattar N, Pavo I, Haupt A, Duffin KL, Yang Z, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022 Nov;10(11):774–85.
61. DeFronzo RA. The effect of insulin on renal sodium metabolism. A review with clinical implications. Diabetologia. 1981 Sep;21(3):165–71.
62. Morillas C, D'Marco L, Puchades MJ, Solá-Izquierdo E, Gorriz-Zambrano C, Bermúdez V, et al. Insulin Withdrawal in Diabetic Kidney Disease: What Are We Waiting for? Int J Environ Res Public Health. 2021 May 18;18(10).
63. Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017 Aug 24;377(8):723–32.
64. SPRINT Research Group, Wright Jr J, Williamson J, Whelton P, Snyder JK, Sink KM. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. New England Journal of Medicine. 2015 Nov 26;373(22):2103–16.
65. Estacio R, Coll J, Tran Z, Schrier R. Effect of Intensive Blood Pressure Control With Valsartan on Urinary Albumin Excretion in Normotensive Patients With Type 2 Diabetes. Am J Hypertens. 2006 Dec;19(12):1241–8.
66. ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575–85.
67. Patel A, ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, Woodward M, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. The Lancet. 2007 Sep;370(9590):829–40.
68. Schrier RW, Estacio RO, Mehler PS, Hiatt WR. Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial. Nat Clin Pract Nephrol. 2007 Aug;3(8):428–38.
69. Arpitha KS, Lakshminarayana K. A comparative study of efficacy of enalapril versus telmisartan in patients with diabetic nephropathy. Natl J Physiol Pharm Pharmacol. 2020;(0):1.
70. Fernandez Juarez G, Luño J, Barrio V, De Vinuesa SG, Praga M, Goicoechea M, et al. Effect of dual blockade of the renin-angiotensin system on the progression of type 2

diabetic nephropathy: A randomized trial. American Journal of Kidney Diseases. 2013 Feb;61(2):211–8.

71. Ruggenenti P, Trillini M, P. Barlovic D, Cortinovis M, Pisani A, Parvanova A, et al. Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial. Diabetes Obes Metab. 2019 May 22;21(5):1177–90.
72. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, et al. Angiotensin-Receptor Blockade versus Converting-Enzyme Inhibition in Type 2 Diabetes and Nephropathy. N Engl J Med [Internet]. 2004;351:1952–61. Available from: www.nejm.org
73. Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, et al. Effects of Blood Pressure Level on Progression of Diabetic Nephropathy: Results From the RENAAL Study. Arch Intern Med. 2003 Jul 14;163(13):1555.
74. Imai E, Chan JCN, Ito S, Yamasaki T, Kobayashi F, Haneda M, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: A multicentre, randomised, placebo-controlled study. Diabetologia. 2011 Dec;54(12):2978–86.
75. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes. New England Journal of Medicine. 2001 Sep 20;345(12):851–60.
76. Hase M, Babazono T, Ujihara N, Uchigata Y. Comparison of spironolactone and trichlormethiazide as add-on therapy to renin-angiotensin blockade for reduction of albuminuria in diabetic patients. J Diabetes Investig. 2013 May;4(3):316–9.
77. van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, et al. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J Hypertens. 2006 Nov;24(11):2285–92.
78. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2020 Dec 3;383(23):2219–29.
79. Ito S, Shikata K, Nangaku M, Okuda Y, Sawanobori T. Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria A randomized, double-blind, placebo-controlled, phase ii trial. Clinical Journal of the American Society of Nephrology. 2019 Aug 7;14(8):1161–72.

80. Agarwal R, Ruilope LM, Ruiz-Hurtado G, Haller H, Schmieder RE, Anker SD, et al. Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes. J Hypertens. 2023 Feb;41(2):295–302.
81. Bakris GL, Oparil S, Purkayastha D, Yadao AM, Alessi T, Sowers JR. Randomized Study of Antihypertensive Efficacy and Safety of Combination Aliskiren/Valsartan vs Valsartan Monotherapy in Hypertensive Participants With Type 2 Diabetes Mellitus. J Clin Hypertens. 2013 Feb;15(2):92–100.
82. Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH. Impact of baseline renal function on the efficacy and safety of Aliskiren added to losartan in patients with type 2 diabetes and nephropathy. Diabetes Care. 2010 Nov;33(11):2304–9.
83. Uzu T, Araki SI, Kashiwagi A, Haneda M, Koya D, Yokoyama H, et al. Comparative effects of direct renin inhibitor and angiotensin receptor blocker on albuminuria in hypertensive patients with type 2 diabetes. A randomized controlled trial. PLoS One. 2016 Dec 1;11(12).
84. Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, et al. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. Circulation. 2018 Jan 9;137(2):119–29.
85. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2019 Jan 24;380(4):347–57.
86. Grunberger G, Camp S, Johnson J, Huyck S, Terra SG, Mancuso JP, et al. Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study. 2018; Available from: https://doi.org/10.1007/s13300-
87. Heerspink HJL, Sjöström CD, Jongs N, Chertow GM, Kosiborod M, Hou FF, et al. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a prespecified analysis from the DAPA-CKD randomized controlled trial. Eur Heart J. 2021 Mar 31;42(13):1216–27.
88. Baigent C, Emberson JonathanR, Haynes R, Herrington WG, Judge P, Landray MJ, et al. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. The Lancet. 2022 Nov;400(10365):1788–801.

89. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001 Sep 20;345(12):870–8.
90. Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, et al. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study. Hypertens Res. 2008 Apr;31(4):657–64.
91. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. New England Journal of Medicine. 2001 Sep 20;345(12):861–9.
92. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. The Lancet. 2008 Aug;372(9638):547–53.
93. ONTARGET Investigators. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. New England Journal of Medicine. 2008 Apr 10;358(15):1547–59.
94. Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2019 Aug 29;381(9):841–51.
95. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. New England Journal of Medicine. 2021 Dec 9;385(24):2252–63.
96. Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022 Feb 10;43(6):474–84.
97. Hostetter TH, Meyer TW, Rennke HG, Brenner BM, Noddin with the technical assistance of JA, Sandstrom DJ. Chronic effects of dietary protein in the rat with intact and reduced renal mass. Kidney Int. 1986 Oct;30(4):509–17.
98. Ikizler TA, Burrowes JD, Byham-Gray LD, Campbell KL, Carrero JJ, Chan W, et al. KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update. American Journal of Kidney Diseases. 2020 Sep;76(3):S1–107.

99. Molina P, Gavela E, Vizcaíno B, Huarte E, Carrero JJ. Optimizing Diet to Slow CKD Progression. Front Med (Lausanne). 2021 Jun 25;8.
100. Klahr S, Buerkert J, Purkerson ML. Role of dietary factors in the progression of chronic renal disease. Kidney Int. 1983 Nov;24(5):579–87.
101. Hahn D, Hodson EM, Fouque D. Low protein diets for non-diabetic adults with chronic kidney disease. Cochrane Database of Systematic Reviews. 2018 Oct 4;
102. Nezu U, Kamiyama H, Kondo Y, Sakuma M, Morimoto T, Ueda S. Effect of low-protein diet on kidney function in diabetic nephropathy: meta-analysis of randomised controlled trials. BMJ Open. 2013;3(5):e002934.
103. Jiang S, Fang J, Li W. Protein restriction for diabetic kidney disease. Cochrane Database of Systematic Reviews. 2023 Jan 3;2023(1).
104. Ko G, Kalantar-Zadeh K, Goldstein-Fuchs J, Rhee C. Dietary Approaches in the Management of Diabetic Patients with Kidney Disease. Nutrients. 2017 Jul 31;9(8):824.
105. ElSayed NA, Aleppo G, Bannuru RR, Bruemmer D, Collins BS, Das SR, et al. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes. Diabetes Care. 2024 Jan 1;47(Supplement_1):S179–218.
106. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227–337.
107. Dawson J, Béjot Y, Christensen LM, De Marchis GM, Dichgans M, Hagberg G, et al. European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack. Eur Stroke J. 2022 Sep 3;7(3):I–XLI.
108. Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023 Oct 14;44(39):4043–140.
109. Rossing P, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, Khunti K, et al. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022 Nov;102(5):S1–127.
110. Sleem A, Effron MB, Stebbins A, Wruck LM, Marquis-Gravel G, Muñoz D, et al. Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease. JAMA Cardiol. 2023 Nov 1;8(11):1061.

111. Gorog DA, Ferreiro JL, Ahrens I, Ako J, Geisler T, Halvorsen S, et al. De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis. Nat Rev Cardiol. 2023 Dec 20;20(12):830–44.
112. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. ACC/AHA 2016 Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2016 Sep 6;134(10).
113. Gao C, Tomaniak M, Takahashi K, Kawashima H, Wang R, Hara H, et al. Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial. Cardiovasc Diabetol. 2020 Dec 16;19(1):179.
114. Dehghani P, Cao D, Baber U, Nicolas J, Sartori S, Pivato CA, et al. Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. Eur Heart J Cardiovasc Pharmacother. 2022 Sep 29;8(7):707–16.
115. Franchi F, James SK, Ghukasyan Lakic T, Budaj AJ, Cornel JH, Katus HA, et al. Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y12 Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial. J Am Heart Assoc. 2019 Mar 19;8(6).
116. Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, et al. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. New England Journal of Medicine. 2019 Oct 3;381(14):1309–20.
117. Bhatt DL, Steg PG, Mehta SR, Leiter LA, Simon T, Fox K, et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. The Lancet. 2019 Sep;394(10204):1169–80.
118. Bhatt DL, Bonaca MP, Bansilal S, Angiolillo DJ, Cohen M, Storey RF, et al. Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS–TIMI 54. J Am Coll Cardiol. 2016 Jun;67(23):2732–40.
119. Dasgupta A, Steinhubl SR, Bhatt DL, Berger PB, Shao M, Mak KH, et al. Clinical Outcomes of Patients With Diabetic Nephropathy Randomized to Clopidogrel Plus

Aspirin Versus Aspirin Alone (A post hoc Analysis of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance [CHARISMA] Trial). Am J Cardiol. 2009 May;103(10):1359–63.

120. Pan Y, Elm JJ, Li H, Easton JD, Wang Y, Farrant M, et al. Outcomes Associated With Clopidogrel-Aspirin Use in Minor Stroke or Transient Ischemic Attack. JAMA Neurol. 2019 Dec 1;76(12):1466.
121. Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, et al. Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. New England Journal of Medicine. 2020 Jul 16;383(3):207–17.
122. Baaten CCFMJ, Schröer JR, Floege J, Marx N, Jankowski J, Berger M, et al. Platelet Abnormalities in CKD and Their Implications for Antiplatelet Therapy. Clinical Journal of the American Society of Nephrology. 2022 Jan;17(1):155–70.
123. ASCEND Study Collaborative Group. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. New England Journal of Medicine. 2018 Oct 18;379(16):1529–39.
124. Saito Y, Morimoto T, Ogawa H, Nakayama M, Uemura S, Doi N, et al. Low-Dose Aspirin Therapy in Patients With Type 2 Diabetes and Reduced Glomerular Filtration Rate. Diabetes Care. 2011 Feb 1;34(2):280–5.
125. Saito Y, Okada S, Ogawa H, Soejima H, Sakuma M, Nakayama M, et al. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. Circulation. 2017 Feb 14;135(7):659–70.
126. Yusuf S, Joseph P, Dans A, Gao P, Teo K, Xavier D, et al. Polypill with or without Aspirin in Persons without Cardiovascular Disease. New England Journal of Medicine. 2021 Jan 21;384(3):216–28.
127. Mann JFE, Joseph P, Gao P, Pais P, Tyrwhitt J, Xavier D, et al. Effects of aspirin on cardiovascular outcomes in patients with chronic kidney disease. Kidney Int. 2023 Feb;103(2):403–10.
128. Bhatt DL, Eikelboom JW, Connolly SJ, Steg PG, Anand SS, Verma S, et al. Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease. Circulation. 2020 Jun 9;141(23):1841–54.
129. Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. New England Journal of Medicine. 2020 May 21;382(21):1994–2004.

130. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine. 2017 Oct 5;377(14):1319–30.
131. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021 Feb 1;42(5):373–498.
132. Seyed Ahmadi S, Svensson AM, Pivodic A, Rosengren A, Lind M. Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: a Swedish cohort study. Cardiovasc Diabetol. 2020 Dec 18;19(1):9.
133. Ha JT, Freedman S Ben, Kelly DM, Neuen BL, Perkovic V, Jun M, et al. Kidney Function, Albuminuria, and Risk of Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis. American Journal of Kidney Diseases. 2023 Sep;
134. Hart RG, Pearce LA, Albers GW. Independent predictors of stroke in patients with atrial fibrillation. Neurology. 2007 Aug 7;69(6):546–54.
135. Ding WY, Potpara TS, Blomström- Lundqvist C, Boriani G, Marin F, Fauchier L, et al. Impact of renal impairment on atrial fibrillation: ESC- EHRA EORP- AF Long-Term General Registry. Eur J Clin Invest. 2022 Jun 17;52(6).
136. Overvad TF, Skjøth F, Lip GYH, Lane DA, Albertsen IE, Rasmussen LH, et al. Duration of Diabetes Mellitus and Risk of Thromboembolism and Bleeding in Atrial Fibrillation. Stroke. 2015 Aug;46(8):2168–74.
137. Harrington J, Carnicelli AP, Hua K, Wallentin L, Patel MR, Hohnloser SH, et al. Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF. Circulation. 2023 Jun 6;147(23):1748–57.
138. Echouffo-Tcheugui JB, Shrader P, Thomas L, Gersh BJ, Kowey PR, Mahaffey KW, et al. Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes. J Am Coll Cardiol. 2017 Sep;70(11):1325–35.
139. Cases A, Gomez P, Broseta JJ, Perez Bernat E, Arjona Barrionuevo J de D, Portolés JM, et al. Non-valvular Atrial Fibrillation in CKD: Role of Vitamin K Antagonists and Direct Oral Anticoagulants. A Narrative Review. Front Med (Lausanne). 2021 Sep 17;8.

140. Patti G, Di Gioia G, Cavallari I, Nenna A. Safety and efficacy of nonvitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: A study- level meta- analysis of phase III randomized trials. Diabetes Metab Res Rev. 2017 Mar 27;33(3).

141. Bonde A, Lip G, Kamper AL, Staerk L, Torp-Pedersen C, Gislason G, et al. Renal Function, Time in Therapeutic Range and Outcomes in Warfarin-Treated Atrial Fibrillation Patients: A Retrospective Analysis of Nationwide Registries. Thromb Haemost. 2017 Dec 6;117(12):2291–9.

142. Kakkos SK, Gohel M, Baekgaard N, Bauersachs R, Bellmunt-Montoya S, Black SA, et al. 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. European Journal of Vascular and Endovascular Surgery. 2021 Jan;61(1):9–82.

143. Konstantinides S V, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020 Jan 21;41(4):543–603.

144. Gaertner S, Cordeanu EM, Mirea C, Frantz AS, Auger C, Bilbault P, et al. Increased risk and severity of unprovoked venous thromboembolism with clustering cardiovascular risk factors for atherosclerosis: Results of the REMOTEV registry. Int J Cardiol. 2018 Feb;252:169–74.

145. Wattanakit K, Cushman M, Stehman-Breen C, Heckbert SR, Folsom AR. Chronic Kidney Disease Increases Risk for Venous Thromboembolism. Journal of the American Society of Nephrology. 2008 Jan;19(1):135–40.

146. van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014 Sep 18;124(12):1968–75.

147. Zhou B, Wu H, Wang C, Lou B, She J. Impact of Age, Sex, and Renal Function on the Efficacy and Safety of Direct Oral Anticoagulants vs. Vitamin K Antagonists for the Treatment of Acute Venous Thromboembolism: A Meta-Analysis of 22,040 Patients. Front Cardiovasc Med. 2021 Sep 8;8.

148. Volkl AA, Moore KT, Haskell L, Barnathan ES. Updated Renal Dosage Recommendations for Rivaroxaban in Patients Experiencing or at Risk of Thromboembolic Disease. American Journal of Cardiovascular Drugs. 2023 May 28;23(3):247–55.

149. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine. 2017 Aug 17;377(7):644–57.

150. Muskiet MHA, Tonneijck L, Huang Y, Liu M, Saremi A, Heerspink HJL, et al. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018 Nov 1;6(11):859–69.

151. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2016 Jul 28;375(4):311–22.

152. Holman RR, Bethel MA, George J, Sourij H, Doran Z, Keenan J, et al. Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. Am Heart J. 2016 Apr;174:103–10.

153. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet. 2019 Jul 13;394(10193):121–30.

PIE DE FIGURAS

Figure 1 – Drug therapy for metabolic control in patients with T2D and CKD



Figure 2 – General management of patients with type 2 diabetes and chronic kidney disease



Figure 2. Chapter 4. Patients with diabetes and chronic kidney disease (CKD) should receive a holistic approach to avoid cardiovascular complications. This approach should consider lifestyle changes focused on nutrition with special attention to weight control, regular physical exercise, and smoking cessation, adding the use of first-line drugs, according to the clinical characteristics of each patient and prioritizing those with proven benefit from the cardiorenal point of view. Glycemic control is based on insulin therapy in type 1 diabetes mellitus (T1DM) and a combination of metformin and sodium-glucose cotransporter 2 inhibitors (SGLT2i) for type 2 diabetes mellitus (T2DM). Metformin can be used when the estimated glomerular filtration rate (eGFR) is greater than 30 ml/min per 1.73 m2, adjusting the metformin doses when eGFR would be between 30-45 ml/min per 1.73 m^2. iSGLT2 should be initiated when the eGFR is greater than 20 ml/min per 1.73 m2 and continued until starting treatment with

dialysis or transplant. Angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARBs) should be first-line drugs for hypertension when albuminuria is present. Otherwise, dihydropyridine calcium channel blockers (CCBs) or a diuretic may also be considered. All three classes are often required to achieve blood pressure (BP) goals. Adequate control of lipids with different pharmacological groups is crucial, and the use of statins is recommended for most patients with T1DM or T2DM and CKD.

Glucagon-like peptide receptor agonists (GLP-1 RA) are the preferred hypoglycemic medications for people with T2DM when metabolic control objectives cannot be achieved with metformin and SGLT2i. A nonsteroidal mineralocorticoid receptor antagonist (ns-MRA) such as finerenone may be added to the first-line treatment for cases with T2DM and high risks of CKD progression and cardiovascular events, depending on the patient's albuminuria (>30 mg/g).

Depending on the patient's characteristics, different pharmacological groups increase the therapeutic arsenal for improving the metabolic control of patients, including dipeptidyl peptidase-4 inhibitors (DPP-4i), meglitinides, insulin, or thiazolidinediones (TZD). Other additional therapies, such as steroidal mineralocorticoid receptor antagonists, may also be used to achieve BP targets if potassium (K) levels allow it. Aspirin should generally be used for life for secondary prevention in patients with established cardiovascular problems and may be considered in primary prevention in those at high risk of atherosclerotic cardiovascular problems (ASCVD).

Abbreviations: ACEi, angiotensin-converting enzyme inhibitors; ACR, albumin-creatinine ratio; ARBs, angiotensin II receptor blockers; ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure; CCB, calcium channel blocker; CVD, cardiovascular disease; DPP-4i, dipeptidyl peptidase-4 inhibitors; eGFR, estimated glomerular filtration rate; GLP-1 RA, glucagon-like peptide-1 receptor agonist; MRA, mineralocorticoid receptor antagonist; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor; RAS, renin-angiotensin system; SGLT2i, sodium-glucose cotransporter-2 inhibitor; TZD, thiazolidinediones.

Table 1 - Clinical questions and systematic review topics in the PICO format

Guideline Chapter 1	Screening and diagnosis of diabetic kidney disease
Clinical question	How and when is it recommended to screen for kidney disease in people with diabetes?
Clinical question	What are the criteria for referring people with diabetes to a nephrologist?
Clinical question	When is a kidney biopsy indicated in people with diabetes and kidney disease?
Population	Adults with CKD (G1–G5, G5D) and diabetes (T1D and T2D)
Study design	RCT, studies that used a pre/post or case-control design, prospective and retrospective studies (cohorts or registry), and systematic reviews and guidelines from other societies
Guideline Chapter 2	Metabolic control in people with diabetes and CKD
Clinical question	In patients with T1D or T2D and CKD, what are the effects of glucose-lowering medication on clinically relevant outcomes and clinically relevant harms?
Population	Adults with CKD (G1–G5, G5D, G1T–G5T) and diabetes (T1D or T2D)
Intervention	Older therapies—metformin, sulfonylureas, or thiazolidinediones More recent therapies—alpha-glucosidase inhibitors, GLP-1 RA, DPP-4 inhibitors, SGLT2i In T1D: different types of insulin
Comparator	Standard of care/placebo
Outcomes	Critical and important outcomes: mortality (all causes), cardiovascular death, death from kidney causes, need for initiation of RRT, doubling of serum creatinine, new onset of albuminuria > 300 mg/g, kidney composite, major adverse cardiovascular events, heart failure, myocardial infarction, stroke, treatment dropouts due to adverse effects, serious adverse effects, hyperkalemia, HbA1c (%), eGFR, % change from baseline uACR, diabetic retinopathy progression, diabetic ketoacidosis, urinary tract infections,

	gastrointestinal adverse effects, hypoglycemia, amputations, fractures.
Study design	RCT
Guideline Chapter 3	Blood pressure control in people with diabetic kidney disease
Clinical question	In patients with T1D or T2D and CKD, what is the target blood pressure levels?
Population	Adults with CKD (G1–G5, G5D, G1T–G5T) and diabetes (T1D or T2D)
Intervention	Intensive blood pressure control
Comparator	Standard blood pressure control
Outcomes	Critical and important outcomes: systolic and diastolic blood pressure, need for initiation of RRT, doubling of serum creatinine, eGFR, uACR, mortality (all causes), cardiovascular death, heart failure, myocardial infarction, hyperkalemia and treatment dropouts due to adverse effects.
Study design	RCT
Clinical question	In patients with T1D or T2D and CKD, what are the effects of different therapies for hypertension on clinically relevant outcomes and clinically relevant harms?
Population	Adults with CKD (G1–G5, G5D, G1T–G5T) and diabetes (T1D or T2D)
Intervention	Possible therapies: ARBs, ACEi, nonsteroidal MRA, aliskiren
Comparator	Other therapies/standard of care/placebo
Outcomes	Critical and important outcomes: systolic and diastolic blood pressure, need for initiation of RRT, doubling of serum creatinine, eGFR, uACR, mortality (all causes), cardiovascular death, heart failure, myocardial infarction, hyperkalemia and treatment dropouts due to adverse effects.
Study design	RCT
Guideline Chapter 4	Treatment targeting progression of CKD in people with diabetic kidney disease

Clinical question	In patients with T1D or T2D and CKD, what are the effects of different therapies targeting progression of CKD on clinically relevant outcomes and clinically relevant harms?
Population	Adults with CKD (G1–G5, G5D, G1T–G5T) and diabetes (T1D or T2D)
Intervention	Possible therapies: ARBs, ACEi, steroidal and nonsteroidal MRA, aliskiren, SGLT2i, GLP1RA, GLP1 RA/GIP, DPP4i, pentoxifyline, protein restriction
Comparator	Other therapies/standard of care/placebo
Outcomes	Critical and important outcomes: mortality (all causes), cardiovascular death, death from kidney causes, need for initiation of RRT, doubling of serum creatinine, new onset of albuminuria > 300 mg/g, kidney composite, major adverse cardiovascular events, heart failure, myocardial infarction, stroke, treatment dropouts due to adverse effects, serious adverse effects, hyperkalemia, HbA1c (%), eGFR, % change from baseline uACR, diabetic retinopathy progression, diabetic ketoacidosis, urinary tract infections, gastrointestinal adverse effects, hypoglycemia, amputations, fractures.
Study design	RCT
Guideline Chapter 5	Antiplatelet or anticoagulant therapy in people with diabetes and CKD
Clinical question	In patients with T1D or T2D and CKD, what are the indications and effects of antiplatelet or anticoagulant therapy on clinically relevant outcomes and clinically relevant harms?
Population	Adults with CKD (G1–G5, G5D, G1T–G5T) and diabetes (T1D or T2D)
Intervention	Antiplatelet (acetylsalicylic acid, phosphodiesterase inhibitors: dipyridamole and cilostazol, and P2Y12 inhibitors: clopidogrel, prasugrel and ticagrelor) and anticoagulant therapy (acenocoumarol, warfarin, apixaban, rivaroxaban, edoxaban and dabigatran)
Comparator	Placebo/other therapy

Outcomes	Critical and important outcomes: mortality (all causes), cardiovascular death, death from kidney causes, myocardial infarction, stroke, treatment dropouts due to adverse effects, serious adverse effects, hemorrhage.
Study design	RCT

Table 2 - Studies with SGLT2i in patients with T2D and CKD

Trials	Year of completion	SGLT2i	Patient population	Number of patients; median follow up	HbA1C (% reduction)	CV outcome			Kidney outcome		
							SGLT2i vs. placebo group	HR (95%CI)		SGLT2i vs. placebo group	HR (95%CI)
EMPA REG[84]	2015	Empaglif lozin (10 /25 mg)	T2D and CV disease	7020 3.1 years	0.24 % (95% CI, 0.40 to 0.08)	MACE	10.5 vs. 12.1%	0.86 (0.74–0.99)	*(Post hoc)* Incident or worsening nephropathy or CV death	16.2 vs. 23.6%	0.61 (0.55-0.69)
						HF or CV death (excluding fatal stroke)	5.7 vs. 8.5%	0.66 (0.55–0.79)	Incident or worsening nephropathy	12.7 vs. 18.8%	0.61 (0.53-0.7)

						CV death	3.7 vs. 5.9	0.62 (0.49-0.77)	Doubling of serum creatinine	1.5 vs. 2.6%	0.56 (0.39-0.79)
									Initiation of kidney replacement therapy	0.3 vs. 0.6%	0.45 (0.21-0.97)
CANVAS[149]	2017	Canagliflozin (100,300 mg)	T2D and high CV disease risk	10142 2.6 years		MACE	26.9 vs. 31.5%	0.86 (0.75-0.97)	Progression of albuminuria	89.4 vs. 128.7 per 1000 patient years	0.73 (0.67-0.79)
						Hospitalization for HF	5.5 vs. 8.68 per 1000 patients/year	0.67 (0.52-0.87)	Sustained 40% reduction in eGFR, need for kidney replacement therapy, or death from kidney causes	5.5 vs. 9.0	0.60 (0.47-0.77)

DECLARE-TIMI58[85]	2018	Dapagliflozin (10 mg)	T2D and ≥ 1 CV disease risk factor	17160 4.6 years	0.42%; 95% confidence interval [CI], 0.40 to 0.45).	MACE	8.8 vs. 9.4%	0.93 (0.84–1.03)	≥ 40% reduction in eGFR, ESKD ≥ 90 days, (dialysis, sustained eGFR < 15 ml/min/1.73 m2, or kidney transplantation), or renal/CV death	4.3 VS5.6%	0.76 (0.67 - 0.87).
						CV death or hospitalization for HF	4.9 vs. 5.8%	0.83 (0.73 -0.95)			
CREDENCE[48]	2019	Canagliflozin (100 mg)	T2DM and CKD	4401		MACE	9.9 vs. 12.2%	0.80 (0.67–0.95)	Doubling of serum creatinine, ESKD	11.1 vs. 15.4%	0.70 (0.59–0.82)

						HF or CV death	8.1 vs. 11.5%	0.69 (0.57–0.83)	(dialysis, kidney transplantation, or sustained eGFR < 15 ml/min/1.73 m2), or renal/CV death		
DAPA-CKD[49]	2020	Dapagliflozin (5/10mg)	CKD (T2D and nondiabetics)	4304 2.4 years	–0.9 [95% CI –1.5, 0.3])	Death CV causes or hospitalization for HF	4.6 vs. 6.4%	0.71 (0.55 -0.92)	Decline in e-GFR of at least 50%, ESKD, or death from kidney or CV causes	9.2 vs. 14.5%	0.61 (0.51 - 0.72)

									Sustained decline in the eGFR of at least 50%, ESKD, or death from kidney causes	6.6 vs. 11.3%	0.56 (0.45 - 0.68)
EMPA-kidney[50]	2022 Early stop due to evidence of efficiency	Empaglifozin (10 mg)	CKD (T2D and nondiabetics)	6609	44.52 mml/mmol (0.14) vs. 44.90 mmol/mmol (0.14) Absolute difference -0.39	Hospitalization for HF or cardiovascular death	4 vs. 4.6%	0.84 (0.67–1.07)	ESKD, a sustained decline in eGFR to <10ml/min/1.73m², renal death, or a sustained decline of ≥40% in eGFR from randomization or	4.9 vs. 6.6%	0.73 (0.59–0.89)
						Occurrences of hospitalizations from any cause	No. of events/100 patient-year 24.8 vs. 29.2	0.86 (0.78–0.95)			
						Death from any cause	4.5 vs. 5.1%	0.87 (0.70–1.08)			

					(-0.77, -0.01)				Cardiovascular death		

CKD: chronic kidney disease; CV: cardiovascular; eGFR: estimated glomerular filtration rate; ESKD: end-stage kidney disease; HF: heart failure; MACE: major adverse cardiovascular events, T2D: type 2 diabetes

Table 3 - Randomized clinical trials with GLP1RA in patients with T2D and CKD

	N	Drug	Dose	HbA1c decrease	MACE-3	Composite kidney outcome including albuminuria > 300 mg/g	Worsening of kidney function
ELIXA[150]	6068	Lixisenatide	20 µg per day	0.27 (0.31 - 0.22)	1.02 (0.89 - 1.17)	0.84 (0.68 – 1.02)	1.16 (0.74 - 1.83)
LEADER[151]	9340	Liraglutide	1.8 mg per day	0.40 (0.45 - 0.34)	0.87 (0.78 - 0.97)	0-78 (0.67 - 0.92)	0.89 (0.67 -1.19)
SUSTAIN-6[56]	3297	Semaglutide sc	1 mg per week	1.1 (1.2 - 0.9)	0.74 (0.58 - 0.95)	0.64 (0.46 - 0.88)	1.28 (0.64 - 2.58)
EXSCEL[152]	14752	Exenatide	2 mg per week	0.53 (0.57 - 0.50)	0.91 (0.83 - 1.00)	0.88 (0.76 - 1.01)	0.88 (0.74 -1.05)
HARMONY OUTCOMES[57]	9463	Albiglutide	30 or 50 mg per week	0.52 (0.58 - 0.45)	0.78 (0.68 - 0.90)	-	-
REWIND[153]	9901	Dulaglutide	1.5 mg per week	0.61 (0.58 - 0.65)	0.88 (0.79 - 0.99)	0.85 (0.77 - 0.93)	0.70 (0.57 - 0.85)

PIONEER 6[94]	3183	Semaglutide oral	14 mg per day	1 (1.2 - 0.9)	0.79 (0.57 – 1.11)	-	-
FLOW[59]	3533	Semaglutide sc	1 mg per week	0.81 (0.9 - 0.72)	0.82 (0.68 - 0.98)	0.79 (0.66 - 0.94)	0.73 (0.59 -0.89)

Table 4 - Key points summarizing treatment for metabolic control in patients with T2D and CKD

1. SGLT-2i are antihyperglycemic drugs with proven cardiovascular and kidney protective effects in patients with T2DM, CKD and CHF.
2. GLP1RA are antihyperglycemic drugs that have also shown kidney benefit in patients with CKD and T2DM.
3. The rest of the pharmacologic classes (including metformin) have not conclusively shown a reduction in kidney events in patients with DM2.
4. The recommended SGLT2i and GLP1RA are those that have demonstrated reduction of kidney events in clinical trials in DM2 designed with this objective (canagliflozin, dapagliflozin, empagliflozin and semaglutide).
5. SGLT2i have a weak antihyperglycemic effect with reduced eGFR, so their combination with other therapeutic classes (preferably with GLP-1ra) is recommended in patients with CKD G3A onwards.
6. GLP-1RA maintains its antihyperglycemic efficacy in patients with advanced CKD.
7. If patients do not have adequate glycemic control with the SGLT2i/GLP1RA combination (or either contraindication or intolerance to any of them), metformin will be prescribed, as long as GFR>30. DPP4i are an alternative with a weak antihyperglycemic effect in patients with contraindications or intolerance to GLP-1RA.
8. Tirzepatide, a dual GLP-1/GIP agonist, is the drug that has demonstrated the greatest antihyperglycemic efficacy in patients with T2DM so far and may be an alternative to GLP-1ra in patients with CKD to improve glycemic control, although there are still no studies published with kidney endpoints and this drug has not yet been approved by the FDA.
9. GLP1RA, DPP4i and tirzepatide do not have an additive or synergistic effect, so they should not be prescribed simultaneously.
10. If patients require insulin, basal insulin therapy with insulin analogs is recommended, due to the lower risk of hypoglycemia. In a CV safety trial (DEVOTE), insulin degludec showed a lower risk of severe hypoglycemia versus glargine U100 in patients with DM2 and high CV risk (including patients with CKD).

SUPPLEMENTARY MATERIAL

- Table S3.1. ARB compared to ACEI in diabetic kidney disease
- Table S3.2. ARB compared to placebo in diabetic kidney disease
- Table S3.3. Steroidal MRA compared to placebo/standard of care in diabetic kidney disease
- Table S3.4. Non-steroidal MRA compared to placebo/standard of care in diabetic kidney disease
- Table S3.5. Aliskiren compared to placebo/standard of care in diabetic kidney disease
- Table S3.6. Intensive blood pressure control vs standard control in diabetic kidney disease

Chapter 4. CKD progression in people with diabetic kidney disease

- Table S4.1. ACEI compared to placebo/standard of care in diabetic kidney disease
- Table S4.2. ARB compared to placebo/standard of care in diabetic kidney disease
- Table S4.3. ACEI compared to ARB in diabetic kidney disease
- Table S4.4. Aliskiren compared to placebo/standard of care in diabetic kidney disease
- Table S4.5. Steroidal MRA compared to placebo/standard of care in diabetic kidney disease
- Table S4.6. Non-steroidal MRA compared to placebo/standard of care in diabetic kidney disease
- Table S4.7. sGLT2i compared to placebo/standard of care in diabetic kidney disease
- Table S4.8. GLP-1A compared to placebo/standard of care in diabetic kidney disease
- Table S4.9. Dual GLP-1/GIP compared to placebo/standard of care in diabetic kidney disease
- Table S4.10. DPP4i compared to placebo/standard of care in diabetic kidney disease
- Table S4.11. Pentoxifylline compared to placebo/standard of care in diabetic kidney disease
- Table S4.12. Protein restriction compared to placebo/standard of care in diabetic kidney disease

Chapter 5. Anticoagulation and antiagregation in people with diabetic kidney disease

- Table S5.1. Ticagrelor compared to clopidogrel in diabetic kidney disease

- Table S5.2. Clopidogrel plus AAS compared to placebo plus AAS in diabetic kidney disease
- Table S5.3. Ticagrelor+AAS followed by ticagrelor monotherapy compared to AAS+clopidogrel/ticagrelor followed by AAS monotherapy in diabetic kidney disease

Appendix 4. Nomenclature and description for rating guideline recommendations

Appendix 1. Search strategies

Search dates: last update: 11/7/2023

Table S1. Search strategies for systematic review topics

Guideline Chapter 1		Screening and diagnosis of diabetic kidney disease
Search strategy-MEDLINE	1	Diabetes Mellitus/
	2	exp Diabetes Mellitus, Type 2/
	3	Diabetic Nephropathies/
	4	diabet$.tw.
	5	(niddm or iddm).tw.
	6	or/1-5
	7	((screen* or check* or evaluat* or assess* or test* or investiga* or scan* or diagnos* or identificat* or recogni* or detect* or confirmat* or result* or prognos* or judge*) adj3 (chronic kidney or chronic renal or CKF or CKD or CRF or CRD or Renal Insufficiency or kidney disease*)).ab,ti.
	8	6 and 7
	9	((kidney or renal) adj3 biopsy):ab,ti,tw.
	10	6 and 9
	11	8 or 10
	12	limit 11 to humans
	13	limit 12 to yr="2000 -Current"

Search strategy-CENTRAL	#1	MeSH descriptor Diabetes Mellitus, this term only
	#2	MeSH descriptor Diabetes Mellitus explode all trees
	#3	MeSH descriptor Diabetes Mellitus, Type 2 explode all trees
	#4	MeSH descriptor Diabetic Nephropathies explode all trees
	#5	diabet*:ti,ab,kw
	#6	(niddm or iddm or T2DM):ab,ti,kw
	#7	(non insulin* depend*):ti,ab,kw
	#8	(noninsulin* depend*):ti,ab,kw
	#9	(noninsulin?depend*):ti,ab,kw
	#10	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9
	#11	screen* NEXT (chronic kidney or chronic renal or CKF or CKD or CRF or CRD or Renal Insufficiency or kidney disease* or kidney failure):ab,ti,kw
	#12	check* NEXT (chronic kidney or chronic renal or CKF or CKD or CRF or CRD or Renal Insufficiency or kidney disease* or kidney failure):ab,ti,kw
	#13	evaluat* NEXT (chronic kidney or chronic renal or CKF or CKD or CRF or CRD or Renal Insufficiency or kidney disease* or kidney failure):ab,ti,kw
	#14	assess* NEXT (chronic kidney or chronic renal or CKF or CKD or CRF or CRD or Renal Insufficiency or kidney disease* or kidney failure):ab,ti,kw
	#15	test* NEXT (chronic kidney or chronic renal or CKF or CKD or CRF or CRD or Renal Insufficiency or kidney disease* or kidney failure):ab,ti,kw

	#16	investiga* NEXT (chronic kidney or chronic renal or CKF or CKD or CRF or CRD or Renal Insufficiency or kidney disease* or kidney failure):ab,ti,kw
	#17	scan* NEXT (chronic kidney or chronic renal or CKF or CKD or CRF or CRD or Renal Insufficiency or kidney disease* or kidney failure):ab,ti,kw
	#18	diagnos* NEXT (chronic kidney or chronic renal or CKF or CKD or CRF or CRD or Renal Insufficiency or kidney disease* or kidney failure):ab,ti,kw
	#19	identificat* NEXT (chronic kidney or chronic renal or CKF or CKD or CRF or CRD or Renal Insufficiency or kidney disease* or kidney failure):ab,ti,kw
	#20	recogni* NEXT (chronic kidney or chronic renal or CKF or CKD or CRF or CRD or Renal Insufficiency or kidney disease* or kidney failure):ab,ti,kw
	#21	detect* NEXT (chronic kidney or chronic renal or CKF or CKD or CRF or CRD or Renal Insufficiency or kidney disease* or kidney failure):ab,ti,kw
	#22	confirmat* NEXT (chronic kidney or chronic renal or CKF or CKD or CRF or CRD or Renal Insufficiency or kidney disease* or kidney failure):ab,ti,kw
	#23	result* NEXT (chronic kidney or chronic renal or CKF or CKD or CRF or CRD or Renal Insufficiency or kidney disease* or kidney failure):ab,ti,kw
	#24	prognos* NEXT (chronic kidney or chronic renal or CKF or CKD or CRF or CRD or Renal Insufficiency or kidney disease* or kidney failure):ab,ti,kw
	#25	judge* NEXT (chronic kidney or chronic renal or CKF or CKD or CRF or CRD or Renal Insufficiency or kidney disease* or kidney failure):ab,ti,kw
	#26	#11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25
	#27	(#10 AND #26)

	#28	((kidney or renal) NEXT biopsy):ab,ti,kw
	#29	(#10 AND #28)
	#30	(#27 OR #29)
	#31	with Cochrane Library publication date from Jan 2000 to Jan 2020, in Cochrane Reviews, Trials, Clinical Answers, Editorials and Special collections
	#32	MeSH descriptor Diabetes Mellitus, this term only
	#33	MeSH descriptor Diabetes Mellitus explode all trees
	#34	MeSH descriptor Diabetes Mellitus, Type 2 explode all trees
	#35	MeSH descriptor Diabetic Nephropathies explode all trees
	#36	diabet*:ti,ab,kw
	#37	(niddm or iddm or T2DM):ab,ti,kw
	#38	(non insulin* depend*):ti,ab,kw
	#39	(noninsulin* depend*):ti,ab,kw
	#40	(noninsulin?depend*):ti,ab,kw

Search Jan 2020 – 2739 citations retrieved; 101 relevant studies identified. Updated Jul 2023 search – 1366 citations retrieved, 20 relevant studies.

Guideline Chapter 2		Metabolic control in people with diabetes and CKD
Search strategy-MEDLINE	1	Kidney Diseases/
	2	exp Renal Replacement Therapy/
	3	Renal Insufficiency/

	4	exp Renal Insufficiency, Chronic/
	5	dialysis.tw.
	6	(haemodialysis or haemodialysis).tw.
	7	(hemofiltration or haemofiltration).tw.
	8	(haemodiafiltration or haemodiafiltration).tw.
	9	(end-stage renal or end-stage kidney or endstage renal or endstage kidney).tw.
	10	(ESRF or ESKF or ESRD or ESKD).tw.
	11	(chronic kidney or chronic renal).tw.
	12	(CKF or CKD or CRF or CRD).tw.
	13	(CAPD or CCPD or APD).tw.
	14	(predialysis or pre-dialysis).tw.
	15	or/1-14
	16	exp diabetes mellitus/
	17	exp Diabetes Mellitus, Type 2/
	18	diabet$.tw.
	19	Diabetic Nephropathies/
	20	(niddm or iddm).tw.
	21	or/16-20
	22	exp Hypoglycemic Agents/
	23	(glucose lowering and (therap$ or agent$ or drug$)).tw.
	24	(hypoglycemic and (agent$ or drug$ or therap$)).tw.
	25	(antidiabet$ and (agent$ or drug$ or therap$)).tw.
	26	metformin.tw.
	27	Thiazolidinediones/
	28	(rosiglitazone or rivoglitazone or pioglitazone or troglitazone).tw.
	29	glitazone$.tw.

	30	exp Sulfonylurea Compounds/
	31	(glipizide or glimepride or gliclazide or glibenclamide or glyburide).tw.
	32	insulin.tw.
	33	(repaglinide or nateglinide or mitiglinide).tw.
	34	Glucagon-Like Peptide 1/
	35	glucagon-like peptide-1.tw.
	36	Incretin mimetic$.tw.
	37	(exenatide or pramlintide or liraglutide or taspoglutide or albiglutide or lixisenatide or dulaglutide).tw.
	38	alpha-Glucosidases/
	39	alpha-glucosidase inhibitor$.tw.
	40	(acarbose or miglitol or voglibose).tw.
	41	Sodium-Glucose Transporter 2/
	42	Sodium glucose co-transporter 2 inhibitor$.tw.
	43	(canagliflozin or dapagliflozin or empagliflozin or remogliflozin or sergliflozin or tofogliflozin or ipragliflozin or ertugliflozin or luseogliflozin or sotagliflozin).tw.
	44	Dipeptidyl-Peptidase IV Inhibitors/
	45	ddp iv inhibitor$.tw.
	46	(sitagliptin or vildagliptin or saxagliptin or linagliptin or alogliptin or gemigliptin or anagliptin or teneligliptin or dutogliptin).tw.
	47	or/22-46
	48	randomized controlled trial.pt.
	49	controlled clinical trial.pt.
	50	randomi?ed.ab,ti.
	51	drug therapy.fs.
	52	randomly.ab,ti.
	53	trial$.ab,ti.
	54	group$.ab,ti.

	55	or/48-54
	56	Meta-analysis.pt.
	57	exp Meta-analysis/
	58	exp Meta-analysis as topic/
	59	(meta analy$ or metaanaly$ or meta?analy$).tw,ot.
	60	mo.fs.
	61	prognos$.tw.
	62	predict$.tw.
	63	course.tw.
	64	exp survival analysis/
	65	or/56-64
	66	55 or 65
	67	(comment or editorial or historical-article or cohort study).pt.
	68	66 not 67
	69	15 and 21 and 47 and 68
	70	exp Blood Glucose/
	71	exp Hemoglobin A, Glycosylated/
	72	Glycemic Index/
	73	glycemic index.tw.
	74	glycemic control$.tw.
	75	glucose target$.tw.
	76	(glucose control$ or glucose lower$ or glucose level$).tw.
	77	tight glycemic.tw.
	78	(tight adj2 glucose$).tw.
	79	or/70-78
	80	15 and 21 and 47 and 68 and 79
	81	69 or 80
	#1	dialysis:ti,ab,kw
	#2	h*emofiltration:ti,ab,kw

Search strategy-CENTRAL	#3	h*emodiafiltration:ti,ab,kw
	#4	(end-stage renal or end-stage kidney or endstage renal or endstage kidney):ti,ab,kw
	#5	(ESRF or ESKF or ESRD or ESKD):ti,ab,kw
	#6	(chronic kidney or chronic renal):ti,ab,kw
	#7	(CKF or CKD or CRF or CRD):ti,ab,kw
	#8	(CAPD or CCPD or APD):ti,ab,kw
	#9	(predialysis or pre-dialysis):ti,ab,kw
	#10	MeSH descriptor Kidney Failure, Chronic, this term only
	#11	MeSH descriptor Renal Replacement Therapy explode all trees
	#12	MeSH descriptor Renal Insufficiency, Chronic explode all trees
	#13	(#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12)
	#14	MeSH descriptor Diabetes Mellitus, this term only
	#15	MeSH descriptor Diabetes Mellitus explode all trees
	#16	MeSH descriptor Diabetes Mellitus, Type 2 explode all trees
	#17	MeSH descriptor Diabetic Nephropathies explode all trees
	#18	diabet*:ti,ab,kw
	#19	(niddm or iddm or T2DM):ab,ti,kw
	#20	(non insulin* depend*):ab,ti,kw or (noninsulin* depend*):ab,ti,kw or (noninsulin?depend*):ab,ti,kw or (non insulin?depend):ab,ti,kw
	#21	(#14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20)
	#22	MeSH descriptor Hypoglycemic Agents explode all trees
	#23	MeSH descriptor Sulfonylurea Compounds explode all trees
	#24	MeSH descriptor Dipeptidyl-Peptidase IV Inhibitors, this term only
	#25	MeSH descriptor Glucagon-Like Peptide 1, this term only
	#26	MeSH descriptor alpha-Glucosidases, this term only
	#27	MeSH descriptor Sodium-Glucose Transporter 2, this term only
	#28	glucose lowering and (therap* or agent* or drug*):ti,ab,kw in Clinical Trials

	#29	hypoglycemi* and (agent* or drug* or therap*):ti,ab,kw in Clinical Trials
	#30	(antidiabet* and (agent* or drug* or therap*)):ti,ab,kw in Clinical Trials
	#31	(insulin*):ti,ab,kw in Clinical Trials
	#32	(metformin):ti,ab,kw in Clinical Trials
	#33	(Rosiglitazone or Rivoglitazone or Pioglitazone or Troglitazone):ti,ab,kw in Clinical Trials
	#34	MeSH descriptor Thiazolidinediones, this term only
	#35	(acarbose or miglitol or voglibose):ti,ab,kw in Clinical Trials
	#36	(repaglinide or nateglinide or mitiglinide):ti,ab,kw in Clinical Trials
	#37	(sitagliptin or vildagliptin or saxagliptin or linagliptin or alogliptin or anagliptin or teneligliptin or gemigliptin or dutogliptin):ti,ab,kw in Clinical Trials
	#38	(glipizide or glimepride or gliclazide or glibenclamide or glyburide):ti,ab,kw in Clinical Trials
	#39	(canagliflozin or dapagliflozin or empagliflozin or remogliflozin or sergliflozin or tofogliflozin or ipragliflozin or ertugliflozin or luseogliflozin or sotagliflozin):ti,ab,kw in Clinical Trials
	#40	(glucagon-like peptide-1):ti,ab,kw in Clinical Trials
	#41	(Incretin mimetic*):ti,ab,kw in Clinical Trials
	#42	(alpha-glucosidase inhibitor*):ti,ab,kw in Clinical Trials
	#43	(exenatide or pramlintide or liraglutide or taspoglutide or albiglutide or lixisenatide or dulaglutide):ti,ab,kw in Clinical Trials
	#44	#23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43)
	#45	(#13 AND #21 AND #44)
	#46	MeSH descriptor Blood Glucose, this term only
	#47	MeSH descriptor Glycemic Index, this term only
	#48	MeSH descriptor Hemoglobin A, Glycosylated, this term only
	#49	(glycemic index):ti,ab,kw in Clinical Trials

	#50	(glycemic control*):ti,ab,kw in Clinical Trials
	#51	(glucose target*):ti,ab,kw in Clinical Trials
	#52	(glucos* near/3 management*):ti,ab,kw
	#53	(glucose NEXT control*):ti,ab,kw in Clinical Trials
	#54	(glucose NEXT lower*):ti,ab,kw in Clinical Trials
	#55	(glucose NEXT level*):ti,ab,kw in Clinical Trials
	#56	(tight NEXT glycemic):ti,ab,kw in Clinical Trials
	#57	(tight NEAR/2 glucose*):ti,ab,kw in Clinical Trials
	#58	(#46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57)
	#59	(#13 AND #21 AND #45 AND #58)
	#60	#45 OR #59
		with Publication Year from 2000 to 2023, with Cochrane Library publication date from Jan 2000 to Jul 2023, in Trials

Search Jan 2020 – 4848 citations retrieved; 146 relevant studies identified. Updated Jul 2023 search – 2505 citations retrieved, 15 relevant studies.

Guideline Chapter 3		Blood pressure control in people with diabetic kidney disease
Search strategy-MEDLINE	1	Diabetes Mellitus/
	2	Diabetes Mellitus, Type 1/
	3	exp Diabetes Mellitus, Type 2/
	4	Diabetic Nephropathies/
	5	diabet$.tw.
	6	(niddm or iddm).tw.
	7	or/1-6
	8	Kidney Diseases/
	9	exp Renal Replacement Therapy/
	10	Renal Insufficiency/
	11	exp Renal Insufficiency, Chronic/
	12	dialysis.tw.

	13	(haemodialysis or haemodialysis).tw.
	14	(hemofiltration or haemofiltration).tw.
	15	(haemodiafiltration or haemodiafiltration).tw.
	16	(end-stage renal or end-stage kidney or endstage renal or endstage kidney).tw.
	17	(ESRF or ESKF or ESRD or ESKD).tw.
	18	(chronic kidney or chronic renal).tw.
	19	(CKF or CKD or CRF or CRD).tw.
	20	(CAPD or CCPD or APD).tw.
	21	(predialysis or pre-dialysis).tw.
	22	or/8-21
	23	exp hypertension/
	24	essential hypertension/
	25	(antihypertens$ or hypertens$).tw,kf.
	26	exp blood pressure/
	27	(blood pressure or bloodpressure).tw,kf.
	28	or/23-27
	29	((below$ or goal? or intens$ or rigorous or standard or strict$ or target$ or tight$ or usual) adj4 (blood pressure or bp or dbp or diastolic or sbp or systolic)).tw,kf.
	30	((goal? or intens$ or rigorous or standard or strict$ or target$ or tight$) adj3 (control$ or level? or treat$)).tw,kf.
	31	((bp or blood pressure) adj2 (lower$ or reduc$)).tw,kf.
	32	or/29-31
	33	randomized controlled trial.pt.
	34	controlled clinical trial.pt.
	35	randomized.ab.
	36	placebo.ab.
	37	clinical trials as topic/
	38	randomly.ab.
	39	trial.ti.
	40	or/33-39

	41	exp Antihypertensive Agents/
	42	(antihypertensive adj2 (agent$ or drug$ or medicat$)).tw.
	43	exp Adrenergic alpha-Antagonists/
	44	(adrenergic adj1 alpha adj1 antagonist$).tw.
	45	((adrenergic or alpha or receptor?) adj2 block$).tw.
	46	(alfuzosin or bunazosin or doxazosin or metazosin or neldazosin or prazosin or silodosin or tamsulosin or terazosin or tiodazosin or trimazosin).tw.
	47	exp Adrenergic beta-Antagonists/
	48	(beta adj2 (adrenergic? or antagonist? or block$ or receptor?)).tw.
	49	(acebutolol or adimolol or afurolol or alprenolol or amosulalol or arotinolol or atenolol or befunolol or betaxolol or bevantolol or bisoprolol or bopindolol or bornaprolol or brefonalol or bucindolol or bucumolol or bufetolol or bufuralol or bunitrolol or bunolol or bupranolol or butofilolol or butoxamine or carazolol or carteolol or carvedilol or celiprolol or cetamolol or cloranolol or cyanoiodopindolol or cyanopindolol or deacetylmetipranolol or diacetolol or dihydroalprenolol or dilevalol or epanolol or esmolol or exaprolol or falintolol or flestolol iodopindolol or iprocrolol or isoxaprolol or labetalol or landiolol or levobunolol or levomoprolol or medroxalol or mepindolol or methylthiopropranolol or flusoxolol or hydroxybenzylpinodolol or hydroxycarteolol or hydroxymetoprolol or indenolol or iodocyanopindolol or metipranolol or metoprolol or moprolol or nadolol or oxprenolol or penbutolol or pindolol or nadolol or nebivolol or nifenalol or nipradilol or oxprenolol or pafenolol or pamatolol or penbutolol or pindolol or practolol or primidolol or prizidilol or procinolol or pronetalol or propranolol or proxodolol or ridazolol or salcardolol or soquinolol or sotalol or spirendolol or talinolol or tertatolol or tienoxolol or tilisolol or timolol or tolamolol or toliprolol or tribendilol or xibenolol).tw.
	50	exp Angiotensin-Converting Enzyme Inhibitors/
	51	exp angiotensin converting enzyme inhibitors/
	52	(ACE adj1 inhibitor$).tw.
	53	exp angiotensin II type 1 receptor blockers/
	54	(angiotensin adj3 blocker$).tw.
	55	angiotensin converting enzyme inhibit$.tw.

	56	(ace adj2 inhibit$).tw.
	57	acei.tw.
	58	(alacepril or altiopril or ancovenin or benazepril$ or captopril or ceranapril or ceronapril or cilazapril$ or deacetylalacepril or delapril or derapril or enalapril$ or epicaptopril or fasidotril$ or foroxymithine or fosinopril$ or gemopatrilat or idapril or imidapril$ or indolapril or libenzapril or lisinopril or moexipril$ or moveltipril or omapatrilat or pentopril$ or perindopril$ or pivopril or quinapril$ or ramipril$ or rentiapril or saralasin or s nitrosocaptopril or spirapril$ or temocapril$ or teprotide or trandolapril$ or utibapril$ or zabicipril$ or zofenopril$ or Aceon or Accupril or Altace or Capoten or Lotensin or Mavik or Monopril or Prinivil or Univas or Vasotec or Zestril).tw.
	59	exp Angiotensin Receptor Antagonists/
	60	(angiotensin adj3 (receptor antagon$ or receptor block$)).tw.
	61	arb?.tw.
	62	(abitesartan or azilsartan or candesartan or elisartan or embusartan or eprosartan or forasartan or irbesartan or losartan or milfasartan or olmesartan or saprisartan or tasosartan or telmisartan or valsartan or zolasartan).tw.
	63	exp Diuretics/
	64	diuretic$.tw.
	65	exp thiazides/
	66	exp sodium chloride symporter inhibitors/
	67	exp sodium potassium chloride symporter inhibitors/
	68	((ceiling or loop) adj diuretic?).tw.
	69	(amiloride or benzothiadiazine or bendroflumethiazide or bumetanide or chlorothiazide or cyclopenthiazide or furosemide or hydrochlorothiazide or hydroflumethiazide or methyclothiazide or metolazone or polythiazide or trichlormethiazide or veratide or thiazide?).tw.
	70	(chlorthalidone or chlortalidone or phthalamudine or chlorphthalidolone or oxodoline or thalitone or hygroton or indapamide or metindamide).tw.
	71	spironolactone.tw.

	72	exp Ganglionic Blockers/
	73	exp Vasodilator Agents/
	74	exp Aldosterone Antagonists/
	75	exp calcium channel blockers/
	76	(calcium adj2 (antagonist? or block$ or inhibit$)).tw.
	77	(amlodipine or aranidipine or barnidipine or bencyclane or benidipine or bepridil or cilnidipine or cinnarizine or clentiazem or darodipine or diltiazem or efonidipine or elgodipine or etafenone or fantofarone or felodipine or fendiline or flunarizine or gallopamil or isradipine or lacidipine or lercanidipine or lidoflazine or lomerizine or manidipine or mibefradil or nicardipine or nifedipine or niguldipine or nilvadipine or nimodipine or nisoldipine or nitrendipine or perhexiline or prenylamine or semotiadil or terodiline or tiapamil or verapamil).tw.
	78	(methyldopa or alphamethyldopa or amodopa or dopamet or dopegyt or dopegit or dopegite or emdopa or hyperpax or hyperpaxa or methylpropionic acid or dopergit or meldopa or methyldopate or medopa or medomet or sembrina or aldomet or aldometil or aldomin or hydopa or methyldihydroxyphenylalanine or methyl dopa or mulfasin or presinol or presolisin or sedometil or sembrina or taquinil or dihydroxyphenylalanine or methylphenylalanine or methylalanine or alpha methyl dopa).tw.
	79	(reserpine or serpentina or rauwolfia or serpasil).tw.
	80	(clonidine or adesipress or arkamin or caprysin or catapres$ or catasan or chlofazolin or chlophazolin or clinidine or clofelin$ or clofenil or clomidine or clondine or clonistada or clonnirit or clophelin$ or dichlorophenylaminoimidazoline or dixarit or duraclon or gemiton or haemiton or hemiton or imidazoline or isoglaucon or klofelin or klofenil or m-5041t or normopresan or paracefan or st-155 or st 155 or tesno timelets).tw.
	81	exp hydralazine/
	82	(hydralazin$ or hydrallazin$ or hydralizine or hydrazinophtalazine or hydrazinophthalazine or hydrazinophtalizine or dralzine or hydralacin or hydrolazine or hypophthalin or hypoftalin or hydrazinophthalazine or idralazina or 1-hydrazinophthalazine or apressin or nepresol or apressoline

		or apresoline or apresolin or alphapress or alazine or idralazina or lopress or plethorit or praeparat).tw.
	83	or/41-82
	84	7 and 22 and 28 and 32 and 40 and 83
	85	limit 84 to humans
	86	limit 85 to yr="2000 -Current"
Search strategy-CENTRAL	#1	dialysis:ti,ab,kw
	#2	h*emofiltration:ti,ab,kw
	#3	h*emodiafiltration:ti,ab,kw
	#4	(end-stage renal or end-stage kidney or endstage renal or endstage kidney):ti,ab,kw
	#5	(ESRF or ESKF or ESRD or ESKD):ti,ab,kw
	#6	(chronic kidney or chronic renal):ti,ab,kw
	#7	(CKF or CKD or CRF or CRD):ti,ab,kw
	#8	(CAPD or CCPD or APD):ti,ab,kw
	#9	(predialysis or pre-dialysis):ti,ab,kw
	#10	MeSH descriptor: [Kidney Failure, Chronic] this term only
	#11	MeSH descriptor: [Renal Replacement Therapy] explode all trees
	#12	MeSH descriptor: [Renal Insufficiency, Chronic] explode all trees
	#13	#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12
	#14	MeSH descriptor: [Diabetes Mellitus] this term only
	#15	MeSH descriptor: [Diabetes Mellitus, Type 1] explode all trees
	#16	MeSH descriptor: [Diabetes Mellitus, Type 2] explode all trees
	#17	MeSH descriptor: [Diabetic Nephropathies] explode all trees
	#18	diabet*:ti,ab,kw
	#19	(niddm or iddm):ab,ti,kw
	#20	#14 or #15 or #16 or #17 or #18 or #19
	#21	MeSH descriptor: [Blood Pressure] explode all trees
	#22	MeSH descriptor: [Hypertension] explode all trees

	#23	(elevate* OR high* OR raise*) NEAR2 blood pressure:ti,ab,kw
	#24	hypertens*:ti,ab,kw
	#25	#21 or #22 or #23 or #24
	#26	MeSH descriptor: [Antihypertensive Agents] explode all trees
	#27	antihypertensive near agent* or drug* or medicat*:ti,a,kw
	#28	MeSH descriptor: [Calcium Channel Blockers] explode all trees
	#29	calcium near2 (antagonist* or block* or inhibit*):ti,ab,kw
	#30	(amlodipine or amrinone or aranidipine or barnidipine or bencyclane or benidipine or bepridil or cilnidipine or cinnarizine or clentiazem or darodipine or diltiazem or efonidipine or elgodipine or etafenone or fantofarone or felodipine or fendiline or flunarizine or gallopamil or isradipine or lacidipine or lercanidipine or lidoflazine or lomerizine or manidipine or mibefradil or nicardipine or nifedipine or niguldipine or nilvadipine or nimodipine or nisoldipine or nitrendipine or perhexiline or prenylamine or semotiadil or terodiline or tiapamil or verapamil):ti,ab,kw
	#31	MeSH descriptor: [Diuretics] explode all trees
	#32	diuretic*:ti,ab,kw
	#33	MESH descriptor: [Thiazides] explode all trees
	#34	MESH descriptor: [Sodium Chloride Symporter Inhibitors] explode all trees
	#35	MESH descriptor: [Sodium Potassium Chloride Symporter Inhibitors] explode all trees
	#36	((loop or ceiling) next (diuretic or diuretics)):ti,ab,kw
	#37	(amiloride or benzothiadiazine or bendroflumethiazide or bumetanide or chlorothiazide or cyclopenthiazide or furosemide or hydrochlorothiazide or hydroflumethiazide or methyclothiazide or metolazone or polythiazide or trichlormethiazide or veratide or thiazide or thiazides):ti,ab,kw
	#38	(chlorthalidone or chlortalidone or phthalamudine or chlorphthalidolone or oxodoline or thalitone or hygroton or indapamide or metindamide):ti,ab,kw
	#39	MeSH descriptor: [Adrenergic beta-Agonists] explode all trees
	#40	beta near2 (adrenergic or antagonist or antagonists or blocker or blockers or blocking or receptor or receptors):ti,ab,kw

	#41	beta next blocker*:ti,ab,kw
	#42	(acebutolol or adimolol or afurolol or alprenolol or amosulalol or arotinolol or atenolol or befunolol or betaxolol or bevantolol or bisoprolol or bopindolol or bornaprolol or brefonalol or bucindolol or bucumolol or bufetolol or bufuralol or bunitrolol or bunolol or bupranolol or butofilolol or butoxamine or carazolol or carteolol or carvedilol or celiprolol or cetamolol or chlortalidone cloranolol or cyanoiodopindolol or cyanopindolol or deacetylmetipranolol or diacetolol or dihydroalprenolol or dilevalol or epanolol or esmolol or exaprolol or falintolol or flestolol or flusoxolol or hydroxybenzylpinodolol or hydroxycarteolol or hydroxymetoprolol or indenolol or iodocyanopindolol or iodopindolol or iprocrolol or isoxaprolol or labetalol or landiolol or levobunolol or levomoprolol or medroxalol or mepindolol or methylthiopropranolol or metipranolol or metoprolol or moprolol or nadolol or oxprenolol or penbutolol or pindolol or nadolol or nebivolol or nifenalol or nipradilol or oxprenolol or pafenolol or pamatolol or penbutolol or pindolol or practolol or primidolol or prizidilol or procinolol or pronetalol or propranolol or proxodolol or ridazolol or salcardolol or soquinolol or sotalol or spirendolol or talinolol or tertatolol or tienoxolol or tilisolol or timolol or tolamolol or toliprolol or tribendilol or xibenolol):ti,ab,kw
	#43	MeSH descriptor: [Adrenergic alpha-Agonists] explode all trees
	#44	adrenergic near2 (alpha or antagonist or antagonists):ti,ab,kw
	#45	(adrenergic or alpha or receptor or receptors) near2 (blocker or blockers or blocking):ti,ab,kw
	#46	(alfuzosin or bunazosin or doxazosin or metazosin or neldazosin or prazosin or silodosin or tamsulosin or terazosin or tiodazosin or trimazosin):ti,ab,kw
	#47	(methyldopa or alphamethyldopa or amodopa or dopamet or dopegyt or dopegit or dopegite or emdopa or hyperpax or hyperpaxa or methylpropionic acid or dopergit or meldopa or methyldopate or medopa or medomet or sembrina or aldomet or aldometil or aldomin or hydopa or methyldihydroxyphenylalanine or methyl dopa or mulfasin or presinol or

		presolisin or sedometil or sembrina or taquinil or dihydroxyphenylalanine or methylphenylalanine or methylalanine or alpha methyl dopa):ti,ab,kw
	#48	MeSH descriptor: [Vasodilator Agents] explode all trees
	#49	(clonidine or adesipress or arkamin or caprysin or catapres$ or catasan or chlofazolin or chlophazolin or clinidine or clofelin$ or clofenil or clomidine or clondine or clonistada or clonnirit or clophelin$ or dichlorophenylaminoimidazoline or dixarit or duraclon or gemiton or haemiton or hemiton or imidazoline or isoglaucon or klofelin or klofenil or m-5041t or normopresan or paracefan or st-155 or st 155 or tesno timelets):ti,ab,kw
	#50	MeSH descriptor: [Hydralazine] explode all trees
	#51	((hydralazin*) or (hydrallazin*) or hydralizine or hydrazinophtalazine or hydrazinophthalazine or hydrazinophtalizine or dralzine or hydralacin or hydrolazine or hypophthalin or hypoftalin or hydrazinophthalazine or idralazina or 1 hydrazinophthalazine or apressin or nepresol or apressoline or apresoline or apresolin or alphapress or alazine or idralazina):ti,ab,kw
	#52	MeSH descriptor: [Angiotensin II Type 1 Receptor Blockers] explode all trees
	#53	MeSH descriptor: [Angiotensin-Converting Enzyme Inhibitors] explode all trees
	#54	angiotensin near blocker*:ti,ab,kw
	#55	ace near3 inhibit*:ti,ab,kw
	#56	acei:ti,ab,kw
	#57	(alacepril or altiopril or ancovenin or benazepril or captopril or ceranapril or ceronapril or cilazapril or deacetylalacepril or delapril or derapril or enalapril or epicaptopril or fasidotril or fosinopril or foroxymithine or gemopatrilat or idapril or imidapril or indolapril or libenzapril or lisinopril or moexipril or moveltipril or omapatrilat or pentopril* or perindopril or pivopril or quinapril or ramipril or ramiprilat or rentiapril or saralasin or s nitrosocaptopril or spirapril or temocapril or teprotide or trandolapril or utibapril or zabicipril or zofenopril):ti,ab,kw
	#58	MeSH descriptor: [Angiotensin Receptor Antagonists] explode all trees
	#59	angiotensin near3 (receptor antagonist* or receptor block*):ti,ab,kw

	#60	(arb OR arbs):ti,ab,kw
	#61	(abitesartan or azilsartan or candesartan or elisartan or embusartan or eprosartan or forasartan or irbesartan or losartan or milfasartan or olmesartan or saprisartan or tasosartan or telmisartan or valsartan or zolasartan):ti,ab,kw
	#62	MeSH descriptor: [Aldosterone Antagonists] explode all trees
	#63	(reserpine or serpentina or rauwolfia or serpasil):ti,ab,kw
	#64	#26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63
	#65	#13 AND #20 AND #25 AND #64
		with Publication Year from 2000 to 2023, with Cochrane Library publication date from Jan 2000 to Jul 2023, in Trials

Search Jan 2020 – 1979 citations retrieved; 57 relevant studies identified. Updated Jul 2023 search – 1035 citations retrieved, 8 relevant studies.

Guideline Chapter 4		Treatment targeting progression of CKD in people with diabetic kidney disease
Search strategy-Medline	1	exp Aldosterone Antagonists/
	2	Canrenoate Potassium.tw.
	3	Canrenone$.tw.
	4	spironolactone$.tw.
	5	aldosterone antagonist$.tw.
	6	aldactone$.tw.
	7	sc-9420$.tw.
	8	sc-14266$.tw.
	9	soldactone$.tw.
	10	soludactone$.tw.
	11	aldadiene$.tw.
	12	eplerenone$.tw.

	13	exp angiotensin converting enzyme inhibitors/
	14	(ACE adj1 inhibitor$).tw.
	15	exp angiotensin II type 1 receptor blockers/
	16	(angiotensin adj3 blocker$).tw.
	17	angiotensin converting enzyme inhibit$.tw.
	18	(ace adj2 inhibit$).tw.
	19	acei.tw.
	20	(alacepril or altiopril or ancovenin or benazepril$ or captopril or ceranapril or ceronapril or cilazapril$ or deacetylalacepril or delapril or derapril or enalapril$ or epicaptopril or fasidotril$ or foroxymithine or fosinopril$ or gemopatrilat or idapril or imidapril$ or indolapril or libenzapril or lisinopril or moexipril$ or moveltipril or omapatrilat or pentopril$ or perindopril$ or pivopril or quinapril$ or ramipril$ or rentiapril or saralasin or s nitrosocaptopril or spirapril$ or temocapril$ or teprotide or trandolapril$ or utibapril$ or zabicipril$ or zofenopril$ or Aceon or Accupril or Altace or Capoten or Lotensin or Mavik or Monopril or Prinivil or Univas or Vasotec or Zestril).tw.
	21	exp Angiotensin Receptor Antagonists/
	22	(angiotensin adj3 (receptor antagon$ or receptor block$)).tw.
	23	arb?.tw.
	24	(abitesartan or azilsartan or candesartan or elisartan or embusartan or eprosartan or forasartan or irbesartan or losartan or milfasartan or olmesartan or saprisartan or tasosartan or telmisartan or valsartan or zolasartan).tw.
	25	Glucagon-Like Peptide 1/
	26	glucagon-like peptide-1.tw.
	27	Incretin mimetic$.tw.
	28	(exenatide or pramlintide or liraglutide or taspoglutide or albiglutide or lixisenatide or dulaglutide).tw.
	29	Sodium-Glucose Transporter 2/
	30	Sodium glucose co-transporter 2 inhibitor$.tw.

	31	(canagliflozin or dapagliflozin or empagliflozin or remogliflozin or sergliflozin or tofogliflozin or ipragliflozin or ertugliflozin or luseogliflozin or sotagliflozin).tw.
	32	exp vitamin d/
	33	Diet Therapy/
	34	Diet, Protein Restricted/
	35	(protein$ and diet$).tw.
	36	protein restrict$.tw.
	37	protein reduc$.tw.
	38	low protein diet$.tw.
	39	Pentoxifylline/
	40	oxpentifylline.tw.
	41	pentoxifylline.tw.
	42	trental.tw.
	43	torental.tw.
	44	BL-191.tw.
	45	agapurin.tw.
	46	or/1-45
	47	Renal Insufficiency/
	48	exp Renal Insufficiency, Chronic/
	49	Kidney Diseases/
	50	(chronic kidney or chronic renal).tw.
	51	(CKF or CKD or CRF or CRD).tw.
	52	(predialysis or pre-dialysis).tw.
	53	exp Uremia/
	54	uremi.tw.
	55	(pre-dialy$ or predialy$).tw.
	56	or/47-55
	57	exp Diabetes Mellitus/
	58	Diabetic Nephropathies/
	59	diabetic nephropath$.tw.

	60	((diabetic or diabetes) and (kidney$ or renal$ or nephros$ or nephritis or glomerulo)).tw.
	61	or/57-60
	62	46 and 56 and 61
	63	limit 62 to humans
	64	limit 63 to yr="2000 -Current"
Search strategy-CENTRAL	#1	MeSH descriptor Aldosterone Antagonists explode all trees
	#2	(Canrenoate Potassium*):ti,ab,kw in Clinical Trials
	#3	(Canrenone*):ti,ab,kw in Clinical Trials
	#4	(spironolactone*):ti,ab,kw in Clinical Trials
	#5	(aldosterone antagonist*):ti,ab,kw in Clinical Trials
	#6	(aldactone*):ti,ab,kw in Clinical Trials
	#7	(soldactone*):ti,ab,kw in Clinical Trials
	#8	(soludactone*):ti,ab,kw in Clinical Trials
	#9	(phanurane*):ti,ab,kw in Clinical Trials
	#10	(eplerenone*):ti,ab,kw in Clinical Trials
	#11	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10
	#12	MeSH descriptor: [Angiotensin II Type 1 Receptor Blockers] explode all trees
	#13	MeSH descriptor: [Angiotensin-Converting Enzyme Inhibitors] explode all trees
	#14	angiotensin near blocker*:ti,ab,kw
	#15	ace near3 inhibit*:ti,ab,kw
	#16	acei:ti,ab,kw
	#17	(alacepril or altiopril or ancovenin or benazepril or captopril or ceranapril or ceronapril or cilazapril or deacetylalacepril or delapril or derapril or enalapril or epicaptopril or fasidotril or fosinopril or foroxymithine or gemopatrilat or idapril or imidapril or indolapril or libenzapril or lisinopril or moexipril or moveltipril or omapatrilat or pentopril* or perindopril or pivopril or quinapril or ramipril or ramiprilat or rentiapril or saralasin or s nitrosocaptopril or spirapril or temocapril or teprotide or trandolapril or utibapril or zabicipril or zofenopril):ti,ab,kw
	#18	MeSH descriptor: [Angiotensin Receptor Antagonists] explode all trees

	#19	angiotensin near3 (receptor antagonist* or receptor block*):ti,ab,kw
	#20	(arb OR arbs):ti,ab,kw
	#21	(abitesartan or azilsartan or candesartan or elisartan or embusartan or eprosartan or forasartan or irbesartan or losartan or milfasartan or olmesartan or saprisartan or tasosartan or telmisartan or valsartan or zolasartan):ti,ab,kw
	#22	MeSH descriptor Glucagon-Like Peptide 1, explode all trees
	#23	MeSH descriptor Sodium-Glucose Transporter 2, explode all trees
	#24	(canagliflozin or dapagliflozin or empagliflozin or remogliflozin or sergliflozin or tofogliflozin or ipragliflozin or ertugliflozin or luseogliflozin or sotagliflozin):ti,ab,kw in Clinical Trials
	#25	(glucagon-like peptide-1):ti,ab,kw in Clinical Trials
	#26	(Incretin mimetic*):ti,ab,kw in Clinical Trials
	#27	(exenatide or pramlintide or liraglutide or taspoglutide or albiglutide or lixisenatide or dulaglutide):ti,ab,kw in Clinical Trials
	#28	#12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27
	#29	MeSH descriptor vitamin d explode all trees
	#30	vitamin d:ti,ab,kw in Clinical Trials
	#31	#29 OR #30
	#32	MeSH descriptor Diet Therapy, explode all trees
	#33	MeSH descriptor Diet, Protein-Restricted, explode all trees
	#34	(protein*):ti,ab,kw and (diet*):ti,ab,kw in Trials
	#35	(protein NEAR/2 restrict*):ti,ab,kw in Trials
	#36	(protein NEAR/2 reduc*):ti,ab,kw in Trials
	#37	(low protein diet*):ti,ab,kw in Trials
	#38	#32 OR #33 OR #34 OR #35 OR #36 OR #37
	#39	MeSH descriptor Pentoxifylline, explode all trees
	#40	(oxpentifylline):ti,ab,kw in Clinical Trials
	#41	(trental):ti,ab,kw in Clinical Trials
	#42	(torental):ti,ab,kw in Clinical Trials
	#43	(agapurin):ti,ab,kw in Clinical Trials

	#44	(bl-191):ti,ab,kw in Clinical Trials
	#45	(pentoxifylline):ti,ab,kw in Clinical Trials
	#46	#39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45
	#47	MeSH descriptor Renal Insufficiency, Chronic explode all trees
	#48	(chronic kidney disease* or chronic renal disease*):ti,ab,kw in Clinical Trials
	#49	(chronic kidney failure* or chronic renal failure*):ti,ab,kw in Clinical Trials
	#50	(chronic kidney insufficiency or chronic renal insufficiency):ti,ab,kw in Clinical Trials
	#51	MeSH descriptor Renal Insufficiency, explode all trees
	#52	MeSH descriptor Kidney Diseases, explode all trees
	#53	(CKF or CKD or CRF or CRD):ti,ab,kw in Trials
	#54	(predialysis or pre-dialysis):ti,ab,kw in Trials
	#55	MeSH descriptor Uremia, explode all trees
	#56	uremia or uraemia or uremic or uraemic:ti,ab,kw in Trials
	#57	#47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56
	#58	MeSH descriptor Diabetes Mellitus explode all trees
	#59	MeSH descriptor Diabetic Nephropathies, this term only
	#60	(diabetic nephropath*):ti,ab,kw in Clinical Trials
	#61	((diabetic or diabetes) and (kidney* or renal or nephro* or nephritis* or glomerulo*)):ti,ab,kw in Clinical Trials
	#62	#58 OR #59 OR #60 OR #61
	#63	#11 OR #28 OR #31 OR #38 OR #46
	#64	#57 AND #62 AND #63
		with Cochrane Library publication date from Jan 2000 to Jul 2023, in Trials
Search Jan 2020 – 4462 citations retrieved; 171 relevant studies identified. Updated Jul 2023 search – 1847 citations retrieved, 15 relevant studies.		

Guideline Chapter 5		Antiplatelet or anticoagulant therapy in people with diabetes and CKD
Search strategy-Medline	1	exp Renal Dialysis/
	2	(haemodialysis or haemodialysis).tw.
	3	(hemofiltration or haemofiltration).tw.

	4	(haemodiafiltration or haemodiafiltration).tw.
	5	dialysis.tw.
	6	(PD or CAPD or CCPD or APD).tw.
	7	Renal Insufficiency/
	8	Kidney Failure/
	9	exp Renal Insufficiency, Chronic/
	10	Kidney Diseases/
	11	Uremia/
	12	(end-stage renal or end-stage kidney or endstage renal or endstage kidney).tw.
	13	(ESRF or ESKF or ESRD or ESKD).tw.
	14	(chronic kidney or chronic renal).tw.
	15	(CKF or CKD or CRF or CRD).tw.
	16	(predialysis or pre-dialysis).tw.
	17	ur?emi$.tw.
	18	or/1-17
	19	exp diabetes mellitus/
	20	exp Diabetes Mellitus, Type 1/
	21	exp Diabetes Mellitus, Type 2/
	22	Diabetic Nephropathies/
	23	diabet$.tw.
	24	(niddm or iddm).tw.
	25	or/19-24
	26	Atrial Fibrillation/
	27	atrial fibrillation.tw.
	28	auricular fibrillation.tw.
	29	or/26-28
	30	(new adj3 anticoagulant*).tw.
	31	dabigatran.tw,rn.
	32	apixaban.tw,rn.
	33	rivaroxaban.tw,rn.
	34	edoxaban.tw,rn.

	35	direct thrombin inhibit*.tw.
	36	Anticoagulants/ and Factor Xa/
	37	factor xa inhibit*.tw.
	38	or/30-37
	39	and/18,25,29,38
	40	exp Platelet Aggregation Inhibitors/
	41	exp Phosphodiesterase Inhibitors/
	42	Adenosine Diphosphate/ai [Antagonists & Inhibitors]
	43	Platelet Glycoprotein GPIIb-IIIa Complex/ai [Antagonists & Inhibitors]
	44	Sulfinpyrazone/
	45	(antiplatelet agents$ or anti-platelet agent$).tw.
	46	(antiplatelet therap$ or anti-platelet therap$).tw.
	47	platelet aggregation inhibit$.tw.
	48	phosphodiesterase inhibit$.tw.
	49	thrombocyte aggregation inhibit$.tw.
	50	(antithrombocytic agent$ or anti-thrombocytic agent$).tw.
	51	(antithrombocytic therap$ or anti-thrombocytic therap$).tw.
	52	alprostadil.tw.
	53	aspirin.tw.
	54	acetylsalicylic acid.tw.
	55	(adenosine reuptake inhibit$ or adenosine re-uptake inhibit$).tw.
	56	adenosine diphosphate receptor inhibit$.tw.
	57	dipyridamole.tw.
	58	disintegrins.tw.
	59	epoprostenol.tw.
	60	iloprost.tw.
	61	ketanserin.tw.
	62	milrinone.tw.
	63	pentoxifylline.tw.
	64	S-nitrosoglutathione.tw.
	65	S-nitrosothioles.tw.
	66	trapidil.tw.

	67	ticlopidine.tw.
	68	clopidogrel.tw.
	69	(sulfinpyrazone or sulphinpyrazone).tw.
	70	cilostazol.tw.
	71	(P2Y12 adj2 antagonis$).tw.
	72	prasugrel.tw.
	73	ticagrelor.tw.
	74	cangrelor.tw.
	75	elinogrel.tw.
	76	glycoprotein IIB IIIA inhibitors.tw.
	77	abciximab.tw.
	78	eptifibatide.tw.
	79	tirofiban.tw.
	80	defibrotide.tw.
	81	picotamide.tw.
	82	beraprost.tw.
	83	ticlid.tw.
	84	aggrenox.tw.
	85	ditazole.tw.
	86	or/40-85
	87	and/18,25,86
	88	39 or 87
Search strategy-CENTRAL	#1	MeSH descriptor Phosphodiesterase Inhibitors explode all trees
	#2	MeSH descriptor Adenosine Diphosphate, this term only
	#3	MeSH descriptor Platelet Glycoprotein GPIIb-IIIa Complex, this term only
	#4	((antiplatelet next agent*) or (anti-platelet next agent*)):ti,ab,kw
	#5	((antiplatelet therap*) or (anti-platelet therap*)):ti,ab, kw
	#6	(platelet next aggregation next inhibit*):ti,ab,kw
	#7	(phosphodiesterase next inhibit*):ti,ab,kw
	#8	(thrombocyte next aggregation next inhibit*):ti,ab,kw
	#9	((antithrombocytic next agent*) or (anti-thrombocytic next agent*)):ti,ab,kw

	#10	((antithrombocytic next therap*) or (anti-thrombocytic next therap*)):ti,ab,kw
	#11	alprostadil:ti,ab,kw
	#12	aspirin:ti,ab,kw
	#13	acetylsalicylic acid:ti,ab,kw
	#14	((adenosine next reuptake inhibit*) or (adenosine reuptake inhibit*)):ti,ab,kw
	#15	(adenosine next diphosphate next receptor next inhibit*):ti,ab,kw
	#16	dipyridamole:ti,ab,kw
	#17	disintegrins:ti,ab,kw
	#18	epoprostenol:ti,ab,kw
	#19	iloprost:ti,ab,kw
	#20	ketanserin:ti,ab,kw
	#21	milrinone:ti,ab,kw
	#22	pentoxifylline:ti,ab,kw
	#23	(S-nitrosoglutathione):ti,ab,kw
	#24	S-nitrosothiols:ti,ab,kw
	#25	trapidil:ti,ab,kw
	#26	ticlopidine:ti,ab,kw
	#27	clopidogrel:ti,ab,kw
	#28	(sulfinpyrazone or sulphinpyrazone):ti,ab,kw
	#29	cilostazol:ti,ab,kw
	#30	(P2Y12 NEAR/2 antagonis*):ti,ab,kw
	#31	prasugrel:ti,ab,kw
	#32	ticagrelor:ti,ab,kw
	#33	cangrelor:ti,ab,kw
	#34	elinogrel:ti,ab,kw
	#35	“glycoprotein IIB IIIA inhibitors”:ti,ab,kw
	#36	abciximab:ti,ab,kw
	#37	eptifibatide:ti,ab,kw
	#38	tirofiban:ti,ab,kw
	#39	defibrotide:ti,ab,kw

	#40	picotamide:ti,ab,kw
	#41	beraprost:ti,ab,kw
	#42	ticlid:ti,ab,kw
	#43	aggrenox:ti,ab,kw
	#44	ditazole:ti,ab,kw
	#45	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44
	#46	dialysis:ti,ab,kw
	#47	(haemodialysis or haemodialysis):ti,ab,kw
	#48	(hemofiltration or haemofiltration):ti,ab,kw
	#49	(haemodiafiltration or haemodiafiltration):ti,ab,kw
	#50	(PD or CAPD or CCPD or APD):ti,ab,kw
	#51	(renal next insufficiency):ti,ab,kw
	#52	(kidney next failure):ti,ab,kw
	#53	(kidney next disease*):ti,ab,kw
	#54	ur*emi*:ti,ab,kw
	#55	((chronic next kidney) or (chronic next renal)):ti,ab, kw
	#56	(CKF or CKD or CRF or CRD):ti,ab,kw
	#57	predialysis:ti,ab,kw
	#58	((end-stage next renal) or (end-stage next kidney) or (endstage next renal) or (endstage next kidney)):ti,ab,kw
	#59	(ESKD or ESRD or ESKF or ESRF):ti,ab,kw
	#60	(#46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59)
	#61	(#45 AND #60)
	#62	MeSH descriptor Diabetes Mellitus, this term only
	#63	MeSH descriptor Diabetes Mellitus, Type 1 explode all trees
	#64	MeSH descriptor Diabetes Mellitus, Type 2 explode all trees
	#65	MeSH descriptor Diabetic Nephropathies explode all trees

	#66	diabet*:ti,ab,kw
	#67	(niddm or iddm):ab,ti,kw
	#68	#62 OR #63 OR #64 OR #65 OR #66 OR #67
	#69	#68 AND #61
	#70	#45 AND #69
	#71	"atrial fibrillation":ti,ab,kw
	#72	"auricular fibrillation":ti,ab,kw
	#73	#71 OR #72
	#74	(new near/3 anticoagulant*):ti,ab,kw
	#75	dabigatran:ti,ab,kw
	#76	apixaban:ti,ab,kw
	#77	rivaroxaban:ti,ab,kw
	#78	edoxaban:ti,ab,kw
	#79	(thrombinnextinhibit*):ti,ab,kw
	#80	((factor next xa next inhibit*) or (factor next 10a next inhibit*)):ti,ab,kw
	#81	MeSH descriptor: [Anticoagulants] this term only
	#82	MeSH descriptor: [Factor Xa] this term only
	#83	#74 OR #75 OR #76 OR #77 OR #78 OR #79 OR #80 OR #81 OR #82
	#84	#68 AND #61 AND #73 AND #83
	#85	#70 OR #84
		with Cochrane Library publication date from Jan 2000 to Jul 2023, in Trials

Search Jan 2020 – 1135 citations retrieved; 19 relevant studies identified. Updated Oct 2023 search – 594 citations retrieved, 1 relevant study.

Appendix 2. Concurrence with Institute of Medicine (IOM) standards for guideline development

Table S2. Guideline development checklist - IOM standards for development of trustworthy clinical practice guidelines

IOM Standard	Description	Addressed in 2023 SEN Diabetes in CKD guideline
Establishing transparency	Clear description on the process of guideline development.	See Methods for Guideline Development
Management of conflicts of interests	Disclosure of a comprehensive conflict of interests of the Work Group against a set-criteria and a clear strategy to manage conflicts of interests	See Work Group Financial Disclosures
Guideline group composition and guideline development	Appropriate clinical and methodological expertise in the Work Group. The processes of guideline development are transparent and allow for involvement of all Work Group Members	For guideline group composition – see Work Group Membership. For guideline development process see Methods for Guideline Development
Establishing evidence foundations for rating strength of recommendations	Rationale is provided for the rating the strength of the recommendation and the transparency for the rating the quality of the evidence.	See Methods for Guideline Development

Articulation of recommendations	Clear and standardized wording of recommendations	All recommendations were written to standards of GRADE and were actionable statements.
External review	An external review of relevant experts and stakeholders was conducted. All comments received from external review are considered for finalization of the guideline.	An external public review was undertaken in Feb 2024.
Updating	An update for the guidelines is planned, with a provisional timeframe provided.	The SEN clinical practice guideline will be updated. However, no set timeframe has been provided.

** Reference: Institute of Medicine (US). Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. In: Graham R, Mancher M, Miller Wolman DW, et al., eds. Clinical Practice Guidelines We Can Trust. National Academies Press (US); 2011*

Appendix 3. Summary of findings (SoF) tables cited in the guideline text.

Chapter 2. Metabolic control in people with diabetic kidney disease

Table S2.1. sGLT2i compared to placebo/standard of care in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: sGLT2i

Comparison: placebo/standard of care

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with control	Risk with sGLT2i			
Mortality (all causes)	RR 0.91 (0.84 to 0.98)	72 per 1000	66 per 1000	36759 (11)[1–11]	⊕⊕⊕⊕ high	sGLT2i decrease all-cause mortality.
		Difference: 6 fewer per 1000 (11 fewer – 1 fewer)				
Death due to renal cause	RR 0.54 (0.23 to 1.27)	1 per 1000	0 per 1000	21561 (2)[6,10]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision	sGTL2i probably results in little to no difference in death due to renal cause.
		Difference: 1 fewer per 1000 (1 fewer – 0 more)				
Cardiovascular death	RR 0.88 (0.79 to 0.99)	37 per 1000	33 per 1000	35452 (6)[1,6,9–12]	⊕⊕⊕⊕ high	sGLT2i decrease cardiovascular death.
		Difference: 4 fewer per 1000 (7 fewer – 1 fewer)				
Kidney composite	RR 0.62 (0.52 to 0.75)	32 per 1000	20 per 1000	32145 (3)[1,6,10]	⊕⊕⊕⊕ high	sGLT2i decrease kidney composite outcomes.
		Difference: 12 fewer per 1000 (15 fewer – 8 fewer)				
Acute kidney injury	RR 0.77 (0.65 to 0.92)	25 per 1000	19 per 1000	22759 (6)[2–4,6,10,11]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision	sGLT2i probably decrease slightly acute kidney injury.
		Difference: 6 fewer per 1000 (9 fewer – 2 fewer)				
Doubling serum creatinine	RR 0.63 (0.51 to 0.78)	79 per 1000	49 per 1000	4950 (3)[5–7]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision	sGLT2i probably decrease doubling serum creatinine.
		Difference: 30 fewer per 1000 (40 fewer – 18 fewer)				
Myocardial infarction	RR 0.86 (0.75 to 0.97)	64 per 1000	54 per 1000	22618 (4)	⊕⊕⊕⊕ high	sGLT2i decrease myocardial infarction.
		Difference: 10 fewer				

		per 1000 (16 fewer – 3 fewer)			
Heart failure	RR 0.71 (0.61 to 0.83)	35 per 1000 / 26 per 1000 Difference: 9 fewer per 1000 (12 fewer – 5 fewer)	20933 (5)[3,9–12]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision	sGLT2i probably decrease heart failure.
Non-fatal stroke	RR 1.00 (0.84 to 1.20)	26 per 1000 / 25 per 1000 Difference: 1 fewer per 1000 (5 fewer – 4 more)	18683 (4)[3,10–12]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision	sGLT2i probably do not decrease non-fatal stroke.
Treatment dropouts due to adverse effects	RR 1.07 (0.84 to 1.37)	66 per 1000 / 76 per 1000 Difference: 10 more per 1000 (6 fewer – 31 more)	20771 (11)[2–5,8,10–13]	⊕⊕⊕⊖ moderate Due to serious risk of inconsistency	sGLT2i probably do not increase treatment dropouts due to adverse effects.
Hypoglycemia	RR 0.99 (0.88 to 1.12)	255 per 1000 / 261 per 1000 Difference: 6 more per 1000 (23 fewer – 40 more)	2834 (8)[2–5,11–14]	⊕⊕⊕⊖ moderate Due to serious risk of bias	sGLT2i probably have little or no difference on hypoglycemia.
Fracture	RR 0.98 (0.74 to 1.29)	45 per 1000 / 46 per 1000 Difference: 1 more per 1000 (10 fewer – 15 more)	23780 (8)[2,5–7,10–12,14]	⊕⊕⊕⊖ moderate Due to serious risk of inconsistency	sGLT2i probably have little or no difference on fracture.
Hyperkalemia	RR 0.71 (0.45 to 1.13)	78 per 1000 / 59 per 1000 Difference: 19 fewer per 1000 (40 fewer – 16 more)	5115 (3)[3,6,11]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision.	sGLT2i probably have little or no difference on hyperkalemia.
Amputations	RR 1.09 (0.89 to 1.33)	16 per 1000 / 17 per 1000 Difference: 1 more per 1000 (2 fewer – 5 more)	22641 (4)[6,7,10,12]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision.	sGLT2i probably have little or no difference on amputations.

HbA1c	--	Difference: MD 0.19 lower (0.30 lower to 0.09 lower)	35559 (12)[1–8,10–12,15]	⊕⊕⊖⊖ low Due to very serious risk of inconsistency.	sGLT2i may decrease HbA1c.
eGFR (mL/min)	--	Difference: MD 0.98 lower (2.63 lower to 0.67 higher)	6229 (6)[2,4,6,7,12,16]	⊕⊕⊖⊖ low Due to very serious risk of inconsistency.	sGLT2i may have little or no difference on eGFR.
UACR (% change from baseline)	--	Difference: MD 27.08 lower (27.46 lower to 26.71 lower)	4698 (2)[6,7]	⊕⊕⊕⊕ high	sGLT2i decrease UACR.

CI: confidence interval, eGFR: estimated glomerular filtration rate, MD: mean difference, UACR: urine creatinine albumin ratio, RR: risk ratio

Table S2.2. GLP-1 RA compared to placebo/standard of care in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: GLP-1 RA

Comparison: placebo/standard of care

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with control	Risk with GLP-1 RA			
Mortality (all causes)	RR 0.89 (0.79 to 0.99)	78 per 1000	66 per 1000	27100 (6)[17–22]	⊕⊕⊕⊕ high	GLP-1 RA reduce all-cause mortality.
		Difference: 12 fewer per 1000 (19 fewer – 5 fewer)				
Cardiovascular death	RR 0.90 (0.80 to 1.00)	48 per 1000	41 per 1000	27094 (6) [17–22]	⊕⊕⊕⊕ high	GLP-1 RA reduce cardiovascular death.
		Difference: 7 fewer per 1000 (12 fewer – 2 fewer)				
Myocardial infarction	RR 0.86 (0.66 to 1.11)	32 per 1000	28 per 1000	10555 (3)[17,19,20]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision.	GLP-1 RA probably does not reduce myocardial infarction.
		Difference: 4 fewer per 1000 (10 fewer - 4 more)				
Heart failure	RR 0.99 (0.85 to 1.15)	47 per 1000	42 per 1000	19800 (5)[17,19–21,23]	⊕⊕⊕⊕ high	GLP-1 RA does not reduce heart failure.
		Difference: 5 fewer per 1000 (11 fewer - 2 more)				
Stroke	RR 0.83 (0.55 to 1.26)	19 per 1000	17 per 1000	12548 (4)[17,19–21]	⊕⊕⊖⊖ low Due to serious risk of imprecision and inconsistency.	GLP-1 RA may not reduce stroke.
		Difference: 2 fewer per 1000 (8 fewer - 7 more)				

Acute kidney injury	RR 0.92 (0.70 to 1.20)	33 per 1000	30 per 1000 Difference: 3 fewer per 1000 (10 fewer - 6 more)	6480 (2)[19,20]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision.	GLP-1 RA does not reduce acute kidney injury.
Treatment dropouts due to adverse events	RR 1.66 (1.32 to 2.08)	65 per 1000	107 per 1000 Difference: 42 more per 1000 (20 more - 69 more)	16004 (5)[19–21,23,24]	⊕⊕⊕⊖ moderate Due to serious risk of inconsistency.	GLP-1 RA probably increase the risk of treatment dropouts due to adverse effects.
Gastrointestinal adverse events	RR 2.35 (1.27 to 4.33)	57 per 1000	92 per 1000 Difference: 35 more per 1000 (7 fewer - 112 more)	6783 (4)[19,20,24,25]	⊕⊕⊕⊖ moderate Due to serious risk of inconsistency.	GLP-1 RA probably increase the risk of gastrointestinal effects.
HbA1c	--	Difference: MD 0.68 lower (1.00 lower to 0.35 lower)		11435 (6)[17,19,20,22,24,25]	⊕⊕⊖⊖ low Due to very serious risk of inconsistency.	GLP-1 RA may reduce HbA1c.
Weight (kg)	--	Difference: MD 2.89 lower (3.70 lower to 2.08 lower)		10834 (4)[12,19,20,24]	⊕⊕⊖⊖ low Due to very serious risk of inconsistency.	GLP-1 RA may reduce weight.
eGFR (mL/min)	--	Difference: MD 1.08 lower (1.87 lower to 0.30 lower)		856 (2)[22,24]	⊕⊖⊖⊖ Very low Due to very serious risk of inconsistency and serious risk of imprecision.	The evidence is very uncertain about the effect of GLP-1 RA on eGFR.

Table S2.3. Dual GLP-1/GIP compared to placebo/standard of care in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: GLP-1/GIP

Comparison: placebo/standard of care

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with control	Risk with GLP-1/GIP			
HbA1c	--	Difference: MD 0.88 lower (1.23 lower to 0.53 lower)		2036 (2)[26,27]	⊕⊕⊕⊖ moderate Due to serious risk of inconsistency	GLP-1/GIP may reduce HbA1c.
eGFR (mL/min)	--	Difference: MD 2.20 higher (1.88 higher to 2.53 higher)		2036 (2) [26,27]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision	GLP-1/GIP probably increase eGFR slightly.
UACR (mean change from baseline %)	--	Difference: MD 28.46 lower (58.47 lower to 1.54 higher)		2036 (2) [26,27]	⊕⊕⊖⊖ low Due to very serious risk of inconsistency	GLP-1/GIP may have little to no effect on UACR.
Treatment dropouts due to adverse effects	RR 1.88 (1.37 to 2.58)	54 per 1000	101 per 1000	2036 (2) [26,27]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision	GLP-1/GIP probably increase treatment dropouts due to adverse effects.
		Difference: 47 more per 1000 (19 more – 84 more)				
Gastrointestinal adverse effects		0 per 1000	16 per 1000	2036 (2) [26,27]	⊕⊕⊕⊖	GLP-1/GIP probably increase

	RR 15.58 (2.10 to 115.40)	Difference: 16 more per 1000 (12 more – 22 more)		moderate Due to serious risk of imprecision	gastrointestinal adverse effects.

Table S2.4. DPP4i compared to placebo/standard of care in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: DPP4i

Comparison: placebo/standard of care

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with DPP4i	Risk with DPP4i			
Mortality (all causes)	RR 0.98 (0.85 to 1.12)	97 per 1000	90 per 1000	8339 (7)[28–34]	⊕⊕⊕⊖ moderate Due to serious risk of bias.	DPP4i probably have little or no difference on mortality.
		Difference: 7 fewer per 1000 (18 fewer – 6 more)				
Stroke	RR 0.92 (0.68 to 1.23)	25 per 1000	23 per 1000	7112 (2)[32,35]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision.	DPP4i probably have little or no difference on stroke.
		Difference: 2 fewer per 1000 (8 fewer - 6 more)				
Treatment dropouts due to adverse effects	RR 1.00 (0.82 to 1.23)	110 per 1000	103 per 1000	8501 (9) [32,35]	⊕⊕⊕⊖ moderate Due to serious risk of bias.	DPP4i probably have little or no difference on treatment dropouts due to adverse effects.
		Difference: 7 fewer per 1000 (25 fewer - 17 more)				
Amputations	RR 1.14 (0.99 to 1.33)	58 per 1000	66 per 1000	10303 (2)[32,36]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision	DPP4i probably have little or no difference on amputations.
		Difference: 8 more per 1000 (1 fewer - 19 more)				
Hypoglycemia	RR 1.06 (0.80 to 1.42)	277 per 1000	278 per 1000	8315 (8)[28–30,32,33,35,37,38]	⊕⊕⊖⊖ low Due to serious risk of bias and inconsistency	DPP4i may have little or no effect on hypoglycemia.
		Difference: 1 more per 1000 (67 fewer - 95 more)				

HbA1c	--	Difference: MD 0.37 lower (0.55 lower to 0.20 lower)	8444 (11)[28–30,32–35,38–41]	⊕⊖⊖⊖ very low Due to very serious risk of inconsistency and serious risk of bias.	The evidence is very uncertain about the effect of DPP4i on HbA1c.
eGFR (mL/min)	--	Difference: MD 4.02 higher (0.34 higher to 7.71 higher)	195 (2)[34,40]	⊕⊖⊖⊖ very low Due to very serious risk of inconsistency, and serious risk of bias and imprecision.	The evidence is very uncertain about the effect of DPP4i on eGFR.

Table S2.5. Non-steroidal MRA compared to placebo/standard of care in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: Non-steroidal MRA

Comparison: placebo/standard of care

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with control	Risk with non-steroidal MRA			
Mortality (all causes)	RR 0.90 (0.80 to 1.00)	94 per 1000	85 per 1000	13050 (3)[42–44]	⊕⊕⊕⊕ high	Non-steroidal MRA have little or no effect on all-cause mortality.
		Difference: 9 fewer per 1000 (18 fewer – 0 fewer)				
Cardiovascular death	RR 0.88 (0.76 to 1.02)	56 per 1000	49 per 1000	13026 (2)[42,43]	⊕⊕⊕⊕ high	Non-steroidal MRA have little or no effect on cardiovascular death.
		Difference: 7 fewer per 1000 (14 fewer – 1 more)				
Death from renal cause	RR 0.62 (0.12 to 3.23)	1 per 1000	0 per 1000	13026 (2)[42,43]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision	Non-steroidal MRA probably does not reduce death from renal cause.
		Difference: 1 fewer per 1000 (1 fewer – 0 fewer)				
Kidney composite	RR 0.86 (0.79 to 0.93)	153 per 1000	131 per 1000	13026 (2)[42,43]	⊕⊕⊕⊕ high	Non-steroidal MRA decrease composite kidney outcome.
		Difference: 22 fewer per 1000 (33 fewer – 11 fewer)				
Heart failure	RR 0.79 (0.66 to 0.94)	50 per 1000	39 per 1000	13026 (2)[42,43]	⊕⊕⊕⊖ moderate	Non-steroidal MRA probably decrease heart failure.
		Difference: 11 fewer per 1000				

		(17 fewer – 4 fewer)		Due to serious risk of imprecision	
Myocardial infarction	RR 0.91 (0.74 to 1.12)	29 per 1000 / 24 per 1000 Difference: 5 fewer per 1000 (9 fewer – 1 more)	13847 (3)[42,43,45]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision	Non-steroidal MRA probably have little or no difference on myocardial infarction.
Stroke	RR 0.99 (0.82 to 1.20)	30 per 1000 / 27 per 1000 Difference: 3 fewer per 1000 (8 fewer – 3 more)	13847 (3)[42,43,45]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision	Non-steroidal MRA probably have little or no difference on stroke.
Treatment dropouts due to adverse effects	RR 1.19 (1.04 to 1.36)	54 per 1000 / 64 per 1000 Difference: 10 more per 1000 (2 more – 19 more)	13903 (5)[42–46]	⊕⊕⊕⊖ moderate Due to serious risk of bias	Non-steroidal MRA probably increase treatment dropouts due to adverse events slightly.
Serious adverse events	RR 1.43 (0.95 to 2.14)	13 per 1000 / 23 per 1000 Difference: 21 more per 1000 (2 more – 21 more)	6479 (2)[42,45]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision	Non-steroidal MRA probably increase serious adverse events slightly.
Hyperkalemia	RR 2.03 (1.83 to 2.27)	68 per 1000 / 128 per 1000 Difference: 60 more per 1000 (47 more – 75 more)	13863 (4)[42,43,45,46]	⊕⊕⊕⊕ high	Non-steroidal MRA increase hyperkalemia.

Table S2.6. Degludec compared to glargine of care in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: degludec

Comparison: glargine

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with glargine	Risk with degludec			
HbA1c	--	Difference: MD 0.30 higher (0.30 lower to 0.91 higher)		7732 (2)[47,48]	⊕⊕⊖⊖ low Due to very serious risk of inconsistency	Degludec may result in little to no difference in HbA1c.

Table S2.7. Thiazolidinedione compared to placebo/standard of care in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: thiazolidinedione

Comparison: placebo/standard of care

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with control	Risk with thiazolidinedione			
HbA1c	--	Difference: MD 0.29 lower (0.64 lower to 0.05 higher)		641 (8)[49–56]	⊕⊖⊖⊖ very low Due to very serious risk of inconsistency and bias	The evidence is very uncertain about the effect of thiazolidinedione on HbA1c.
Weight (kg)	--	Difference: MD 3.96 higher (1.62 lower to 9.53 higher)		206 (4)[49,52,53,56]	⊕⊖⊖⊖ very low Due to very serious risk of inconsistency and serious risk of bias and imprecision	The evidence is very uncertain about the effect of thiazolidinedione on weight.
eGFR (mL/min)	--	Difference: MD 0.20 lower (2.92 lower to 2.52 higher)		983 (3)[52,54,57]	⊕⊕⊖⊖ low Due to very serious risk of inconsistency	Thiazolidinedione may have little to no effect on eGFR.
Hypoglycemia		149 per 1000	101 per 1000	457 (2)[52,54]	⊕⊕⊖⊖	Thiazolidinedione may have little to

	RR 0.58 (0.19 to 1.72)	Difference: 48 fewer per 1000 (115 fewer – 150 more)		low Due to serious risk of imprecision and inconsistency .	no effect on hypoglycemia.

Table S2.8. Probiotics compared to placebo/standard of care in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: probiotics

Comparison: placebo/standard of care

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with control	Risk with probiotics			
HbA1c	--	Difference: MD 0.15 lower (0.54 lower to 0.24 higher)		120 (2)[58,59]	⊕⊖⊖⊖ very low Due to very serious risk of bias and serious risk of imprecision.	The evidence is very uncertain about the effect of probiotics on HbA1c.

Table S2.9. Exercise compared to standard of care in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: exercise

Comparison: standard of care

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with control	Risk with exercice			
HbA1c	--	Difference: MD 0.03 lower (0.84 lower to 0.77 higher)		52 (2)[60,61]	⊕⊕⊖⊖ low Due to serious risk of bias and imprecision.	Exercise may have little or no effect on HbA1c.

Table S2.10. Antioxidative compared to placebo/standard of care in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: Antioxidative

Comparison: placebo/standard of care

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with control	Risk with antioxidative			
HbA1c	--	Difference: MD 0.23 lower (0.13 lower to 0.59 higher)		2464 (3)[62–64]	⊕⊖⊖⊖ very low Due to very serious risk of inconsistency and serious risk of bias.	The evidence is very uncertain about the effect of antioxidative on HbA1c.
Weight (kg)	--	Difference: MD 6.53 lower (18.34 lower to 5.28 higher)		320 (3)[62,63,65]	⊕⊖⊖⊖ very low Due to very serious risk of inconsistency and serious risk of bias.	The evidence is very uncertain about the effect of antioxidative on weight.
BMI	--	Difference: MD 0.10 lower (0.18 lower to 0.03 lower)		320 (3) [62,63,65]	⊕⊖⊖⊖ very low Due to serious risk of imprecision, inconsistency and bias.	The evidence is very uncertain about the effect of antioxidative on BMI.

Chapter 3. Blood pressure control in people with diabetic kidney disease

Table S3.1. Intensive blood pressure control vs standard control in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: Intensive blood pressure control

Comparison: Standard blood pressure control

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with clopidogrel	Risk with ticagrelor			
All-cause mortality	RR 0.89 (0.71 to 1.12)	84 per 1000	71 per 1000	16353 (3)[66–68]	⊕⊕⊖⊖ low Due to serious risk of bias and inconsistency	Intensive blood pressure control may result in little to no difference in all-cause mortality.
		Difference: 13 fewer per 1000 (27 fewer – 5 more)				
Cardiovascular mortality	RR 0.88 (0.71 to 1.08)	40 per 1000	34 per 1000	15873 (2)[66,67]	⊕⊕⊕⊖ moderate Due to serious risk of inconsistency	Intensive blood pressure control probably results in little to no difference in cardiovascular mortality.
		Difference: 6 fewer per 1000 (12 fewer – 2 more)				
Cardiovascular events	RR 0.89 (0.74 to 1.06)	98 per 1000	86 per 1000	4862 (2)[66,69]	⊕⊕⊖⊖ low Due to serious risk of imprecision and risk of bias.	Intensive blood pressure control may result in little to no difference in cardiovascular events.
		Difference: 12 fewer per 1000 (26 fewer - 5 more)				
Myocardial infarction	RR 0.88 (0.79 to 0.98)	85 per 1000	75 per 1000	16353 (3)[66–68]	⊕⊕⊕⊖ moderate Due to serious risk of bias	Intensive blood pressure control probably reduces myocardial infarction.
		Difference: 10 fewer per 1000 (18 fewer – 1 fewer)				

Stroke	RR 0.67 (0.41 to 1.11)	46 per 1000	40 per 1000	16353 (3)[66–68]	⊕⊕⊖⊖ low Due to serious risk of bias and inconsistency	Intensive blood pressure control may result in little to no difference in stroke.
		Difference: 6 fewer per 1000 (22 fewer - 20 more)				
Heart failure	RR 0.95 (0.72 to 1.25)	39 per 1000	36 per 1000	5213 (2)[66,68]	⊕⊕⊖⊖ low Due to serious risk of bias and imprecision	Intensive blood pressure control may result in little to no difference in heart failure.
		Difference: 3 fewer per 1000 (12 fewer - 8 more)				

CI: confidence interval, RR: risk ratio

Table S3.2. ARB compared to ACEI in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: ARB

Comparison: ACEI

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with ACEI	Risk with ARB			
Systolic blood pressure (mmHg)	--	Difference: MD 0.25 lower (1.50 lower to 1.01 higher)		163 (2)[70,71]	⊕⊖⊖⊖ very low Due to serious risk of bias, inconsistency and imprecision.	The evidence is very uncertain about the effect of ARB on systolic blood pressure compared to ACEI.
Diastolic blood pressure (mmHg)	--	Difference: MD 2.00 lower (5.92 lower to 1.92 higher)		163 (2)[70,71]	⊕⊖⊖⊖ very low Due to serious risk of bias, inconsistency	The evidence is very uncertain about the effect of ARB on diastolic blood pressure compared to ACEI.

					and imprecision.	
Need of initiation of RRT	RR 0.46 (0.20 to 1.07)	34 per 1000	16 per 1000	897 (2)[72,73]	⊕⊕⊖⊖ low Due to serious risk of bias and imprecision.	ARB may result in little to no difference in need of initiation of RRT compared to ACEI.
		Difference: 18 fewer per 1000 (27 fewer – 3 more)				
Mortality (all causes)	RR 1.12 (0.68 to 1.85)	36 per 1000	52 per 1000	1210 (4)[71–74]	⊕⊕⊕⊖ moderate Due to serious risk of bias	ARB likely results in little to no difference in mortality compared to ACEI.
		Difference: 16 more per 1000 (5 fewer – 50 more)				
Cardiovascular death	RR 0.98 (0.39 to 2.45)	21 per 1000	20 per 1000	897 (2)[72,73]	⊕⊕⊖⊖ low Due to serious risk of bias and imprecision.	ARB may result in little to no difference in cardiovascular death compared to ACEI.
		Difference: 1 fewer per 1000 (13 fewer - 29 more)				
Heart failure	RR 1.23 (0.49 to 3.07)	49 per 1000	58 per 1000	320 (2)[73,74]	⊕⊕⊖⊖ low Due to serious risk of bias and imprecision.	ARB may result in little to no difference in heart failure compared to ACEI.
		Difference: 9 more per 1000 (26 fewer – 96 more)				
Myocardial infarction	RR 1.52 (0.59 to 3.91)	43 per 1000	64 per 1000	320 (2)[73,74]	⊕⊕⊖⊖ low Due to serious risk of bias and imprecision.	ARB may result in little to no difference in myocardial infarction compared to ACEI.
		Difference: 21 more per 1000 (18 fewer – 122 more)				
Doubling serum creatinine	RR 0.96 (0.41 to 2.24)	61 per 1000	54 per 1000	313 (2)[71,74]	⊕⊕⊕⊖ moderate Due to serious imprecision.	ARB likely results in little to no difference in doubling serum creatinine compared to ACEI.
		Difference: 7 fewer per 1000 (38 fewer – 65 more)				

CI: confidence interval, MD: mean difference, RR: risk ratio

Table S3.3. ARB compared to placebo in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: ARB

Comparison: placebo/standard of care

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with control	Risk with ARB			
Systolic blood pressure (mmHg)	--	Difference: 4.76 lower (7.55 lower to 1.78 lower)		3227 (3)[75–77]	⊕⊕⊖⊖ low Due to very serious risk of inconsistency.	ARB may reduce systolic blood pressure compared to standard of care.
Diastolic blood pressure (mmHg)	--	Difference: MD 1.67 lower (3.64 lower to 0.31 higher)		3227 (3)[75–77]	⊕⊕⊖⊖ low Due to very serious risk of inconsistency.	ARB may result in slight reduction to no difference in diastolic blood pressure compared to standard of care.
Need of initiation of RRT	RR 0.78 (0.67 to 0.91)	222 per 1000	172 per 1000	2661 (2)[75,77]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision. [75–77]	ARB probably reduces the need of initiation of RRT compared to standard of care.
		Difference: 50 fewer per 1000 (74 fewer – 21 fewer)				
Mortality (all causes)	RR 0.99 (0.85 to 1.15)	166 per 1000	164 per 1000	3227 (3)[75–77]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision.	ARB probably results in little to no difference in all-cause mortality compared to standard of care.
		Difference: 2 fewer per 1000 (25 fewer – 24 more)				
Hyperkalemia	RR 2.49 (0.88 to 7.03)	20 per 1000	43 per 1000	1714 (2)[76,77]	⊕⊕⊖⊖ low	ARB may result in slightly higher risk to no difference in
		Difference: 23 more				

		per 1000 (5 fewer - 102 more)			Due to serious risk of inconsistency and imprecision.	hyperkalemia compared to standard of care.
Heart failure	RR 0.71 (0.57 to 0.90)	145 per 1000	104 per 1000	2079 (2)[75,76]	⊕⊕⊕⊖ moderate Due to serious imprecision.	ARB probably reduces the risk of heart failure compared to standard of care.
		Difference: 41 fewer per 1000 (13 fewer – 62 fewer)				
Myocardial infarction	RR 0.72 (0.51 to 1.01)	72 per 1000	51 per 1000	2079 (2)[75,76]	⊕⊕⊕⊖ moderate Due to serious imprecision.	ARB probably reduces the risk of myocardial infarction slightly compared to standard of care.
		Difference: 21 fewer per 1000 (36 fewer – 1 more)				
Doubling serum creatinine	RR 0.82 (0.73 to 0.92)	280 per 1000	227 per 1000	3227 (3)[75–77]	⊕⊕⊕⊕ high	ARB reduces the risk of doubling serum creatinine compared to standard of care.
		Difference: 53 fewer per 1000 (77 fewer - 25 more)				

CI: confidence interval, MD: mean difference, RR: risk ratio

Table S3.4. Steroidal MRA compared to placebo/standard of care in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: Steroidal MRA

Comparison: Placebo/standard of care

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with control	Risk with steroidal MRA			

Systolic blood pressure (mmHg)	--	Difference: MD 5.62 lower (8.28 lower to 2.95 lower)	86 (2)[78,79]	⊕⊕⊖⊖ low Due to serious risk of bias and imprecision.	Steroidal MRA may reduce systolic blood pressure compared to standard of care.
Diastolic blood pressure (mmHg)	--	Difference: MD 4.10 lower (4.93 lower to 3.27 lower)	86 (2)[78,79]	⊕⊕⊖⊖ low Due to serious risk of bias and imprecision.	Steroidal MRA may reduce diastolic blood pressure compared to standard of care.
eGFR (mL/min)	--	Difference: MD 4.65 lower (12.47 lower to 3.17 higher)	86 (2)[78,79]	⊕⊖⊖⊖ very low Due to serious risk of bias and very serious risk of inconsistency.	Steroidal MRA may reduce eGFR decline compared to standard of care but the evidence is very uncertain.
UACR (mg/g)	--	Difference: MD 20.75 lower (40.90 lower to 0.60 lower)	86 (2)[78,79]	⊕⊕⊖⊖ low Due to serious risk of bias and inconsistency.	Steroidal MRA may reduce UACR slightly compared to standard of care.

CI: confidence interval, eGFR: estimated glomerular filtration rate, MD: mean difference, RR: risk ratio, UACR: urine albumin creatinine ratio.

Table S3.5. Non-steroidal MRA compared to placebo/standard of care in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: Non-steroidal MRA

Comparison: Placebo/standard of care

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with control	Risk with non steroidal MRA			
Systolic blood pressure (mmHg)	--	Difference: MD 6.12 lower (10.10 lower to 2.15 lower)		6134 (3)[42,80,81]	⊕⊕⊖⊖ low Due to very serious risk of inconsistency.	Non-steroidal MRA may reduce systolic blood pressure compared to standard of care.
Diastolic blood pressure (mmHg)	--	Difference: MD 1.38 lower (2.35 lower to 0.41 lower)		6015 (2)[42,81]	⊕⊕⊖⊖ low Due to very serious risk of inconsistency.	Non-steroidal MRA may reduce diastolic blood pressure slightly compared to standard of care.
Mortality (all-cause)	RR 0.90 (0.76 to 1.07)	84 per 1000	70 per 1000	6032 (2)[42,81]	⊕⊕⊕⊖ moderate Due to serious imprecision.	Non-steroidal MRA probably results in small decrease to no difference in all-cause mortality compared to standard of care.
		Difference: 14 fewer per 1000 (25 fewer - 1 more)				

Treatment dropouts due to adverse effects	RR 1.25 (1.03 to 1.52)	59 per 1000	73 per 1000	6016 (2)[42,81]	⊕⊕⊕⊖ moderate Due to serious imprecision.	Non-steroidal MRA probably increases the risk of treatment dropouts due to adverse effects compared to standard of care.
		Difference: 14 more per 1000 (1 more – 30 more)				
Hyperkalemia	RR 2.04 (1.75 to 2.37)	77 per 1000	154 per 1000	6016 (2)[42,81]	⊕⊕⊕⊕ high	Non-steroidal MRA increases the risk of hyperkalemia compared to standard of care.
		Difference: 77 more per 1000 (55 more – 102 more)				

CI: confidence interval, eGFR: estimated glomerular filtration rate, MD: mean difference, RR: risk ratio, UACR: urine albumin creatinine ratio.

Table S3.6. Aliskiren compared to placebo/standard of care in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: Aliskiren

Comparison: Placebo/standard of care

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with control	Risk with aliskiren			
Systolic blood pressure (mmHg)	--	Difference: MD 0.10 higher (3.83 lower to 4.03 higher)		225 (1)[82]	⊕⊖⊖⊖ very low Due to serious risk of bias and very serious risk of inconsistency	The evidence is very uncertain about the effect of aliskiren on PAS.
Diastolic blood pressure (mmHg)	--	Difference: MD 1.00 lower (1.56 lower to 0.44 lower)		225 (1) [82]	⊕⊖⊖⊖ very low Due to serious risk of bias and very serious risk of inconsistency	Aliskiren may reduce diastolic blood pressure slightly compared to standard of care, but the evidence is very uncertain.

CI: confidence interval, eGFR: estimated glomerular filtration rate, MD: mean difference, UACR: urine albumin creatinine ratio.

Table S3.7. Aliskiren+ARB compared to ARB in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: Aliskiren+ARB

Comparison: ARB

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with control	Risk with aliskiren			
Systolic blood pressure (mmHg)	--	Difference: MD 2.73 lower (4.62 lower to 0.84 lower)		1744 (2)[83,84]	⊕⊕⊖⊖ low Due to serious risk of bias and inconsistency	Aliskiren+ARB may reduce systolic blood pressure slightly compared to ARB.
Diastolic blood pressure (mmHg)	--	Difference: MD 1.75 lower 3.00 lower to 0.50 lower)		1744 (2)[83,84]	⊕⊖⊖⊖ very low Due to serious risk of bias and very serious risk of inconsistency	Aliskiren+ARB may reduce diastolic blood pressure slightly compared to ARB, but the evidence is very uncertain.
eGFR (mL/min)	--	Difference: MD 0.33 lower (2.16 lower to 1.51 higher)		1744 (2)[83,84]	⊕⊕⊖⊖ low Due to very serious risk of inconsistency	Aliskiren+ARB has little to no difference in eGFR compared to ARB.
UACR (% mean change)	--	Difference: MD 16.39 lower (18.74 lower to 14.04 lower)		589 (1)[83]	⊕⊕⊖⊖ low Due to very serious risk of inconsistency.	Aliskiren+ARB may reduce albuminuria compared to ARB.

Any adverse event	RR 1.10 (0.97 to 1.23)	298 per 1000	336 per 1000	1744 (2)[83,84]	⊕⊖⊖⊖ very low Due to serious risk of bias and very serious risk of inconsistency	The evidence is very uncertain about the effect of aliskiren+ARB on any adverse event compared to ARB.
		Difference: 38 more per 1000 (2 less – 77 more)				
Treatment discontinuation due to adverse effects	RR 1.43 (0.78 to 2.62)	19 per 1000	28 per 1000	1744 (2)[83,84]	⊕⊖⊖⊖ very low Due to serious risk of bias and very serious risk of inconsistency	The evidence is very uncertain about the effect of aliskiren+ARB on treatment discontinuation due to adverse effects compared to ARB.
		Difference: 9 more per 1000 (4 less to 32 more)				

CI: confidence interval, eGFR: estimated glomerular filtration rate, MD: mean difference, UACR: urine albumin creatinine ratio.

Chapter 4. CKD progression in people with diabetic kidney disease

Table S4.1. ACEI compared to placebo/standard of care in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: ACEI

Comparison: Placebo/standard of care

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with control	Risk with ACEI			
Mortality (all causes)	RR 1.04 (0.91 to 1.19)	103 per 1000	107 per 1000	7500 (9)[85–93]	⊕⊕⊕⊖ moderate Due to serious risk of bias	ACEI probably results in little to no difference in mortality compared to placebo/standard of care.
		Difference: 4 more per 1000 (9 fewer – 19 more)				
Cardiovascular death	RR 1.02 (0.84 to 1.25)	60 per 1000	61 per 1000	5912 (6)[85,87–91]	⊕⊕⊖⊖ low Due to serious risk of bias and imprecision	ACEI may result in little to no difference in cardiovascular death compared to placebo/standard of care.
		Difference: 1 more per 1000 (10 fewer – 15 more)				
Doubling serum creatinine	RR 0.81 (0.57 to 1.17)	24 per 1000	20 per 1000	5298 (3)[88,94,95]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision	ACEI probably results in little to no difference in doubling serum creatinine compared to placebo/standard of care.
		Difference: 4 fewer per 1000 (10 fewer - 5 more)				
New onset of macroalbuminuria	RR 0.73 (0.48 to 1.11)	83 per 1000	59 per 1000	1178 (5)[85,89,92,96,97]	⊕⊖⊖⊖ very low Due to serious risk of imprecision and very	The evidence is very uncertain about the effect of ACEI on new onset of macroalbuminuria compared to
		Difference: 24 fewer per 1000 (44 fewer – 7 more)				

					serious risk of bias	placebo/standard of care.
Need of initiation of RRT	RR 0.55 (0.18 to 1.70)	3 per 1000	2 per 1000	6567 (9)[85,86,88–92,95,96]	⊕⊖⊖⊖ very low Due to very serious risk of imprecision and bias	The evidence is very uncertain about the effect of ACEI on need of initiation of RRT compared to placebo/standard of care.
		Difference: 1 fewer per 1000 (2 fewer – 3 more)				
Major adverse cardiovascular events	RR 0.81 (0.43 to 1.54)	128 per 1000	91 per 1000	6209 (5)[86–89,96]	⊕⊕⊖⊖ low Due to serious risk of bias and inconsistency	ACEI may result in little to no difference in major cardiovascular events compared to placebo/ standard of care.
		Difference: 37 fewer per 1000 (79 fewer – 45 more)				
Heart failure	0.84 (0.69 to 1.02)	54 per 1000	45 per 1000	7365 (4)[88,89,93,96]	⊕⊕⊖⊖ low Due to serious risk of bias and imprecision	ACEI may result in slight decrease to no difference in heart failure compared to placebo/standard of care.
		Difference: 9 fewer per 1000 (17 fewer – 1 more)				
Myocardial infarction	RR 0.97 (0.65 to 1.45)	33 per 1000	31 per 1000	7365 (4)[88,89,93,96]	⊕⊖⊖⊖ very low Due to serious risk of imprecision, inconsistency and bias	The evidence is very uncertain about the effect of ACEI on myocardial infcarction compared to placebo/standard of care.
		Difference: 2 fewer per 1000 (12 fewer – 13 more)				
Stroke	RR 1.06 (0.72 to 1.56)	29 per 1000	31 per 1000	7365 (4)[88,89,93,96]	⊕⊕⊖⊖ low Due to serious risk of bias and imprecision	ACEI may result in little to no difference in stroke compared to placebo/ standard of care.
		Difference: 2 more per 1000 (8 fewer – 17 more)				
Treatment dropouts due to adverse effects	RR 1.12 (1.01 to 1.23)	184 per 1000	205 per 1000	6424 (8)[85–89,92,94,96]	⊕⊕⊕⊖ moderate	ACEI probably increases treatment dropouts due to

		Difference: 21 more per 1000 (1 more – 41 more)		Due to serious risk of bias	adverse effects compared to placebo/ standard of care.
Serious adverse effects	RR 0.98 (0.84 to 1.14)	454 per 1000 / 438 per 1000 Difference: 16 fewer per 1000 (79 fewer – 56 more)	6614 (3)[87,88,93]	⊕⊕⊖⊖ low Due to very serious risk of inconsistency	ACEI may result in little to no difference in serious adverse effects compared to placebo/ standard of care.
HbA1c (%)	--	Difference: MD 0.30 higher (0.68 lower to 1.28 higher)	95 (2)[85,86]	⊕⊖⊖⊖ very low Due to very serious risk of bias and inconsistency	The evidence is very uncertain about the effect of ACEI on HbA1c compared to placebo/standard of care.
eGFR (mL/min)	--	Difference: MD 0.17 lower (0.66 lower to 0.32 higher)	659 (2)[89,92]	⊕⊕⊖⊖ low Due to serious risk of inconsistency and imprecision	ACEI may result in little to no difference in eGFR decline compared to placebo/standard of care.
UACR (% change from baseline)	--	Difference: MD 48.74 lower (137.04 lower to 39.55 higher)	146 (2)[85,90]	⊕⊖⊖⊖ very low Due to very serious risk of bias, inconsistency and imprecision.	The evidence is very uncertain about the effect of ACEI on UACR compared to placebo/standard of care.

CI: confidence interval, MD: mean difference, UACR: urine albumin creatinine ratio, RR: risk ratio

Table S4.2. ARB compared to placebo/standard of care in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: ARB

Comparison: Placebo/standard of care

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with control	Risk with ARB			
Mortality (all causes)	RR 1.03 (0.93 to 1.13)	92 per 1000	94 per 1000	14508 (6)[75,76,98–101]	⊕⊕⊕⊕ high	ARB results in little to no difference in mortality compared to placebo/standard of care.
		Difference: 2 more per 1000 (7 fewer – 11 more)				
Death from renal causes	RR 0.97 (0.77 to 1.22)	182 per 1000	180 per 1000	7439 (2)[75,100]	⊕⊕⊖⊖ low Due to very serious risk of inconsistency	ARB may result in little to no difference in death from renal causes compared to placebo/standard of care.
		Difference: 2 fewer per 1000 (39 fewer – 44 more)				
Cardiovascular death	RR 1.56 (0.51 to 4.73)	68 per 1000	72 per 1000	6616 (3)[76,100,101]	⊕⊕⊖⊖ low Due to serious risk of inconsistency and imprecision	ARB may result in little to no difference in cardiovascular death compared to placebo/standard of care.
		Difference: 4 more per 1000 (44 fewer - 150 more)				
Kidney composite	RR 1.03 (0.74 to 1.43)	53 per 1000	54 per 1000	6492 (2)[76,100]	⊕⊕⊖⊖ low Due to serious risk of inconsistency	ARB may result in little to no difference in kidney composite compared to placebo/standard of care.
		Difference: 1 more per 1000				

		(14 fewer – 22 more)			and imprecision	
New onset of macroalbuminuria	RR 0.52 (0.31 to 0.87)	292 per 1000	160 per 1000	1222 (3)[100,102,103]	⊕⊕⊖⊖ low Due to serious risk of inconsistency and bias	ARB may reduce new onset of macroalbuminuria compared to placebo/standard of care.
		Difference: 132 fewer per 1000 (177 fewer – 70 fewer)				
Doubling serum creatinine	RR 0.90 (0.72 to 1.13)	102 per 1000	89 per 1000	9514 (5)[75,76,98,100,104]	⊕⊕⊖⊖ low Due to serious risk of inconsistency and bias	ARB may result in little to no difference in doubling serum creatinine compared to placebo/standard of care.
		Difference: 13 fewer per 1000 (31 fewer – 10 more)				
Need of initiation of RRT	RR 0.79 (0.68 to 0.92)	68 per 1000	55 per 1000	9221 (6)[75,98,100,101,103,104]	⊕⊕⊕⊖ moderate Due to serious risk of bias	ARB probably reduces the need of initiation of RRT compared to placebo/standard of care.
		Difference: 13 fewer per 1000 (29 fewer – 16 fewer)				
Major adverse cardiovascular events	RR 0.93 (0.85 to 1.02)	207 per 1000	192 per 1000	7439 (2)[75,100]	⊕⊕⊕⊕ high	ARB results in little to no difference in major adverse cardiovascular events compared to placebo/standard of care.
		Difference: 15 fewer per 1000 (32 fewer – 4 more)				
Heart failure	RR 0.83 (0.65 to 1.06)	87 per 1000	75 per 1000	8005 (3)[75,76,100]	⊕⊕⊕⊖ moderate Due to serious risk of inconsistency	ARB probably results in little to no difference in heart failure compared to placebo/standard of care.
		Difference: 12 fewer per 1000 (28 fewer – 9 more)				
		55	42	8005 (3)[75,76,100]	⊕⊕⊕⊖	

Myocardial infarction	RR 0.77 (0.63 to 0.93)	per 1000	per 1000 Difference: 13 fewer per 1000 (20 fewer – 4 fewer)		moderate Due to serious risk of imprecision	ARB probably reduces myocardial infarction compared to placebo/standard of care.
Stroke	RR 0.82 (0.65 to 1.04)	45 per 1000	37 per 1000 Difference: 8 fewer per 1000 (15 fewer – 2 more)	6492 (2)[76,100]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision	ARB probably results in little to no effect in stroke compared to placebo/standard of care.
Treatment dropouts due to adverse effects	RR 0.84 (0.71 to 0.98)	73 per 1000	63 per 1000 Difference: 10 fewer per 1000 (20 fewer – 1 more)	7382 (4)[75,99,101,102]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision	ARB probably results in little to no difference in treatment dropouts due to adverse effects compared to placebo/standard of care.
Hyperkalemia	RR 1.83 (1.16 to 2.90)	19 per 1000	33 per 1000 Difference: 14 more per 1000 (2 more – 33 more)	12871 (4)[76,98–100]	⊕⊕⊖⊖ low Due to serious risk of inconsistency and imprecision	ARB may increase hyperkalemia compared to placebo/standard of care.
UACR (% change from baseline)	--	Difference: MD 47.99 lower (71.37 lower to 24.62 lower)		932 (2)[102,105]	⊕⊕⊖⊖ low Due to very serious risk of inconsistency	ARB may reduce UACR compared to placebo/standard of care.

Table S4.3. ACEI compared to ARB in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: ACEI

Comparison: ARB

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with ARB	Risk with ACEI			
Mortality (all causes)	RR 1.02 (0.38 to 2.77)	24 per 1000	26 per 1000	603 (6)[71,74,106–109]	⊕⊕⊖⊖ low Due to serious risk of bias and imprecision	ACEI may result in little to no difference in all-cause mortality compared to ARB.
		Difference: 2 more per 1000 (14 fewer – 47 more)				
Cardiovascular death	RR 0.62 (0.10 to 3.62)	13 per 1000	8 per 1000	466 (4)[74,107–109]	⊕⊕⊖⊖ low Due to serious risk of bias and imprecision	ACEI may result in little to no difference in cardiovascular death compared to ARB.
		Difference: 5 fewer per 1000 (12 fewer - 34 more)				
New onset of macroalbuminuria	RR 2.05 (0.96 to 4.39)	66 per 1000	156 per 1000	208 (3)[106–108]	⊕⊖⊖⊖ very low Due to very serious risk of bias, and serious risk of imprecision	The evidence is very uncertain about the effect of ACEI on new onset macroalbuminuria compared to ARB.
		Difference: 90 more per 1000 (7 more – 268 more)				
Heart failure	RR 0.72 (0.28 to 1.87)	54 per 1000	40 per 1000	342 (2)[74,107]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision	ACEI probably results in little to no difference in heart failure compared to ARB.
		Difference: 14 fewer per 1000 (38 fewer – 50 more)				
Myocardial infarction		54 per 1000	34 per 1000	342 (2)[74,107]	⊕⊕⊕⊖	ACEI probably results in little to no

	RR 0.62 (0.23 to 1.68)	Difference: 20 fewer per 1000 (41 fewer – 38 more)		moderate Due to serious risk of imprecision	difference in myocardial infarction compared to ARB.
Stroke	RR 1.06 (0.37 to 3.01)	32 per 1000 / 36 per 1000 Difference: 4 more per 1000 (19 fewer – 70 more)	384 (3)[74,107,108]	⊕⊕⊖⊖ low Due to serious risk of bias and imprecision	ACEI may result in little to no difference in stroke compared to ARB.
Treatment dropouts due to adverse effects	RR 1.35 (0.83 to 2.21)	97 per 1000 / 137 per 1000 Difference: 40 more per 1000 (12 fewer – 127 more)	461 (4)[74,106–108]	⊕⊖⊖⊖ very low Due to very serious risk of bias, and serious risk of imprecision	The evidence is very uncertain about the effect of ACEI on treatment dropouts due to adverse effects compared to ARB.
HbA1c	--	Difference: MD 0.50 higher (0.40 higher to 0.60 higher)	116 (2)[106,108]	⊕⊖⊖⊖ very low Due to very serious risk of bias, and serious risk of imprecision.	The evidence is very uncertain about the effect of ACEI on HbA1c compared to ARB.
UACR (% change from baseline)	--	Difference: MD 43.18 higher (30.03 higher to 56.32 higher)	124 (2)[108,109]	⊕⊖⊖⊖ very low Due to very serious risk of bias, and serious risk of imprecision.	The evidence is very uncertain about the effect of ACEI on UACR compared to ARB.

Table S4.4. Aliskiren compared to placebo/standard of care in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: Aliskiren

Comparison: Placebo/standard of care

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with control	Risk with aliskiren			
UACR (% change from baseline)	--	Difference: MD 9.94 lower (18.80 lower to 1.07 lower)		9385 (3) [82,110,111]	⊕⊖⊖⊖ very low Due to very serious risk of inconsistency, and serious risk of bias.	The evidence is very uncertain about the effect of aliskiren on UACR compared to placebo/standard of care.

Table S4.5. Steroidal MRA compared to placebo/standard of care in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: Steroidal MRA

Comparison: Placebo/standard of care

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with control	Risk with steroidal MRA			
Hyperkalemia	RR 2.17 (0.43 to 11.03)	24 per 1000	66 per 1000	246 (2)[112,113]	⊕⊕⊖⊖ low Due to serious risk of imprecision and bias	Steroidal MRA may result in little to no difference in hyperkalemia compared to control.
		Difference: 42 more per 1000 (11 fewer – 311 more)				
HbA1c (%)	--	Difference: MD 0.00 lower (0.11 lower to 0.10 higher)		239 (2)[78,112]	⊕⊕⊖⊖ low Due to serious risk of imprecision and bias	Steroidal MRA may result in little to no difference in HbA1c compared to control.
eGFR (mL/min)	--	Difference: MD 2.02 lower (3.49 lower to 0.55 lower)		353 (3)[78,112,114]	⊕⊖⊖⊖ very low Due to very serious risk of bias, and serious risk of imprecision.	The evidence is very uncertain about the effect of steroidal MRA on eGFR.
UACR (% change from baseline)	--	Difference: MD 31.32 lower (51.45 lower to 11.18 lower)		424 (4)[78,112,114,115]	⊕⊖⊖⊖ very low Due to very serious risk of bias and inconsistency,	Steroidal MRA may reduce UACR, but the evidence is very uncertain.

				and serious risk of imprecision.	

Table S4.6. Non-steroidal MRA compared to placebo/standard of care in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: Non-steroidal MRA

Comparison: Placebo/standard of care

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with control	Risk with non-steroidal MRA			
Mortality (all causes)	RR 0.90 (0.80 to 1.00)	94 per 1000	85 per 1000	13050 (3)[42–44]	⊕⊕⊕⊕ high	Non-steroidal MRA have little or no effect on all-cause mortality.
		Difference: 9 fewer per 1000 (18 fewer – 0 fewer)				
Cardiovascular death	RR 0.88 (0.76 to 1.02)	56 per 1000	49 per 1000	13026 (2)[42,43]	⊕⊕⊕⊕ high	Non-steroidal MRA have little or no effect on cardiovascular death.
		Difference: 7 fewer per 1000 (14 fewer – 1 more)				
Death from renal cause	RR 0.62 (0.12 to 3.23)	1 per 1000	0 per 1000	13026 (2)[42,43]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision	Non-steroidal MRA probably does not reduce death from renal cause.
		Difference: 1 fewer per 1000 (1 fewer – 0 fewer)				
Kidney composite	RR 0.86 (0.79 to 0.93)	153 per 1000	131 per 1000	13026 (2)[42,43]	⊕⊕⊕⊕ high	Non-steroidal MRA decrease composite kidney outcome.
		Difference: 22 fewer per 1000 (33 fewer – 11 fewer)				
Heart failure	RR 0.79 (0.66 to 0.94)	50 per 1000	39 per 1000	13026 (2)[42,43]	⊕⊕⊕⊖ moderate	Non-steroidal MRA probably decrease heart failure.
		Difference: 11 fewer per 1000				

		(17 fewer – 4 fewer)		Due to serious risk of imprecision	
Myocardial infarction	RR 0.91 (0.74 to 1.12)	29 per 1000 / 24 per 1000 Difference: 5 fewer per 1000 (9 fewer – 1 more)	13847 (3)[42,43,45]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision	Non-steroidal MRA probably have little or no difference on myocardial infarction.
Stroke	RR 0.99 (0.82 to 1.20)	30 per 1000 / 27 per 1000 Difference: 3 fewer per 1000 (8 fewer – 3 more)	13847 (3)[42,43,45]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision	Non-steroidal MRA probably have little or no difference on stroke.
Treatment dropouts due to adverse effects	RR 1.19 (1.04 to 1.36)	54 per 1000 / 64 per 1000 Difference: 10 more per 1000 (2 more – 19 more)	13903 (5)[42–46]	⊕⊕⊕⊖ moderate Due to serious risk of bias	Non-steroidal MRA probably increase treatment dropouts due to adverse events slightly.
Serious adverse events	RR 1.43 (0.95 to 2.14)	13 per 1000 / 23 per 1000 Difference: 21 more per 1000 (2 more – 21 more)	6479 (2)[42,45]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision	Non-steroidal MRA probably increase serious adverse events slightly.
Hyperkalemia	RR 2.03 (1.83 to 2.27)	68 per 1000 / 128 per 1000 Difference: 60 more per 1000 (47 more – 75 more)	13863 (4)[42,43,45,46]	⊕⊕⊕⊕ high	Non-steroidal MRA increase hyperkalemia.

Table S4.7. sGLT2i compared to placebo/standard of care in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: sGLT2i

Comparison: Placebo/standard of care

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with control	Risk with sGLT2i			
Mortality (all causes)	RR 0.91 (0.85 to 0.98)	72 per 1000	65 per 1000	37044 (9)[1–3,6,7,9–11,116]	⊕⊕⊕⊕ high	sGLT2i decrease all-cause mortality.
		Difference: 7 fewer per 1000 (11 fewer – 2 fewer)				
Cardiovascular death	RR 0.89 (0.79 to 0.99)	36 per 1000	33 per 1000	35451 (6)[1,6,9–12]	⊕⊕⊕⊕ high	sGLT2i decrease cardiovascular death.
		Difference: 3 fewer per 1000 (6 fewer – 0 fewer)				
Kidney composite	RR 0.62 (0.52 to 0.75)	32 per 1000	20 per 1000	32145 (3)[1,6,10]	⊕⊕⊕⊕ high	sGLT2i decrease kidney composite outcomes.
		Difference: 12 fewer per 1000 (15 fewer – 8 fewer)				
Acute kidney injury	RR 0.83 (0.67 to 1.05)	25 per 1000	21 per 1000	22979 (7)[2,3,6,7,10,11,117]	⊕⊕⊕⊖ moderate Due to serious risk of bias	sGTL2i probably does not decrease acute kidney injury.
		Difference: 4 fewer per 1000 (8 fewer – 2 more)				
Doubling serum creatinine	RR 0.63 (0.50 to 0.78)	80 per 1000	50 per 1000	4698 (2)[6,7]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision.	sGLT2i probably reduce the risk of doubling serum creatinine.
		Difference: 30 fewer per 1000 (40 fewer – 18 fewer)				
		58	44			

Myocardial infarction	RR 0.85 (0.74 to 0.96)	per 1000 Difference: 14 fewer per 1000 (20 fewer – 8 fewer)	per 1000	26646 (10)[3,6,7,10–12,116,118–120]	⊕⊕⊕⊖ moderate Due to serious risk of bias	sGLT2i probably decrease myocardial infarction.
Heart failure	RR 0.71 (0.61 to 0.83)	32 per 1000 Difference: 9 fewer per 1000 (12 fewer – 5 fewer)	23 per 1000	23234 (8) [3,7,9–12,116,118]	⊕⊕⊕⊖ moderate Due to serious risk of bias	sGLT2i probably decrease heart failure.
Stroke	RR 0.99 (0.83 to 1.18)	24 per 1000 Difference: 3 fewer per 1000 (6 fewer – 1 more)	21 per 1000	21747 (8) [3,7,9–12,116,118]	⊕⊕⊕⊖ moderate Due to serious risk of bias	sGLT2i probably does not reduce stroke.
Treatment dropouts due to adverse effects	RR 1.07 (0.80 to 1.43)	64 per 1000 Difference: 7 more per 1000 (11 more – 31 more)	71 per 1000	21087 (9) [2,3,7,10–12,118–120]	⊕⊕⊕⊖ moderate Due to serious risk of bias	sGLT2i probably does not increase treatment dropouts due to adverse effects.
Serious adverse effects	RR 0.93 (0.90, 0.96)	328 per 1000 Difference: 45 fewer per 1000 (54 fewer – 36 fewer)	283 per 1000	26436 (12) [2,3,6,7,10,11,116–121]	⊕⊕⊕⊖ moderate Due to serious risk of bias	sGLT2i probably reduce serious adverse effects.
Diabetic retinopathy progression	RR 0.50 (0.05 to 4.78)	2 per 1000 Difference: 1 fewer per 1000 (2 fewer – 8 more)	1 per 1000	1948 (2)[116,119]	⊕⊕⊖⊖ low Due to very serious risk of imprecision	sGLT2i may result in little to no difference in diabetic retinopathy progression.
Diabetic ketoacidosis	RR 8.40 (2.79 to 25.31)	0 per 1000 Difference: 4 more per 1000 (1 more - 12 more)	4 per 1000	21247 (4)[2,6,10,11]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision	sGTL2i probably increase diabetic ketoacidosis.
Urinary tract infections		23 per 1000	30 per 1000	22033 (11) [2,3,7,10,11,116–121]	⊕⊕⊕⊖	sGLT2i probably have little or no

	RR 1.04 (0.88 to 1.22)	Difference: 7 more per 1000 (2 more – 12 more)		moderate Due to serious risk of bias	difference on urinary tract infections.
Gastrointestinal adverse effects	RR 0.94 (0.68 to 1.31)	60 per 1000 / 61 per 1000; Difference: 1 more per 1000 (16 fewer – 25 more)	5085 (8)[3,11–13,116,118–120]	⊕⊕⊖⊖ low Due to very serious risk of imprecision and bias	sGLT2i may have little or no difference on gastrointestinal adverse effects.
Hyperkalemia	RR 0.80 (0.65 to 0.98)	74 per 1000 / 59 per 1000; Difference: 15 fewer per 1000 (26 fewer – 2 fewer)	5260 (4)[3,6,7,11]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision	sGLT2i probably reduce hyperkalemia.
Hypoglycemia	RR 0.77 (0.50 to 1.19)	178 per 1000 / 132 per 1000; Difference: 46 fewer per 1000 (92 fewer – 26 more)	5994 (11) [2,3,7,11,12,116–121]	⊕⊖⊖⊖ very low Due to very serious risk of inconsistency, and serious risk of bias	sGLT2i may have little or no difference on hypoglycemia, but the evidence is very uncertain.
Amputations	RR 0.99 (0.68 to 1.44)	1 per 1000 / 15 per 1000; Difference: 14 more per 1000 (9 more – 21 more)	26142 (9)[3,6,7,10–12,116,118,120]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision	sGLT2i probably have little or no difference on amputation.
Fractures	RR 0.99 (0.81 to 1.21)	42 per 1000 / 38 per 1000; Difference: 4 fewer per 1000 (11 fewer – 4 more)	26969 (11) [2,3,6,7,10–12,116,118–120]	⊕⊕⊕⊖ moderate Due to serious risk of bias	sGLT2i probably have little or no difference on fractures.
HbA1c (%)	--	Difference: MD 0.15 lower (0.23 lower to 0.07 lower)	25406 (11) [2,3,6,7,10–12,116,117,121,122]	⊕⊕⊖⊖ low Due to very serious risk of imprecision	sGLT2i may decrease HbA1c.

UACR (% change from baseline)	--	Difference: MD 26.30 lower (26.74 lower to 25.85 lower)	4738 (3)[6,7,121]	⊕⊕⊕⊖ moderate Due to serious risk of bias	sGLT2i probably reduce UACR.
eGFR (mL/min)	--	Difference: MD 0.42 lower (1.46 lower to 0.63 higher)	7816 (7) [2,6,7,11,12,116,122]	⊕⊕⊖⊖ low Due to very serious risk of imprecision	The evidence suggests that sGLT2i results in little to no difference in eGFR.

Table S4.8. GLP-1A compared to placebo/standard of care in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: GLP-1 RA

Comparison: Placebo/standard of care

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with control	Risk with GLP-1 RA			
Mortality (all causes)	RR 0.91 (0.83 to 0.99)	93 per 1000	79 per 1000	21978 (4)[17,18,21,22]	⊕⊕⊕⊕ high	GLP-1RA reduce all-cause mortality.
		Difference: 14 fewer per 1000 (20 fewer – 7 fewer)				
Cardiovascular death	RR 0.86 (0.75 to 1.00)	46 per 1000	39 per 1000	27101 (6) [17–22]	⊕⊕⊕⊕ high	GLP-1RA reduce cardiovascular death.
		Difference: 7 fewer per 1000 (12 fewer – 1 fewer)				
Kidney composite	RR 0.79 (0.64 to 0.98)	193 per 1000	157 per 1000	13976 (2)[17,18]	⊕⊕⊕⊖ moderate Due to serious risk of inconsistency.	GLP-1RA probably reduce kidney composite outcome.
		Difference: 36 fewer per 1000 (66 fewer - 0 fewer)				
New onset macroalbuminuria	RR 0.76 (0.70 to 0.82)	93 per 1000	77 per 1000	23316 (3)[17,18,123]	⊕⊕⊕⊕ high	GLP-1 RA reduce new onset macroalbuminuria.
		Difference: 16 fewer per 1000 (22 fewer – 10 fewer)				
Doubling serum creatinine	RR 0.97 (0.76 to 1.23)	17 per 1000	16 per 1000	15408 (2)[21,123]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision.	GLP-1RA probably reduce doubling serum creatinine.
		Difference: 1 fewer per 1000 (4 fewer - 5 more)				

Need of initiation RRT	RR 0.85 (0.62 to 1.16)	9 per 1000	7 per 1000	19241 (2)[18,123]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision.	GLP-1RA probably have little or no difference on need of initiation of RRT.
		Difference: 2 fewer per 1000 (4 fewer - 1 more)				
Myocardial infarction	RR 0.96 (0.85 to 1.08)	51 per 1000	48 per 1000	26524 (5) [17–22]	⊕⊕⊕⊕ high	GLP-1 RA does not reduce myocardial infarction.
		Difference: 3 fewer per 1000 (9 fewer - 3 more)				
Heart failure	RR 0.91 (0.77 to 1.07)	41 per 1000	35 per 1000	20044 (3) [17–22]	⊕⊕⊕⊕ high	GLP-1 RA does not reduce heart failure.
		Difference: 6 fewer per 1000 (11 fewer – 0 fewer)				
Stroke	RR 0.87 (0.69 to 1.11)	31 per 1000	25 per 1000	20044 (3) [17–22]	⊕⊕⊕⊖ moderate Due to serious risk of inconsistency.	GLP-1 RA probably does not reduce stroke.
		Difference: 6 fewer per 1000 (11 fewer - 1 more)				
Treatment dropouts due to adverse effects	RR 1.60 (1.37 to 1.87)	25 per 1000	37 per 1000	6719 (3)[21,22,124]	⊕⊕⊕⊕ high	GLP-1 RA increase the risk of treatment dropouts due to adverse effects.
		Difference: 12 more per 1000 (7 more - 18 more)				
Gastrointestinal adverse effects	RR 1.92 (1.09 to 3.37)	106 per 1000	163 per 1000	12572 (4)[21,25]	⊕⊕⊕⊖ moderate Due to serious risk of inconsistency.	GLP-1 RA may increase gastrointestinal adverse effects.
		Difference: 57 more per 1000 (13 fewer - 180 more)				
Hypoglycemia	RR 0.64 (0.27 to 1.49)	161 per 1000	138 per 1000	6645 (2)[21,22]	⊕⊕⊖⊖ low Due to very serious risk of inconsistency.	GLP-1 RA may have little to no difference in hypoglycemia.
		Difference: 23 fewer per 1000 (102 fewer–160 more)				

HbA1c	--	Difference: MD 0.55 lower (1.19 lower to 0.09 higher)	4766 (5)[17,22,25,124,125]	⊕⊕⊖⊖ low Due to serious risk of bias and very serious risk of inconsistency.	GLP-1 RA may have little to no difference in HbA1c.

Table S4.9. Dual GLP-1/GIP compared to placebo/standard of care in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: GLP-1/GIP

Comparison: Placebo/standard of care

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with control	Risk with GLP-1/GIP			
HbA1c	--	Difference: MD 0.88 lower (1.23 lower to 0.53 lower)		2036 (2)[26,27]	⊕⊕⊕⊖ moderate Due to serious risk of inconsistency	GLP-1/GIP may reduce HbA1c.
eGFR (mL/min)	--	Difference: MD 2.20 higher (1.88 higher to 2.53 higher)		2036 (2) [26,27]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision	GLP-1/GIP probably increase eGFR slightly.
UACR (mean change from baseline %)	--	Difference: MD 28.46 lower (58.47 lower to 1.54 higher)		2036 (2) [26,27]	⊕⊕⊖⊖ low Due to very serious risk of inconsistency	GLP-1/GIP may have little to no effect on UACR.
Treatment dropouts due to adverse effects	RR 1.88 (1.37 to 2.58)	54 per 1000	101 per 1000	2036 (2) [26,27]	⊕⊕⊕⊖ moderate Due to serious risk of imprecision	GLP-1/GIP probably increase treatment dropouts due to adverse effects.
		Difference: 47 more per 1000 (19 more – 84 more)				
Gastrointestinal adverse effects		0 per 1000	16 per 1000	2036 (2) [26,27]	⊕⊕⊕⊖	GLP-1/GIP probably increase

	RR 15.58 (2.10 to 115.40)	Difference: 16 more per 1000 (12 more – 22 more)		moderate Due to serious risk of imprecision	gastrointestinal adverse effects.

Table S4.10. DPP4i compared to placebo/standard of care in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: DPP4i

Comparison: Placebo/standard of care

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with control	Risk with DPP4i			
HbA1c	--	Difference: MD 0.46 lower (0.65 lower to 0.26 lower)		7249 (3)[32,34,38]	⊕⊕⊖⊖ low Due to serious risk of bias and inconsistency.	DPP4i may reduce HbA1c slightly.
Mortality (all causes)	RR 0.98 (0.86 to 1.12)	103 per 1000	101 per 1000	7250 (3) [32,34,38]	⊕⊕⊖⊖ low Due to serious risk of bias and imprecision.	DPP4i may have little to no effect on mortality.
		Difference: 2 fewer per 1000 (14 fewer – 12 more)				
Need of initiation of RRT	RR 0.98 (0.70 to 1.39)	18 per 1000	17 per 1000	7143 (2)[32,34]	⊕⊕⊖⊖ low Due to serious risk of bias and imprecision.	DPP4i may have little to no effect on need of initiation of RRT.
		Difference: 1 fewer per 1000 (6 fewer – 6 more)				
Treatment dropouts due to adverse effects	RR 0.89 (0.78 to 1.02)	114 per 1000	101 per 1000	7086 (2)[32,38]	⊕⊕⊕⊕ high	DPP4i do not increase treatment dropouts due to adverse effects.
		Difference: 13 fewer per 1000 (25 fewer - 2 more)				

Table S4.11. Pentoxifylline compared to placebo/standard of care in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: Pentoxifylline

Comparison: Placebo/standard of care

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with control	Risk with pentoxifylline			
HbA1c	--	Difference: MD 0.40 lower (1.29 lower to 0.50 higher)		230 (3)[126–128]	⊕⊖⊖⊖ very low Due to very serious risk of inconsistency and serious risk of imprecision.	The evidence is very uncertain about the effect of pentoxifylline on HbA1c.
Treatment dropouts due to adverse effects	RR 1.00 (0.15 to 6.73)	38 per 1000	30 per 1000	119 (2)[126,127]	⊕⊕⊖⊖ low Due to serious risk of bias and imprecision.	Pentoxifylline may have little to no effect on treatment dropouts due to adverse effects.
		Difference: 8 fewer per 1000 (33 fewer – 164 more)				

Table S4.12. Protein restriction compared to placebo/standard of care in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: Low protein diet

Comparison: Normal protein diet

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with normal protein diet	Risk with low protein diet			
eGFR (mL/min)	--	Difference: MD 0.50 lower (1.41 lower to 0.40 higher)		231 (3)[129–131]	⊕⊖⊖⊖ very low Due to very serious risk of bias and serious risk of imprecision.	The evidence is very uncertain about the effect of low protein diet on eGFR.

Chapter 5. Anticoagulation and antiagregation in people with diabetic kidney disease

Table S5.1. Ticagrelor compared to clopidogrel in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: Ticagrelor

Comparison: Clopidogrel

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with clopidogrel	Risk with ticagrelor			
Major bleeding	RR 1.02 (0.76 to 1.36)	147 per 1000	150 per 1000	1058 (1)[132]	⊕⊕⊖⊖ low Due to very serious risk of imprecision.	Ticagrelor may result in little to no difference in major bleeding.
		Difference: 3 more per 1000 (35 fewer – 53 more)				
Cardiovascular death	RR 0.74 (0.53 to 1.02)	143 per 1000	106 per 1000	1058 (1)[132]	⊕⊕⊖⊖ low Due to very serious risk of imprecision.	Ticagrelor may result in little to no difference in cardiovascular death.
		Difference: 37 fewer per 1000 (67 fewer – 3 more)				
Myocardial infarction	RR 0.74 (0.53 to 1.04)	134 per 1000	100 per 1000	1058 (1)[132]	⊕⊕⊖⊖ low Due to very serious risk of imprecision.	Ticagrelor may result in little to no difference in myocardial infarction.
		Difference: 34 fewer per 1000 (62 fewer - 7 more)				
All-cause mortality	RR 0.79 (0.58 to 1.07)	153 per 1000	121 per 1000	1058 (1)[132]	⊕⊕⊖⊖ low Due to very serious risk of imprecision.	Ticagrelor may result in little to no difference in all-cause mortality.
		Difference: 32 fewer per 1000 (64 fewer - 11 more)				
Stroke	RR 0.74 (0.37 to 1.50)	34 per 1000	25 per 1000	1058 (1)[132]	⊕⊕⊖⊖ low	Ticagrelor may result in little to no difference in stroke.
		Difference: 9 fewer per 1000				

		(22 fewer - 17 more)		Due to very serious risk of imprecision.	

CI: confidence interval, RR: risk ratio

Table S5.2. Clopidogrel plus AAS compared to placebo plus AAS in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: Clopidogrel+AAS

Comparison: Placebo+AAS

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with placebo + AAS	Risk with clopidogrel + AAS			
Minor bleeding	RR 1.16 (0.68 to 1.99)	24 per 1000	28 per 1000	2009 (1)[133]	⊕⊖⊖⊖ very low Due to very serious risk of imprecision and risk of bias.	The evidence is very uncertain about the effect of clopidogrel plus aspirin on minor bleeding.
		Difference: 4 more per 1000 (8 fewer – 24 more)				
Major bleeding	RR 1.73 (0.92 to 3.24)	15 per 1000	26 per 1000	2009 (1)[133]	⊕⊖⊖⊖ very low Due to very serious risk of imprecision and risk of bias.	The evidence is very uncertain about the effect of clopidogrel plus aspirin on major bleeding.
		Difference: 11 more per 1000 (2 fewer – 34 more)				
Cardiovascular death	RR 1.64 (1.06 to 2.54)	31 per 1000	51 per 1000	2009 (1)[133]	⊕⊕⊖⊖ low Due to serious risk of bias and imprecision	Clopidogrel plus aspirin may increase cardiovascular mortality.
		Difference: 20 more per 1000 (2 more - 59 more)				
Myocardial infarction	RR 0.76 (0.44 to 1.31)	29 per 1000	22 per 1000	2009 (1)[133]	⊕⊖⊖⊖ very low Due to very serious risk of imprecision	The evidence is very uncertain about the effect of clopidogrel plus aspirin on
		Difference: 7 fewer per 1000 (16 fewer - 9 more)				

				and risk of bias.	myocardial infarction.
All-cause mortality	RR 1.67 (1.18 to 2.38)	45 per 1000 / 73 per 1000 Difference: 28 more per 1000 (6 more - 59 more)	2009 (1)[133]	⊕⊕⊖⊖ low Due to serious risk of bias and imprecision.	Clopidogrel plus aspirin may increase all-cause mortality.
Stroke	RR 0.91 (0.50 to 1.65)	22 per 1000 / 20 per 1000 Difference: 2 fewer per 1000 (11 fewer - 14 more)	2009 (1)[133]	⊕⊖⊖⊖ very low Due to very serious risk of imprecision and risk of bias.	The evidence is very uncertain about the effect of clopidogrel plus aspirin on stroke.

CI: confidence interval, RR: risk ratio

Table S5.3. Ticagrelor+AAS followed by ticagrelor monotherapy compared to AAS+clopidogrel/ticagrelor followed by AAS monotherapy in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: Ticagrelor+AAS followed by ticagrelor monotherapy

Comparison: AAS+clopidogrel/ticagrelor followed by AAS montherapy

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with comparison	Risk with intervention			
All-cause mortality	RR 0.78 (0.49 to 1.23)	90 per 1000	70 per 1000	838 (1)[134]	⊕⊕⊖⊖ low Due to very serious risk of imprecision.	Ticagrelor+AAS followed by ticagrelor monotherapy may result in little to no difference in all-cause mortality.
		Difference: 20 fewer per 1000 (46 fewer – 21 more)				
Myocardial infarction	RR 0.92 (0.55 to 1.55)	66 per 1000	61 per 1000	838 (1)[134]	⊕⊕⊖⊖ low Due to very serious risk of imprecision.	Ticagrelor+AAS followed by ticagrelor monotherapy may result in little to no difference in myocardial infarction.
		Difference: 5 fewer per 1000 (30 fewer – 36 more)				
Stroke	RR 1.06 (0.44 to 2.59)	22 per 1000	23 per 1000	838 (1)[134]	⊕⊕⊖⊖ low Due to very serious risk of imprecision.	Ticagrelor+AAS followed by ticagrelor monotherapy may result in little to no difference in stroke.
		Difference: 1 more per 1000 (12 fewer - 35 more)				
Bleeding	HR 0.86 (0.45 to 1.64)	46 per 1000	42 per 1000	838 (1)[134]	⊕⊕⊖⊖ low	Ticagrelor+AAS followed by ticagrelor
		Difference: 4 fewer				

		per 1000 (24 fewer - 34 more)		Due to very serious risk of imprecision.	monotherapy may result in little to no difference in bleeding.

CI: confidence interval, RR: risk ratio

Table S5.4. Ticagrelor+AAS followed by AAS+ticagrelor or placebo+ticagrelor in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: Ticagrelor+AAS followed by tica+placebo

Comparison: Ticagrelor+AAS followed by tica+AAS

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with comparison	Risk with intervention			
Primary composite (death, MI or stroke)	RR 1.39 (0.89 to 2.18)	78 per 1000	56 per 1000	1111 (1)[135]	⊕⊕⊖⊖ low Due to very serious risk of imprecision	Ticagrelor+placebo after 3 months of ticagrelor+AAS may have little to no difference in the primary composite.
		Difference: 22 fewer per 1000 (42 fewer – 10 more)				
All-cause death	RR 1.08 (0.52 to 2.21)	25 per 1000	27 per 1000	1111 (1) [135]	⊕⊕⊖⊖ low Due to very serious risk of imprecision	Ticagrelor+placebo after 3 months of ticagrelor+AAS may have little to no difference in all-cause death.
		Difference: 2 more per 1000 (12 fewer – 30 more)				
Myocardial infarction	RR 1.29 (0.74 to 2.26)	38 per 1000	49 per 1000	1111 (1) [135]	⊕⊕⊖⊖ low Due to very serious risk of imprecision	Ticagrelor+placebo after 3 months of ticagrelor+AAS may have little to no difference in myocardial infarction.
		Difference: 11 more per 1000 (10 fewer - 48 more)				
Bleeding	RR 0.51 (0.32 to 0.82)	88 per 1000	45 per 1000	1111 (1) [135]	⊕⊕⊖⊖ low Due to very serious risk of imprecision	Ticagrelor+placebo after 3 months of ticagrelor+AAS may decrease the risk of bleeding.
		Difference: 43 fewer per 1000 (60 fewer – 16 fewer)				

CI: confidence interval, RR: risk ratio

Table S5.5. Aspirin compared to no aspirin as primary prevention in diabetic kidney disease

Patient or population: CKD with diabetes

Intervention: Aspirin

Comparison: No aspirin

Outcomes	Relative effect (95% CI)	Absolute effect estimates (95% CI)		No of Participants (studies)	Quality of the evidence (GRADE)	Comments
		Risk with aspirin	Risk with no aspirin			
Any atherosclerotic event	RR 0.80 (0.57 to 1.11)	74 per 1000	59 per 1000	2005 (1)[136]	⊕⊕⊖⊖ low Due to very serious risk of imprecision	Aspirin may result in little to no difference in any atherosclerotic event.
		Difference: 15 fewer per 1000 (32 fewer – 8 more)				
Haemorrhagic events	RR 1.00 (0.32, 3.09)	6 per 1000	6 per 1000	2005 (1)[136]	⊕⊕⊖⊖ low Due to very serious risk of imprecision	Aspirin may result in little to no difference in haemorrhagic events.
		Difference: 0 fewer per 1000 (4 fewer – 13 more)				

CI: confidence interval, RR: risk ratio

References

1. Bhatt, D. L. *et al.* Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. *New England Journal of Medicine* 384, 129–139 (2021).
2. Fioretto, P. *et al.* Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. *Diabetes Obes Metab* 20, 2532–2540 (2018).
3. Grunberger, G. *et al.* Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study. (2018) doi:10.1007/s13300.
4. Haneda, M. *et al.* Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus. *Clin Ther* 38, 66-88.e20 (2016).
5. Kohan, D. E., Fioretto, P., Tang, W. & List, J. F. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. *Kidney Int* 85, 962–971 (2014).
6. Perkovic, V. *et al.* Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. *New England Journal of Medicine* 380, 2295–2306 (2019).
7. Pollock, C. *et al.* Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. *Lancet Diabetes Endocrinol* 7, 429–441 (2019).
8. Scott, R. *et al.* A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study. *Diabetes Obes Metab* 20, 2876–2884 (2018).
9. Wanner, C. *et al.* Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. *Circulation* 137, 119–129 (2018).
10. Wiviott, S. D. *et al.* Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. *New England Journal of Medicine* 380, 347–357 (2019).
11. Yale, J. F. *et al.* Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. *Diabetes Obes Metab* 15, 463–473 (2013).
12. Cherney, D. Z. I. *et al.* Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease. *Diabetes Obes Metab* 25, 1646–1657 (2023).

13. Pollock, C. *et al.* Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. *Lancet Diabetes Endocrinol* 7, 429–441 (2019).

14. Allegretti, A. S. *et al.* Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD. *Am J Kidney Dis* 74, 328–337 (2019).

15. Kashiwagi, A. *et al.* A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 diabetes with renal impairment (LANTERN) study. *Diabetes Obes Metab* 17, 152–60 (2015).

16. Kohan, D. E., Fioretto, P., Tang, W. & List, J. F. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. *Kidney Int* 85, 962–971 (2014).

17. Gerstein, H. C. *et al.* Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial. *Circulation* 147, 1004–1013 (2023).

18. Gerstein, H. C. *et al.* Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. *The Lancet* 394, 121–130 (2019).

19. Husain, M. *et al.* Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *New England Journal of Medicine* 381, 841–851 (2019).

20. Marso, S. P. *et al.* Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *New England Journal of Medicine* 375, 1834–1844 (2016).

21. Muskiet, M. H. A. *et al.* Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. *Lancet Diabetes Endocrinol* 6, 859–869 (2018).

22. Tuttle, K. R. *et al.* Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. *Lancet Diabetes Endocrinol* 6, 605–617 (2018).

23. Holman, R. R. *et al.* Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. *Am Heart J* 174, 103–10 (2016).

24. Davies, M. J. *et al.* Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): A randomized clinical trial. *Diabetes Care* 39, 222–230 (2016).

25. Idorn, T. *et al.* Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: An investigator-initiated, placebo-controlled, double-blind, parallel-group, randomized trial. *Diabetes Care* 39, 206–213 (2016).

26. Parker, V. E. R. *et al.* Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease. *Diabetes Obes Metab* 24, 1360–1369 (2022).

27. Heerspink, H. J. L. *et al.* Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. *Lancet Diabetes Endocrinol* 10, 774–785 (2022).

28. Chan, J. C. N. *et al.* Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. *Diabetes Obes Metab* 10, 545–555 (2008).

29. Arjona Ferreira, J. C. *et al.* Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: A 54-week randomized trial. *American Journal of Kidney Diseases* 61, 579–587 (2013).

30. Groop, P.-H. *et al.* Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial. *Diabetes Obes Metab* 19, 1610–1619 (2017).

31. Kothny, W., Shao, Q., Groop, P.-H. & Lukashevich, V. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. *Diabetes Obes Metab* 14, 1032–9 (2012).

32. McGuire, D. K. *et al.* Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. *Circulation* 139, 351–361 (2019).

33. Nowicki, M. *et al.* Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. *Diabetes Obes Metab* 13, 523–32 (2011).

34. Yagoglu, A. I., Dizdar, O. S., Erdem, S., Akcakaya, B. & Gunal, A. I. The effect of linagliptin on renal progression in type-2 diabetes mellitus patients with chronic kidney disease: A prospective randomized controlled study. *Nefrologia* 40, 664–671 (2020).

35. McGill, J. B. *et al.* Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: A 1-year, randomized, double-blind, placebo-controlled study. *Diabetes Care* 36, 237–244 (2013).

36. Engel, S. S. *et al.* Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS. *Diabetes Obes Metab* 19, 1587–1593 (2017).

37. Han, S. Y. *et al.* Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study. *Diabetes Obes Metab* 20, 292–300 (2018).

38. Kaku, K., Ishida, K., Shimizu, K., Achira, M. & Umeda, Y. Efficacy and safety of trelagliptin in Japanese patients with type 2 diabetes with severe renal impairment or end-stage renal disease: Results from a randomized, phase 3 study. *J Diabetes Investig* 11, 373–381 (2020).

39. Abe, M. *et al.* Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial. *Diabetes Res Clin Pract* 116, 244–252 (2016).

40. Awal, H. B. *et al.* Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin: A randomized controlled trial. *Cardiovasc Diabetol* 19, (2020).

41. Chacra, A. *et al.* A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment. *Int J Clin Pract* 71, (2017).

42. Bakris, G. L. *et al.* Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. *New England Journal of Medicine* 383, 2219–2229 (2020).

43. Pitt, B. *et al.* Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. *New England Journal of Medicine* 385, 2252–2263 (2021).

44. Katayama, S. *et al.* A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. *J Diabetes Complications* 31, 758–765 (2017).

45. Bakris, G. L. *et al.* Effect of finerenone on albuminuria in patients with diabetic nephropathy a randomized clinical trial. *JAMA - Journal of the American Medical Association* 314, 884–894 (2015).

46. Sato, N. *et al.* A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease. *Circ J* 80, 1113–22 (2016).

47. Haluzík, M. *et al.* Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial. *Diabetes Obes Metab* 22, 1369–1377 (2020).

48. Marso, S. P. *et al.* Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. *New England Journal of Medicine* 377, 723–732 (2017).

49. Abe, M., Kikuchi, F., Kaizu, K. & Matsumoto, K. *Combination Therapy of Pioglitazone with Voglibose Improves Glycemic Control Safely and Rapidly in Japanese Type 2-Diabetic Patients on Hemodialysis*. (2007).

50. Abe, M. *et al.* Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis. *Expert Opin Pharmacother* 11, 1611–1620 (2010).

51. Galle, J. *et al.* Comparison of the Effects of Pioglitazone versus Placebo when Given in Addition to Standard Insulin Treatment in Patients with Type 2 Diabetes Mellitus Requiring Hemodialysis: Results from the PIOren Study. *Nephron Extra* 2, 104–14 (2012).

52. Herz, M. *et al.* Effects of high dose aleglitazar on renal function in patients with type 2 diabetes. *Int J Cardiol* 151, 136–42 (2011).

53. Mohideen, P. *et al.* The metabolic effects of troglitazone in patients with diabetes and end-stage renal disease. *Endocrine* 28, 181–6 (2005).

54. Ruilope, L. *et al.* Effects of the dual peroxisome proliferatoractivated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: A Phase IIb, randomized study. *BMC Nephrol* 15, (2014).

55. Triwatana, W., Satirapoj, B., Supasyndh, O. & Nata, N. Effect of pioglitazone on serum FGF23 levels among patients with diabetic kidney disease: a randomized controlled trial. *Int Urol Nephrol* 55, 1255–1262 (2023).

56. Wong, T. Y.-H. *et al.* Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis. *American Journal of Kidney Diseases* 46, 713–9 (2005).

57. Schneider, C. A. *et al.* Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. *Journal of the American Society of Nephrology* 19, 182–187 (2008).

58. Mafi, A. *et al.* Metabolic and genetic response to probiotics supplementation in patients with diabetic nephropathy: a randomized, double-blind, placebo-controlled trial. *Food Funct* 9, 4763–4770 (2018).

59. Soleimani, A. *et al.* Probiotic supplementation in diabetic hemodialysis patients has beneficial metabolic effects. *Kidney Int* 91, 435–442 (2017).

60. Leehey, D. J. *et al.* Structured Exercise in Obese Diabetic Patients with Chronic Kidney Disease: A Randomized Controlled Trial. *Am J Nephrol* 44, 54–62 (2016).

61. Karelis, A. D., Hébert, M.-J., Rabasa-Lhoret, R. & Räkel, A. Impact of Resistance Training on Factors Involved in the Development of New-Onset Diabetes After Transplantation in Renal Transplant Recipients: An Open Randomized Pilot Study. *Can J Diabetes* 40, 382–388 (2016).

62. Fallah, M., Askari, G., Soleimani, A., Feizi, A. & Asemi, Z. Clinical trial of the effects of coenzyme Q10 supplementation on glycemic control and markers of lipid profiles in diabetic hemodialysis patients. *Int Urol Nephrol* 50, 2073–2079 (2018).

63. Parvanova, A. *et al.* Blood Pressure and Metabolic Effects of Acetyl-l-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial. *J Endocr Soc* 2, 420–436 (2018).

64. Rizk, D. V *et al.* Effects of Bardoxolone Methyl on Magnesium in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. *Cardiorenal Med* 9, 316–325 (2019).

65. Rostamkhani, H., Veisi, P., Niknafs, B., Jafarabadi, M. A. & Ghoreishi, Z. The effect of zingiber officinale on prooxidant-antioxidant balance and glycemic control in diabetic patients with ESRD undergoing hemodialysis: a double-blind randomized control trial. *BMC Complement Med Ther* 23, 52 (2023).

66. The ACCORD Study Group. Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. *New England Journal of Medicine* 362, 1575–1585 (2010).

67. Patel, A. *et al.* Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. *The Lancet* 370, 829–840 (2007).

68. Schrier, R. W., Estacio, R. O., Esler, A. & Mehler, P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. *Kidney Int* 61, 1086–1097 (2002).

69. Estacio, R., Coll, J., Tran, Z. & Schrier, R. Effect of Intensive Blood Pressure Control With Valsartan on Urinary Albumin Excretion in Normotensive Patients With Type 2 Diabetes. *Am J Hypertens* 19, 1241–1248 (2006).

70. Arpitha, K. S. & Lakshminarayana K. A comparative study of efficacy of enalapril versus telmisartan in patients with diabetic nephropathy. *Natl J Physiol Pharm Pharmacol* 1 (2020) doi:10.5455/njppp.2020.10.06172202003072020.

71. Fernandez Juarez, G. *et al.* Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: A randomized trial. *American Journal of Kidney Diseases* 61, 211–218 (2013).

72. Saglimbene, V. *et al.* The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A Randomized, Controlled Trial. *Journal of the American Society of Nephrology* 29, 2890–2899 (2018).

73. Ruggenenti, P. *et al.* Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial. *Diabetes Obes Metab* 21, 1177–1190 (2019).

74. Barnett, A. H. *et al.* Angiotensin-Receptor Blockade versus Converting-Enzyme Inhibition in Type 2 Diabetes and Nephropathy. *N Engl J Med* 351, 1952–1961 (2004).

75. Bakris, G. L. *et al.* Effects of Blood Pressure Level on Progression of Diabetic Nephropathy: Results From the RENAAL Study. *Arch Intern Med* 163, 1555 (2003).

76. Imai, E. *et al.* Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: A multicentre, randomised, placebo-controlled study. *Diabetologia* 54, 2978–2986 (2011).

77. Lewis, E. J. *et al.* Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes. *New England Journal of Medicine* 345, 851–860 (2001).

78. Hase, M., Babazono, T., Ujihara, N. & Uchigata, Y. Comparison of spironolactone and trichlormethiazide as add-on therapy to renin-angiotensin blockade for reduction of albuminuria in diabetic patients. *J Diabetes Investig* 4, 316–319 (2013).

79. van den Meiracker, A. H. *et al.* Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. *J Hypertens* 24, 2285–92 (2006).

80. Agarwal, R. *et al.* Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes. *J Hypertens* 41, 295–302 (2023).

81. Ito, S., Shikata, K., Nangaku, M., Okuda, Y. & Sawanobori, T. Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria A randomized, double-blind, placebo-controlled, phase ii trial. *Clinical Journal of the American Society of Nephrology* 14, 1161–1172 (2019).

82. Uzu, T. *et al.* Comparative effects of direct renin inhibitor and angiotensin receptor blocker on albuminuria in hypertensive patients with type 2 diabetes. A randomized controlled trial. *PLoS One* 11, (2016).

83. Persson, F. *et al.* Impact of baseline renal function on the efficacy and safety of Aliskiren added to losartan in patients with type 2 diabetes and nephropathy. *Diabetes Care* 33, 2304–2309 (2010).

84. Bakris, G. L. *et al.* Randomized Study of Antihypertensive Efficacy and Safety of Combination Aliskiren/Valsartan vs Valsartan Monotherapy in Hypertensive Participants With Type 2 Diabetes Mellitus. *J Clin Hypertens* 15, 92–100 (2013).

85. Deerochanawong, C., Kornthong, P., Phongwiratchai, S. & Serirat, S. Effects on urinary albumin excretion and renal function changes by delapril and manidipine in normotensive type 2 diabetic patients with microalbuminuria. *J Med Assoc Thai* 84, 234–41 (2001).

86. Tong, P. C. Y. *et al.* The efficacy and tolerability of fosinopril in Chinese type 2 diabetic patients with moderate renal insufficiency. *Diabetes Obes Metab* 8, 342–7 (2006).

87. Ruggenenti, P. *et al.* Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. *Hypertension* 58, 776–83 (2011).

88. Marre, M. *et al.* Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). *BMJ* 328, 495 (2004).

89. Marre, M. *et al.* Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. *J Hypertens* 22, 1613–22 (2004).

90. Kvetny, J., Gregersen, G. & Pedersen, R. S. Randomized placebo-controlled trial of perindopril in normotensive, normoalbuminuric patients with type 1 diabetes mellitus. *QJM* 94, 89–94 (2001).

91. The European Study for the Prevention of Renal Disease in Type 1 Diabetes ESPRIT Study Group. Effect of 3 years of antihypertensive therapy on renal structure in type 1 diabetic patients with albuminuria: the European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT). *Diabetes* 50, 843–50 (2001).

92. Chan, J. C. *et al.* Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. *Kidney Int* 57, 590–600 (2000).

93. Fried, L. F. *et al.* Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy. *New England Journal of Medicine* 369, 1892–1903 (2013).

94. Katayama, S. *et al.* Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM). *Diabetes Res Clin Pract* 55, 113–21 (2002).

95. Mann, J. F. E. *et al.* Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. *Am J Kidney Dis* 42, 936–42 (2003).

96. Baba, S. & J-MIND Study Group. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. *Diabetes Res Clin Pract* 54, 191–201 (2001).

97. Jerums, G. *et al.* Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria. *Diabet Med* 21, 1192–9 (2004).

98. Atkins, R. C. *et al.* Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. *Am J Kidney Dis* 45, 281–7 (2005).

99. Bilous, R. *et al.* Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. *Ann Intern Med* 151, 11–20, W3-4 (2009).

100. Mann, J. F. E. *et al.* Effect of telmisartan on renal outcomes: a randomized trial. *Ann Intern Med* 151, 1–10, W1-2 (2009).

101. Sasso, F. C. *et al.* Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study. *Diabetes Care* 25, 1909–13 (2002).

102. Makino, H. *et al.* Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study. *Hypertens Res* 31, 657–64 (2008).

103. Tanamas, S. K. *et al.* Long-term Effect of Losartan on Kidney Disease in American Indians With Type 2 Diabetes: A Follow-up Analysis of a Randomized Clinical Trial. *Diabetes Care* 39, 2004–2010 (2016).

104. Agha, A., Amer, W., Anwar, E. & Bashir, K. Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: A randomized controlled trial. *Saudi J Kidney Dis Transpl* 20, 429–35 (2009).

105. Parving, H. H. *et al.* The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. *N Engl J Med* 345, 870–8 (2001).

106. Goicolea, I. *et al.* Effect of antihypertensive combinations on arterial pressure, albuminuria, and glycemic control in patients with type II diabetic nephropathy: a randomized study. *Nefrologia* 22, 170–8 (2002).

107. Lacourcière, Y. *et al.* Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. *Kidney Int* 58, 762–9 (2000).

108. Ko, G. T. C., Tsang, C.-C. & Chan, H. C. K. Stabilization and regression of albuminuria in Chinese patients with type 2 diabetes: a one-year randomized study of valsartan versus enalapril. *Adv Ther* 22, 155–62 (2005).

109. Lim, S.-C. *et al.* Angiotensin receptor antagonist vs. angiotensin-converting enzyme inhibitor in Asian subjects with type 2 diabetes and albuminuria - a randomized crossover study. *Diabetes Obes Metab* 9, 477–82 (2007).

110. Parving, H.-H., Persson, F., Lewis, J. B., Lewis, E. J. & Hollenberg, N. K. *Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy*. *n engl j med* vol. 358 www.nejm.org (2008).

111. Parving, H.-H. *et al.* Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes. *New England Journal of Medicine* 367, 2204–2213 (2012).

112. Chen, Y. *et al.* Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic Nephropathy. *Am J Med Sci* 355, 418–424 (2018).

113. Schjoedt, K. J. *et al.* Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. *Kidney Int* 70, 536–42 (2006).

114. Esteghamati, A. *et al.* Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: A randomized clinical trial. *Nephrology Dialysis Transplantation* 28, 2823–2833 (2013).

115. Kato, S. *et al.* Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial. *Clin Exp Nephrol* 19, 1098–106 (2015).

116. Cefalu, W. T. *et al.* Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. *The Lancet* 382, 941–950 (2013).

117. Dekkers, C. C. J. *et al.* Effects of the sodium-glucose co-Transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease. *Nephrology Dialysis Transplantation* 33, 2005–2011 (2018).

118. Häring, H. U. *et al.* Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled trial. *Diabetes Care* 36, 3396–3404 (2013).

119. Kovacs, C. S. *et al.* Empagliflozin as Add-on Therapy to Pioglitazone with or Without Metformin in Patients with Type 2 Diabetes Mellitus. *Clin Ther* 37, 1773-1788.e1 (2015).

120. Roden, M. *et al.* Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: A randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Diabetes Endocrinol* 1, 208–219 (2013).

121. Takashima, H. *et al.* Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial. *Diab Vasc Dis Res* 15, 469–472 (2018).

122. Zhang, F. P. & Jiang, X. The efficacy and safety of canagliflozin in the treatment of patients with early diabetic nephropathy. *J Physiol Pharmacol* 73, (2022).

123. Mann, J. F. E. *et al.* Liraglutide and Renal Outcomes in Type 2 Diabetes. *New England Journal of Medicine* 377, 839–848 (2017).

124. Wang, X. *et al.* Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease. *Am J Nephrol* 51, 806–814 (2020).

125. Bouchi, R. *et al.* Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial. *Endocr J* 64, 269–281 (2017).

126. Navarro, J. F., Mora, C., Muros, M., Maca, M. & Garca, J. Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomized study. *Am J Kidney Dis* 42, 264–70 (2003).

127. Roozbeh, J. *et al.* Captopril and Combination Therapy of Captopril and Pentoxifylline in Reducing Proteinuria in Diabetic Nephropathy. *Ren Fail* 32, 172–178 (2010).

128. Ghorbani, A., Omidvar, B., Beladi-Mousavi, S. S., Lak, E. & Vaziri, S. The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial. *Nefrologia* 32, 790–6 (2012).

129. Dussol, B. *et al.* A randomized trial of low-protein diet in type 1 and in type 2 diabetes mellitus patients with incipient and overt nephropathy. *Journal of Renal Nutrition* 15, 398–406 (2005).

130. Hansen, H. P., Tauber-Lassen, E., Jensen, B. R. & Parving, H. H. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. *Kidney Int* 62, 220–228 (2002).

131. Koya, D. *et al.* Long-term effect of modification of dietary protein intake on the progression of diabetic nephropathy: A randomised controlled trial. *Diabetologia* 52, 2037–2045 (2009).

132. Franchi, F. *et al.* Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y12 Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial. *J Am Heart Assoc* 8, (2019).

133. Dasgupta, A. *et al.* Clinical Outcomes of Patients With Diabetic Nephropathy Randomized to Clopidogrel Plus Aspirin Versus Aspirin Alone (A post hoc Analysis of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance [CHARISMA] Trial). *Am J Cardiol* 103, 1359–1363 (2009).

134. Vranckx, P. *et al.* Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. *The Lancet* 392, 940–949 (2018).

135. Stefanini, G. G. *et al.* Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. *Eur Heart J* 42, 4683–4693 (2021).

136. Saito, Y. *et al.* Low-Dose Aspirin Therapy in Patients With Type 2 Diabetes and Reduced Glomerular Filtration Rate. *Diabetes Care* 34, 280–285 (2011).

Appendix 4. Nomenclature and description for rating guideline recommendations

Within each recommendation, the strength of the recommendation is indicated as Level 1 or Level 2, and the quality of the supporting evidence is shown as A, B, C, or D.

	Implications		
Grade	Patients	Clinicians	Policy
Level 1, strong "We recommend"	Most people in your situation would want the recommended course of action, and only a small proportion would not.	Most patients should receive the recommended course of action.	The recommendation can be evaluated as a candidate for developing a policy or a performance measure.
Level 2, weak "We suggest"	The majority of people in your situation would want the recommended course of action, but many would not.	Different choices will be appropriate for different patients. Each patient needs help to arrive at a management decision consistent with her or his values and preferences.	The recommendation is likely to require substantial debate and involvement of stakeholders before policy can be determined.
Grade	Quality of evidence	Meaning	
A	High	We are confident that the true effect is close to the estimate of the effect.	

B	Moderate	The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
C	Low	The true effect may be substantially different from the estimate of the effect.
D	Very low	The estimate of effect is very uncertain, and often it will be far from the true effect.